Autosomal recessive, early-onset Parkinson’s disease by Bonifati, V. (Vincenzo)

Autosomal recessive, early-onset
Parkinson’s disease
Vincenzo Bonifati
This study was performed at the Department of Clinical Genetics, Erasmus MC Rotterdam, 
The Netherlands.
Vincenzo Bonifati gratefully acknowledges the collaboration with the Department of Epidemiology 
and Biostatistics, Erasmus MC Rotterdam; the Department of Neurology, Erasmus MC Rotterdam; 
the INSERM U289, Hôpital de la Salpêtrière, Paris, France; and the Department of Neurological 
Sciences, University “La Sapienza”, Roma, Italy.
The printing of this thesis was supported by the “Internationale Stichting Alzheimer Onderzoek”, 
and Roche Nederland B.V.
Cover: incuse stater, a silver coinage of Sybaris, ca 550-510 b. C., and a masterpiece of the 
archaic art of the “Great Greece”.
ISBN 90-9017491-5
© V. Bonifati, 2003
No part of this book may be reproduced, stored in a retrieval system or transmitted in any form or 
by any means, without permission of the author. The copyright of the published papers remains 
with the publishers.
Layout: Tom de Vries Lentsch
Printed by: Optima Grafi sche Communicatie, Rotterdam
Autosomal recessive, early-onset
Parkinson’s disease
Proefschrift
Ter verkrijging van de graad van doctor
aan de Erasmus Universiteit Rotterdam
Op gezag van de Rector Magnifi cus
Prof.dr.S.W.J. Lamberts
en volgens besluit van het College voor Promoties
De openbare verdediging zal plaatsvinden op
woensdag 10 december 2003 om 13.45 uur
door
Vincenzo Bonifati
geboren te Castrovillari
Promotiecommissie
Promotoren: Prof. dr. B.A. Oostra
 Prof. dr. P. Heutink
Overige leden: Prof. dr. C.M. van Duijn
  Prof. dr. M.H. Breuning
 Dr. J. C. van Swieten
Contents
Introduction
1.1 Genetics of the Mendelian forms, and genome-wide linkage screens in
classical forms of Parkinson’s disease
11
1.2 Pathogenesis of Parkinson’s disease – the contribution of D-synuclein and 
parkin
43
1.3 Scope of this thesis 63
Experimental work
2.1 Association between early-onset Parkinson’s disease and mutations in 
the parkin gene
69
2.2 Three parkin gene mutations in a sibship with autosomal recessive early 
onset parkinsonism
79
2.3 Pseudo-dominant inheritance and exon 2 triplication in a family with
parkin gene mutations
85
2.4 How much phenotypic variation can be attributed to parkin genotype? 91
2.5 PARK7, a novel locus for autosomal recessive early-onset parkinsonism, 
on chromosome 1p36
103
2.6 Localization of autosomal recessive early-onset parkinsonism to
chromosome 1p36 (PARK7) in an independent dataset
111
2.7 Clinical features and neuroimaging of PARK7-linked parkinsonism 117
2.8 Mutations in the DJ-1 gene associated with autosomal recessive
early-onset parkinsonism
127
2.9 Linking DJ-1 to neurodegeneration 139
1
2
3 General discussion 147
Summary 161
Samenvatting 163
Riassunto 166
Curriculum Vitae 168
Selected publications 169
Dankwoord 173
Publications based on the studies described in this thesis
Chapter 1.1
Bonifati V, Heutink P. Chromosome 1 and other hotspots for Parkinson disease genes. In: Kahle 
P and Haass C (Editors), Molecular Mechanisms of Parkinson’s Disease. Landes Bioscience 
Publishers, in press.
Chapter 2.1
Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, 
Denefl e P, Wood NW, Agid Y, Brice A. Association between early-onset Parkinson’s disease and 
mutations in the parkin gene. New England Journal of Medicine 2000; 342: 1560-1567.
Chapter 2.2
Bonifati V, Lucking CB, Fabrizio E, Periquet M, Meco G, Brice A. Three parkin gene mutations in 
a sibship with autosomal recessive early onset parkinsonism. Journal of Neurology Neurosurgery 
and Psychiatry 2001; 71: 531-534.
Chapter 2.3
Lucking CB, Bonifati V, Periquet M, Vanacore N, Brice A, Meco G. Pseudo-dominant inheritance 
and exon 2 triplication in a family with parkin gene mutations. Neurology 2001; 57: 924-927.
Chapter 2.4
Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, Fraix V, Broussolle E, 
Horstink MW, Vidailhet M, Verpillat P, Gasser T, Nicholl D, Teive H, Raskin S, Rascol O, Destee A, 
Ruberg M, Gasparini F, Meco G, Agid Y, Durr A, Brice A. How much phenotypic variation can be 
attributed to parkin genotype? Annals of Neurology 2003; 54: 176-185.
Chapter 2.5
van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, Testers 
L, Breedveld GJ, Horstink M, Sandkuijl LA, van Swieten JC, Oostra BA, Heutink P. PARK7, a novel 
locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. American Journal 
of Human Genetics 2001; 69: 629-634.
Chapter 2.6
Bonifati V, Breedveld GJ, Squitieri F, Vanacore N, Brustenghi P, Harhangi BS, Montagna P, 
Cannella M, Fabbrini G, Rizzu P, van Duijn CM, Oostra BA, Meco G, Heutink P. Localization of 
autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent 
dataset. Annals of Neurology 2002; 51: 253-256. 
Chapter 2.7
Dekker M, Bonifati V, van Swieten J, Leenders N, Galjaard RJ, Snijders P, Horstink M, Heutink 
P, Oostra B, van Duijn C. Clinical features and neuroimaging of PARK7-linked parkinsonism.
Movement Disorders 2003; 18: 751-757.
Chapter 2.8
Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, 
Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn 
CM, Oostra BA, Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-
onset parkinsonism. Science 2003; 299: 256-259.
Chapter 2.9
Bonifati V, Oostra BA, Heutink P. Linking DJ-1 to neurodegeneration offers novel insights for 
understanding the pathogenesis of Parkinson’s disease. Journal of Molecular Medicine, in press.


1Introduction

11
Genetics of the Mendelian forms, and genome-wide linkage 
screens in classical forms of Parkinson’s disease
INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease, with a prevalence of 1-2% in the population aged t 65 years.1
The disease is clinically defi ned by the presence of parkinsonism (the combination of 
akinesia, resting tremor, and muscular rigidity), and a good response to dopaminergic 
therapy. These features are associated at pathological level with neuronal loss and 
gliosis, mainly in the substantia nigra pars compacta but also in other brain areas, and 
formation of cytoplasmic inclusions called Lewy bodies (LB) and Lewy neurites in the 
surviving neurons.2 The role of genetics versus environment in the etiology of PD has 
been a matter of debate for more than a century, with alternating fortunes. 
Genetics versus Environment
Strong support for the “environmental” theories came from the occurrence of post-
encephalitic parkinsonism after the pandemia of infl uenza in the early 1900s, and 
after the more recent discovery of permanent parkinsonism in humans caused by 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a substance similar to widely used 
pesticides.3 However, the disease has survived the era of the post-encephalitic cohort, 
and despite the epidemiological association of PD with environmental factors such as 
rural living and occupational exposure to pesticides, a putative MPTP-like toxin causing 
PD has not been identifi ed yet.
Familial aggregation of PD has been noted for long,4, 5 re-emerging consistently in 
the subsequent surveys6, 7 until the current time,8, 9 and supporting a role for genetic 
factors.
Studies in PD twins, however, have produced confl icting results. According to the 
largest of such studies,10 the pattern of concordance in monozygotic versus dizygotic 
twins differs critically on the basis of PD onset age, in keeping with a prominent role 
for genetic factors in early onset cases (before 50 years of age, according to that 
study), but a negligible role in late-onset PD, which represent the vast majority of cases. 
However, the sample size was still relatively small (less than 200 twins with PD), and the 
study was based on a cross-sectional, clinical survey.10 The period elapsing before a 
co-twin develops clinically overt PD, becoming concordant, can be as long as 20 
years,11 indicating that a longer follow-up is important in studying PD twins. Moreover, 
when positron emission tomography was used to assess the integrity of the nigrostriatal 
dopaminergic system, the concordance between monozygotic twins appeared 
signifi cantly higher than that of dizygotic twins, once again supporting the role of 
genetic factors.12
PD appears today as a sporadic disorder in most patients. However, in a signifi cant 
percentage of cases (10-15% in most studies), the disease runs in families without 
a clearcut Mendelian pattern of inheritance. Recent segregation analyses found 
evidence for a major gene with reduced, age-related penetrance.8, 13 However, these 
studies might be biased toward segregation patterns consistent with major genes 
depending on the ascertainment strategy, and the observed scenario also supports 
the contention of common PD being a complex trait determined by several genetic 
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as well as non-genetic factors. More rarely, the PD phenotype is transmitted as a 
Mendelian trait, with either autosomal dominant or recessive inheritance. 
In the last few years, family-based linkage analysis and positional cloning has led to 
the identifi cation of loci and genes for rare monogenic forms (table 1),14, 15 and more 
recently, of loci harbouring susceptibility genes for common, non-Mendelian PD forms 
of late-onset (table 1).16, 17 Although the monogenic forms so far identifi ed explain a 
very small fraction of PD cases at the population level, they are proving to be extremely 
useful in promoting the understanding of the molecular events and the metabolic 
pathways involved in the common forms of PD as well.
In the light of these fi ndings, the old debate of whether PD is inherited or acquired is 
gradually loosing ground, and more plausible questions are today: 
x is PD a single disease with multiple etiologies, or a group of distinct diseases 
with similar clinical and/or pathological endpoints? 
x how many genes do contribute to determine the susceptibility to common, 
late-onset PD? 
x do different genes play a role in different subgroups of common PD? 
Thanks to the knowledge resulting from the Human Genome project18, 19 and the 
technological revolution in molecular genetics, it is possible to translate these questions 
into feasible research programs.
In this chapter, the growing literature about loci and genes for monogenic forms of PD 
will be reviewed. Moreover, the results of genome-wide screens addressing directly the 
problem of the genetic bases of the common, non-Mendelian forms of the disease will 
be discussed.
Table 1.
Locus
*
PARK1
PARK2
PARK3
PARK4
PARK5
PARK6
PARK7
PARK8
PARK9
PARK10
PARK11
Pending
OMIM
#168601
#600116
602404
605543
191342
605909
#606324
607060
606693
606852
607688
601828
Map position
4q21-q23
6q25-q27
2p13
4p15
4p14
1p36-p35
1p36
12p11-q13
1p36
1p32
2q36-q37
2q22-q23
Gene
α-synuclein
parkin
unknown
unknown
UCH-L1
unknown
DJ-1
unknown
unknown
unknown
unknown
NR4A2 (NURR1)
Inheritance
dominant, high penetrance
recessive
dominant -incomplete penetrance
dominant, high penetrance
dominant
recessive
recessive
dominant - incomplete penetrance
recessive
non-Mendelian
non-Mendelian
dominant
Pathology
LB +
mostly LB negative
LB +
LB +
unknown
unknown
unknown
LB negative
unknown
unknown
unknown
unknown
Ref.
25
142
61
72
79
129
130
94
131
16
17
107
* Named according to HUGO Gene Nomenclature Committee (http://www.gene.ucl.ac.uk/nomenclature)
Current catalogue of genes and loci for PD
THE AUTOSOMAL DOMINANT FORMS OF PD 
PARK1/α-synuclein
A fi rst monogenic PD form was mapped to chromosome 4q21-q23 in 1996, in a large 
Italian-American family known as the “Contursi kindred” (named after the village of 
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origin in Southern Italy), with autosomal dominant PD and Lewy body pathology.20-22
The identifi cation of PARK1 heralded the beginning of the era of genome-wide linkage 
approaches to the genetic bases of PD. Soon after this fi rst form was localised, the 
etiological heterogeneity of PD became evident, as linkage to PARK1 was excluded in 
most autosomal dominant families examined.23, 24
One year later, a missense mutation, A53T, was identifi ed in the gene encoding 
D-synuclein, which co-segregated with PD in the Contursi family and three unrelated, 
smaller Greek kindreds.25 The geographical proximity and historical ties between 
the Southern part of Italy and Greece suggested the possibility of a founder effect 
for the A53T mutation, which was later supported by haplotype analysis.26 The A53T 
mutation has been found in at least fi fteen more families, all of Greek ancestry,27-30
and a second mutation, A30P, was identifi ed in a single German family.31 However, 
extensive mutational analysis in large series of sporadic and familial PD cases were 
negative, in keeping with results from earlier linkage studies, and delineating mutations 
in D-synuclein as a very rare cause of PD.32-39
Nevertheless, the discovery of D-synuclein mutations in PARK1 was a major breakthrough 
for the whole PD fi eld. Not only was it the fi rst identifi ed genetic cause of the disease, but 
especially, it allowed researchers to identify the D-synuclein protein as one of the major 
components of Lewy bodies in classical PD40 and Lewy body dementia,41 and of the 
glial cytoplasmic inclusions in multiple system atrophy,42 a group of neurodegenerative 
disorders also collectively termed “alpha-synucleinopathies”.43
In recent years, several transgenic models have been generated in rodents, fl ies, and 
worms expressing the human wild-type or mutant D-synuclein gene carrying the A53T or 
A30P mutation.44-50 These models show varying degrees of biochemical, pathological 
and behavioural abnormalities reminiscent of PD, and they provide further support to 
the contention that derangements in the D-synuclein pathways are a primary event 
in the pathogenesis of PD. Although mutations in its gene are very rare, D-synuclein
protein plays therefore a central role in PD.
Polymorphisms in the promoter and in a regulatory element 10 kb upstream of the gene 
infl uence D-synuclein expression in cell culture systems. Alleles conferring increased 
expression levels could conceivably act as risk factors for PD.51-53 However, most of the 
studies published so far found no association between these polymorphisms and PD,54-
57 while the fi nding of D-synuclein haplotypes associated with PD awaits replication in 
independent datasets.58
In comparison with classical PD, the clinical phenotype associated with mutations in 
D-synuclein is characterized by an earlier onset (on average in the mid forties), and 
reduced prevalence of tremor.21, 28-30 As tremor is generally less common in early-onset 
PD, a reduced prevalence of tremor in PARK1 might merely refl ect the earlier onset 
age instead of being a consequence of the specifi c etiology. The occurrence of cases 
with rapid progression, dementia, myoclonus, and severe autonomic dysfunctions 
indicates that PARK1 can present as a more widespread neurodegeneration than 
classical PD,21, 28 as confi rmed by recent autopsy studies.59 However, in recent analyses 
of Greek patients carrying the A53T mutation, clinical features and disease course 
appear similar to classical PD,29, 30 and the phenotype is also similar to common PD in 
the German family with the A30P mutation.60 The phenotypical spectrum associated 
with mutations in D-synuclein appears therefore broad, and a wide variability of onset 
ages is observed in the same family.21, 27, 60 This suggests that other genetic, as well as 
non-genetic, factors are most likely playing a role as disease modifi ers.
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PARK3
A second locus for autosomal dominant PD was mapped to chromosome 2p13 in 
a genome-wide scan using large kindreds of European ancestry.61 Four of the six 
families examined yielded support for linkage. The phenotypical spectrum is wide, 
encompassing typical PD of late onset (average onset age of 59 years) and Lewy body 
pathology, but also cases with dementia in addition to parkinsonism, and presence of 
neurofi brillary tangles and senile plaques in addition to Lewy body pathology.62-64  A 
2p13 haplotype is shared by affected individuals in two of the linked families, which 
originate from Northern Germany and Southern Denmark, suggesting the presence of 
a founder mutation. Moreover, on the basis of haplotype analysis, a low penetrance 
(40%) was estimated for the mutation.61 However, the “founder” haplotype was not 
carried by other PD cases collected from the regions of origin of the families initially 
linked to PARK3,65 and linkage to the 2p13 region has not been replicated in other large 
kindreds.
Fine mapping studies refi ned the PARK3 critical region to 2.5 Mb on the physical map, 
but mutational screening of the genes contained in the region has been negative 
so far.66-68 More recently, a genome-wide scan of affected sib-pairs has analysed the 
onset age of PD (instead of the disease status) as the phenotype of interest.69 In this 
study, suggestive evidence for linkage was detected to the PARK3 region, confi rming 
that an important genetic determinant of PD risk and/or modifi er of disease onset age 
might reside in this region. 
PARK4
A large kindred of Iowan origin with autosomal dominant parkinsonism-dementia 
complex and Lewy body pathology could be ascertained by the fi nding of a common 
ancestor pair for two independently reported families.70, 71 A genome-wide search for 
linkage yielded suggestive evidence for the gene defect being located in a region 
on chromosome 4p15.72 The average onset age is 34 years, and average disease 
duration to death is ~8 years. In addition to parkinsonism, affected individuals also 
show severe autonomic dysfunctions, body weight loss, and dementia. Pathology 
shows widespread Lewy bodies, and vacuolisation of brain tissue.70, 71, 73 The clinical and 
pathological spectrum in this family is closer to Lewy-body dementia than to classical 
PD. In addition to patients with the severe clinical form, some carriers of the linked 
haplotype presented with postural tremor only, suggesting that the genetic defect 
might be associated with a very wide range of phenotypes including forms similar to 
essential tremor. This is intriguing in the light of the frequent familial aggregation of PD 
and essential tremor.74 However, a cautionary view seems warranted, as the statistical 
threshold to declare signifi cant linkage at genome-wide level was not reached for 
PARK4 in the initial report, nor was linkage to the 4p15 region replicated in other studies 
since then. 
PARK5/ubiquitin C-terminal hydrolase-L1 (UCH-L1) 
The UCH-L1 gene, located at chromosome 4p14, encodes a 26 kD protein which 
catalyses the hydrolysis of ubiquityl-peptide conjugates in vitro.75 UCH-L1 was therefore 
thought to be important for the recycling of free ubiquitin molecules from the ubiquityl-
peptides fragments produced by the proteasome. However, recent fi ndings in vivo
suggest that the function of UCH-L1 is rather to stabilize the neuronal mono-ubiquitin 
levels by binding mono-ubiquitin and preventing its degradation.76
UCH-L1 is abundant in neurons representing 1-2 % of brain proteins, and it has been 
found in Lewy bodies as well.77 Moreover, a mouse mutant with a homozygous 
Chapter 1.1
15
intragenic deletion of the UCH-L1 gene (the gracile axonal dystrophy mouse) develops 
progressive neuronal degeneration of sensory and motor pathways with accumulation 
of ubiquitylated inclusions.78 For all these reasons, UCH-L1 is considered a candidate 
gene for PD. In the Iowan family with PD linked to a nearby chromosomal region (4p15, 
PARK4), the UCH-L1 gene could be excluded by recombination analysis.72 Linkage 
to the region containing the UCH-L1 gene (4p14) has not emerged in other genome 
scans for PD. 
A single missense mutation (I93M) was found in two German sibs with classical 
PD and a positive family history suggesting autosomal dominant inheritance and 
incomplete penetrance.79 Pathological studies have not been reported in this family. 
The I93M mutation is associated with a marked decrease of the hydrolase activity 
of the protein, and could therefore cause disease by haploinsuffi ciency.79 However, 
subsequent screening of this gene for this and other mutations has consistently been 
negative, suggesting that I93M is either an extremely rare cause of PD or even a neutral 
polymorphism.80-83 However, a different polymorphism (S18Y) in this gene is inversely 
associated with PD in several,84-87 but not all,88-90 studies. The Y18 allele could exert a 
protective role, which seems stronger in early onset cases and for the homozygous 
carriers.91, 92
Last, the report that UCH-L1 also displays a dimerization-dependent ubiquitin ligase 
activity for D-synuclein in vitro lends further support to the contention that UCH-L1 is 
implicated in the pathogenesis of PD.93 The Y18 variant exhibits reduced ubiquitin ligase 
activity for D-synuclein in vitro, and it has been proposed that it could protect from PD 
by altering the balance between the ubiquitin ligase and hydrolase activity of UCH-
L1.93 Another hypothesis, which remains to be tested, is that the Y18 variant infl uences 
the recently discovered ubiquitin-stabilising activity of UCH-L1.
PARK8
This novel locus for autosomal dominant PD was identifi ed in a large pedigree, named 
the “Sagamihara family” from the region of origin in Japan.94 Clinical features in affected 
individuals of the kindred are reported to resemble very closely classical PD, with an 
average disease onset at 51 ± 6 years.95 Yet, a pattern of “pure nigral degeneration” 
without Lewy bodies was found at autopsy in four PD patients examined. Moreover, 
one carrier of the disease-linked haplotype developed pathologically-confi rmed 
striatonigral degeneration, an atypical form of parkinsonism which is known to be 
associated with D-synuclein-positive brain pathology.94
In this family, a genome-wide scan yielded signifi cant evidence for linkage of PD to the 
centromeric region of chromosome 12. The haplotype analysis suggests an incomplete 
penetrance of the mutation. This is of interest because an incomplete, age-related 
penetrance could have masked a Mendelian pattern in other smaller PD families. 
Interestingly, linkage to the same region was found in a genome scan for Alzheimer’s 
disease (AD), the locus being termed AD5, but this linkage was mostly supported by 
the subset of AD families containing at least one affected individual with Lewy body 
pathology.96 Lastly, within a genome scan in a set of 22 families with parkin gene 
mutations, the centromeric region of chromosome 12 yielded the strongest evidence 
of linkage.97 Taken together, these fi ndings suggest that a single locus in this region 
might control susceptibility to a wide range of clinical and pathological phenotypes 
(with or without Lewy bodies). Confi rmation of linkage to PARK8 in other PD families has 
not been reported yet, and the defective gene at this locus remains unknown.
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The NR4A2 gene
The NR4A2 (NURR1) gene, located at 2q22-q23, encodes a member of the nuclear 
receptor superfamily of transcription factors, which is highly expressed in fetal and 
adult dopaminergic (DA) neurons.98, 99 Previous studies showed that NR4A2 is important 
for the genesis and maintenance of dopaminergic neurons. In NR4A2 knock-out mice 
agenesis of DA neurons is observed.100, 101 The NR4A2 hemyzygous mice develop a 
normal set of DA neurons and normal dopamine brain levels, but they show increased 
susceptibility to the dopaminergic neurotoxin MPTP,102 which is also a cause of toxic 
parkinsonism in humans.3
NR4A2 has been considered an excellent candidate for PD for long. However, linkage 
to its chromosomal region has not been found in genome scans, and the NR4A2 locus 
was excluded by linkage and haplotype analysis in families with PD compatible with a 
recessive model of inheritance.103
Evidence for association between a polymorphic variant in intron 6 (IVS6+18 insG) and 
PD has been reported in two studies.104, 105 However, these were based on small samples, 
and the association was detected only in homozygous,104 or only in heterozygous 
carriers105 in the different datasets. The interpretation and relevance of these fi ndings 
remain controversial, also because no data were provided about the functional effects 
of the IVS6+18 insG polymorphism. A third study did not fi nd association between PD 
and three polymorphisms in the NR4A2 gene, including IVS6+18 insG.106
More recently, two heterozygous mutations (-291Tdel and –245TńG) in the non-coding 
region (exon 1) of NR4A2 were identifi ed in 10 out of 107 patients with familial PD.107 In 
most of these ten cases, family history for PD was present in at least two generations, 
suggesting a dominant pattern of inheritance. Onset age (54 ± 7 years) and other 
clinical features were those of typical PD in patients carrying the mutation, whereas 
the associated neuropathology remains unknown. The mutations showed complete 
co-segregation with the disease in families, and absence from control individuals. 
Haplotype analysis suggested a founder effect for the more frequent mutation 
(-291Tdel) in families of German ancestry. The mutations infl uence the expression of 
the gene, and are associated with dramatic decreases of the NR4A2 mRNA levels 
in both transfected cell cultures and in lymphocytes from patients. Moreover, the 
mutations are associated with reduced expression of tyrosine hydroxylase, one of 
the genes targeted by NR4A2.107 In transfected cell lines and patients lymphocytes, 
heterozygous mutations are associated with more than 50% reduction in NR4A2 mRNA 
levels, suggesting a dominant negative effect for these mutations.107 While this would fi t 
with the pattern of inheritance observed in these PD families, the mechanism by which 
the mutation in one allele of NR4A2 could affect the expression of the other allele 
remains unknown. One can speculate that a motif in the mRNA might interfere with 
the other allele, or it might interact with some regulatory DNA- or RNA-binding protein 
in a dominant negative fashion. The discovery of mutations in NR4A2 associated with 
familial PD is an important fi nding. However, evaluation of this gene in other cohorts of 
PD families is warranted in order to accurately assess the frequency of these as well as 
other types of mutations in this gene. The screening of exon 1 of NR4A2 in independent 
datasets has been negative so far, suggesting that mutations is this gene, at least those 
localised in exon 1, are a very rare cause of PD.108-110
Synphilin-1 and susceptibility to PD 
Synphilin-1 is a 919 amino acid polypeptide with different domains involved in 
protein-protein interactions, which was fi rst identifi ed in a yeast two-hybrid screen as 
an interactor of D-synuclein.111 Like D-synuclein, synphilin-1 is enriched in presynaptic 
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terminals, and associates with synaptic vesicles, suggesting interaction with D-
synuclein.112 However, the exact function of synphilin-1 remains unknown.
Synphilin-1 is encoded by the SNCAIP gene, located on chromosome 5q23, and is 
expressed in many tissues and brain areas.113 Immunoreactivity for synphilin-1 is present 
in Lewy bodies in PD and Lewy body dementia, and in glial cytoplasmic inclusions in 
MSA, suggesting that deposition of synphilin-1 is a feature of synucleinopathies.114-116
Overexpression of synphilin-1 alone or in combination with parkin or D-synuclein yields 
ubiquitin positive, cytoplasmic inclusions suggesting a role for synphilin-1 in promoting 
protein aggregation.111, 117, 118
The observation that parkin and dorfi n, two ubiquitin ligases also found in Lewy bodies, 
interact with, and ubiquitylate synphilin-1, suggests that these ligases and D-synuclein
could be involved in a common pathogenic mechanism through the interaction with 
synphilin-1.117, 118
Suggestive evidence for linkage to the chromosomal region containing the SNCAIP
gene (5q) has been detected in different genome screens of late-onset PD,16, 97, 119
making the SNCAIP locus a candidate gene for susceptibility to classical PD. Earlier 
mutation screening of the SNCAIP gene in PD failed to identify any mutation.120, 121
However, a heterozygous missense mutation (R621C) has recently been identifi ed in 
two sporadic German patients with late-onset PD.122 The mutation was absent in a 
large number of control chromosomes, and it appeared to be functionally important 
because in transfected cells it reduced the formation of inclusions in comparison to 
wild type synphilin-1, and increased the susceptibility to staurosporine-induced cell 
death. These fi ndings confi rm that synphilin-1 promotes the formation of inclusions, 
and suggest that it protects cells against stress. Haploinsuffi ciency of synphilin-1 could 
therefore be a risk factor for neurodegeneration, but further work is needed to clarify 
whether genetic variation, including alterations in gene copy number, in SNCAIP
infl uences susceptibility to PD.
Final remark
It is likely that other autosomal dominant forms of PD will be identifi ed in the future as 
most of the previous loci have been excluded in additional pedigrees.123-126 We have 
recently obtained suggestive evidence for linkage to chromosome 19 in a Cuban 
family segregating clinically typical PD of late-onset.127 The pathology of this form 
remains unexplored. 
THE AUTOSOMAL RECESSIVE FORMS OF PD 
Autosomal recessive forms of PD are increasingly recognized, especially among cases 
with early onset (AREP). In Europe, half of the AREP families and almost 20% of isolated 
cases with onset before age of 45, are explained by mutations in the parkin gene
(PARK2 locus).128 The fact that in the remaining AREP families and isolated cases parkin
mutations are not found, clearly suggests the existence of other genes involved. In 
fact, three independent studies have detected linkage to close regions on the short 
arm of chromosome 1 in AREP families, the new loci being termed PARK6, PARK7, and 
PARK9 (fi gure 1).129-131 Yet, linkage exclusion data suggest that additional AREP loci 
remain to be mapped. The responsible gene at PARK7 locus, DJ-1, has been recently 
identifi ed.132 The focus on the short arm of chromosome 1 has been further highlighted 
by the detection of linkage for common PD in the Icelandic population in a fourth, 
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more centromeric region (1p32, fi gure 1).16 This region was also detected in another 
genome search for determinants of the PD onset age.133
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Figure 1. Chromosome 1p map illustrating the position of the novel PD-related loci.
PARK2/parkin
An autosomal recessive form of juvenile parkinsonism (AR-JP) was fi rst described in 
Japanese families,134-136 and a locus for AR-JP was mapped in 1997 to the long arm 
of chromosome 6.137 Subsequent studies confi rmed the linkage to the same region in 
families from several ethnic groups, refi ning the critical interval and delineating PARK2 
as an important locus for early-onset parkinsonism worldwide.138-140
The defective gene of the PARK2 locus was identifi ed, by positional cloning, within a 
microdeletion observed in one of the linked families and termed “parkin”.141, 142 The 
gene extends over more than 1 Mb on chromosome 6. It contains 12 exons, and is 
expressed ubiquitously in the brain, as well as in many extra-cerebral tissues. A survey 
of human cDNA libraries142 and RT-PCR amplifi cation of brain mRNA143 suggest that a 
splice variant is also expressed that lacks exon 5, and encodes an in-frame protein 
lacking 28 amino acids. A different variant lacking exons 3-5, found in RT-PCR analysis 
from human leukocytes, remains unconfi rmed.143 Last, evidence of a splice variant 
encoding a truncated protein has been found for the mouse parkin homolog.144
Homozygous exon deletions were initially reported in patients from different Japanese 
families with AR-JP.142 A large number of mutations in the parkin gene have since been 
identifi ed in families from different populations.83, 128, 145-191 In addition to point mutations, 
large genomic rearrangements (leading to exon deletions and multiplications) are 
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frequently detected, in homozygous or heterozygous state, indicating the importance 
of gene dosage techniques for a sensitive screening of parkin.128, 154, 174 Data from large 
and comprehensive studies indicate that mutations in this gene are responsible for 
about half of the PD families compatible with recessive inheritance and onset before 
age of 45 years, as well as about 15-20 % of sporadic cases with onset before 45 
(chapter 2.1).169, 174 Among the sporadic cases, most of the mutations are found in 
those with a very early-onset (before age of 30) (chapter 2.1)169, whereas after that 
age of onset, mutations in this gene are a much rarer fi nding. In a few families a second 
mutation has not been found even after gene dosage analysis or sequencing of the 
promoter region, suggesting that other mutations (likely in intronic or regulatory regions 
of the gene) still escape detection, or that some of the mutations might be suffi cient to 
cause disease in a heterozygous state.128, 165
The parkin gene promoter has been characterized,192, 193 and ten single nucleotide 
polymorphisms (SNPs) have been identifi ed.165, 194 One of these variants (-258 T/G) is 
located in the core promoter region and the “G” allele is associated with a decreased 
gene expression in cell culture assays.195 The frequency of the “G” allele was increased 
among PD cases with borderline signifi cance, suggesting that this variant can increase 
the risk of late onset PD. 
Reports of parkinsonism and heterozygous parkin mutation in multiple generations also 
suggests that parkin-related disease might sometimes be dominantly inherited.151, 155, 171
PET studies in asymptomatic carriers of heterozygous parkin mutations have revealed 
slight abnormalities of the nigrostriatal pathways, supporting the contention that single 
heterozygous mutations in parkin might be suffi cient to cause subclinical or even overt 
PD, by haploinsuffi ciency of dominant negative mechanism.196, 197 However, pseudo-
dominant inheritance could also explain the disease in multigeneration families. This 
phenomenon has already been documented in different Japanese and Italian families 
(chapters 2.2, 2.3),152, 198 once again indicating that parkin gene mutations might be 
frequent in some populations. 
Haplotype analyses of the recurrent parkin mutations suggest the occurrence of 
a founder effect for some of the point mutations;199, 200 on the contrary, the exon 
rearrangements seem to have arisen from independent mutational events.199 Several 
polymorphisms have been identifi ed in the parkin gene, including missense changes.146,
149, 201 The allelic frequencies show wide variations between ethnic groups, with the 
Ser167Asn and Val380Leu polymorphisms being most frequent among Orientals and 
Caucasians, respectively.149, 201 Other variants are virtually population-specifi c, like 
the Arg366Trp in Orientals and the Asp394Asn in Caucasians.149, 201 The results of allelic 
association studies of these polymorphisms in classical PD have been rather confl icting, 
but none of the analysed variants seems to have strong effects on the risk of classical 
PD.194, 201-209
Only a few brains from patients with parkin mutations have been examined so far.135,
155, 175, 210-214 The commonly observed pathological features were neuronal loss and 
gliosis in the substantia nigra pars compacta and locus coeruleus with deposition of 
extraneuronal melanin in the substantia nigra. In single cases, the neurodegeneration 
was more widespread, including the substantia nigra pars reticulata,175, 211 and the 
spinocerebellar system.213 Lewy bodies were absent in all but one case, who was 
a compound heterozygous carrier of a deletion of 40 bases within exon 3 and the 
missense mutation R275W.155 The last mutation is probably associated with residual 
protein function.117 Interestingly, tau-positive inclusions were found in neurons and 
astrocytes in some of these brains,210, 211, 213 and recently, clinically and pathologically 
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confi rmed progressive supranuclear palsy, another tauopathy, has been reported in 
a carrier of a single heterozygous parkin mutation.214 If these represent coincidental 
fi ndings, or whether tau pathology is in the spectrum of parkin disease remains unclear. 
It would be interesting to screen the parkin gene in tauopathies, and to explore a 
possible interaction between tau and parkin proteins. Perhaps the fi rst description of 
tau pathology in the “parkin disease” dates back to 1989, when Rajput and colleagues 
reported four cases of early-onset levodopa-responsive parkinsonism, with very long 
disease course, absence of Lewy bodies but presence of neurofi brillary tangles in 
substantia nigra and locus coeruleus.215 The clinical and pathological features of these 
cases are strikingly similar to those of the patients with parkin mutations, but genetic 
studies on those brains have not been published yet.
Several studies with fl uorodopa and positron emission tomography (PET) in parkin 
disease have been based on small number of cases,166, 185, 196, 216, 217 and one report 
on a larger series has been published recently.218 These studies confi rm the presence 
of presynaptic dopaminergic dysfunction, as in common PD. Moreover, the PET 
abnormalities in parkin patients display some degrees of left-right asymmetry, although 
this might be less pronounced than in classical PD, and a clear rostro-caudal gradient 
(the putamen being more severely affected than caudate), as observed in classical 
PD.218 Interestingly, the severity of the PET abnormalities does not correlate with the 
clinical disability,218 and the PET abnormalities appear greater than the ones expected 
on the basis of clinical state. Last, a mild but signifi cant PET abnormality was observed in 
asymptomatic heterozygous carriers, suggesting the presence of subclinical disease.196,
197, 219 PET studies also confi rmed that the progression in parkin patients was slower than 
in classical PD.197 Results using the raclopride tracer suggest that the postsynaptic 
dopamine receptors might also be abnormal in parkin patients,196 but this remains to 
be confi rmed in larger studies. 
The protein encoded by the parkin gene possesses 465 amino acids and it contains 
an N-terminal domain homologous to ubiquitin (Ub-L), and two RING fi nger domains 
separated by an IBR (In-Between-RING) domain in the C-terminal part.142, 220 The Ub-L 
domain of parkin adopts the same fold of ubiquitin,221, 222 and it shares a motif with other 
Ub-L-containing proteins, which are known to interact with the proteasome.223 This 
suggests that parkin might also interact with the proteasome, providing a link between 
this last structure and the ubiquitylation machinery. The parkin protein has ubiquitin-
ligase activity, which is impaired by several mutations found in AREP patients.224-226
Different putative substrates for parkin-mediated ubiquitylation have recently 
been described, but their role in vivo remains unclear.117, 226-230 These substrates are 
expected to accumulate in neurons of patients with parkin-disease as a result of 
lack of ubiquitin-ligase activity. This, in turn, might cause neurodegeneration. The 
discovery of an interaction between parkin and a brain-specifi c, glycosylated form of 
D-synuclein, as well as between parkin and synphilin-1 have important implication for 
Parkinson’s disease in general, since these interactions might underlie the deposition 
of ubiquitylated D-synuclein in Lewy bodies.117, 228 To the extent that parkin activity is 
essential for Lewy body formation, its defect can explain the absence of Lewy bodies 
in the brain of patients with parkin mutations.
The clinical phenotype associated with parkin mutations is characterized by early onset 
parkinsonism, good response to levodopa and a benign, slow course. The average 
onset age was in the early 30s in European patients, but late-onset cases have been 
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described up to 70 years of age. Motor fl uctuations and levodopa-induced dyskinesias 
are present, whereas marked cognitive or vegetative disturbances seem rare. 
The age of disease onset is the most important predictor of parkin mutations in that 
the earlier the onset, the more frequent the mutations (chapters 2.1, 2.4).169 There are 
no specifi c clinical features that identify patients with parkin gene mutations from 
other early-onset forms (chapters 2.1, 2.4).169 However, symmetrical onset, dystonia at 
onset and hyperrefl exia, slower progression of the disease, and a tendency towards 
a greater response to levodopa might be more frequent among patients with parkin
mutations (chapter 2.4). The phenotypical spectrum overlaps with classical PD for late-
onset cases (chapter 2.4), and with dopa-responsive dystonia for early-onset ones.178
Rare atypical presentations have also been described, and a wide variability in onset 
ages and phenotype is observed even within the same families (chapter 2.4).171, 184-185, 187, 
200, 213 In conclusion, mutations in the parkin gene represent a frequent cause of familial 
early-onset and isolated juvenile parkinsonism. They must therefore be considered in 
the diagnostic work-up of early onset PD.
PARK7/DJ-1
The short arm of chromosome 1 is emerging as a hot spot for PD-related genes (fi gure 
1), as three novel loci for autosomal recessive forms of early onset (AREP) (PARK6, 
PARK7, and PARK9), and a locus controlling susceptibility to, and/or onset age of late-
onset PD (PARK10) have been mapped to chromosome 1p by fi ve different groups.16,
129-131, 133 Recently, the defective gene at the PARK7 locus, DJ-1, has been identifi ed 
(chapter 2.8). 
In the framework of a large research project for gene mapping in a genetically 
isolated population in the South West of The Netherlands (Genetic Research in 
Isolated Populations, GRIP), a large consanguineous pedigree was ascertained with 
four members affected by early-onset parkinsonism (the onset varying from age 27 
to 40 years). A genome-wide scan in this family using homozygosity mapping yielded 
signifi cant evidence for linkage to the chromosome 1p36 region, and this locus was 
named PARK7 (chapter 2.5). Linkage to the very same region was later confi rmed in 
a consanguineous pedigree from Central Italy with three affected members (chapter 
2.6).
Fine mapping studies and a positional cloning strategy led us to the identifi cation 
of mutations in the DJ-1 gene in the two defi nitely linked families (chapter 2.8). All 
patients of the Dutch kindred carry a homozygous deletion, which removes ~14 kb of 
genomic sequence, including 4 kb upstream of the DJ-1 start codon, and a large part 
of the coding region. In the Italian family, a homozygous missense mutation replaces 
the Leucine at position 166 with Proline (L166P) in the DJ-1 protein. The homozygous 
deletion found in the patients of the Dutch family represents a natural knockout of 
DJ-1, clearly indicating that the loss of function of DJ-1 is pathogenic. The L166P 
mutation is also likely to affect severely the function of DJ-1 because: 
(i) it replaces a highly conserved residue; 
(ii) it destabilizes a carboxy-terminal D-helix of the DJ-1 protein as predicted 
by structural models; 
(iii) it dramatically changes the subcellular localization of the DJ-1 protein in 
transfection experiments (chapter 2.8). 
Our computer-assisted modelling suggested a globular, D/E-sandwich to be the most 
likely structure for DJ-1 (chapter 2.8), which has recently been confi rmed by four 
crystallography studies.231-234
The human DJ-1 is organized in eight exons distributed over 24 kb of genomic DNA. The 
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fi rst two exons are non-coding and alternatively spliced in the two mRNA transcripts.132,
235 Northern blot analysis showed that DJ-1 is ubiquitously and highly expressed in the 
brain areas and extra-cerebral tissues.132, 235 Interestingly, using Northern analysis the 
expression seems more abundant in subcortical regions of the brain than in cortical 
areas. However, further work is needed to explore the regional pattern of DJ-1 
expression at the protein level. 
The genomic structures of the mouse and human DJ-1 genes are similar, and human 
and mouse DJ-1 proteins display 90% amino acid identity.235 Analysis of promoter 
activity using deletion constructs and luciferase assays in HeLa cells identifi ed an Sp1 
(Specifi city Protein1, a transcription factor) dependent site at position –100 from the 
transcription initiation site contributing most of the promoter activity.235
The human DJ-1 protein consists of 189 amino acids and belongs to the ThiJ/PfpI 
superfamily. Several members of this family of proteins are known in prokaryotes: ThiJ, 
involved in the thiamine synthetic pathway, PfpI and other proteases, araC and other 
transcription factors, the glutamine amidotransferase family, which includes some 
bacterial catalases, and fi nally a recently recognized family of bacterial chaperones 
(EcHsp31).
The exact function of the DJ-1 protein is unknown, but the literature suggests a role in 
the oxidative stress response, or in the response to misfolded proteins.236-239. Intriguingly, 
evidence of oxidative stress and protein misfolding has been documented in the brains 
of patients with PD,240, 241 and studies have shown that mutations in D-synuclein and 
parkin, two other PD-related genes, might also be linked to oxidative stress.242, 243
To date only a few mutational analyses in larger series of families and isolated 
early onset PD cases have been performed, and a total number of nine different 
mutations in DJ-1 have been identifi ed so far, including missense, truncating, splice site 
mutations, and large deletions (fi gure 2).132, 244-246 The identifi cation of novel, compound 
heterozygous mutations (including one truncating and one splice site mutation) in a 
further PD patient provides the strongest evidence so far, after our initial report,132 that 
DJ-1 mutations are pathogenic in early onset PD.244 For other mutations, especially 
the single heterozygous ones, a pathogenic role is not defi nitely demonstrated yet. 
While these fi ndings delineate DJ-1 mutations as the second most frequent identifi able 
genetic cause of PD after parkin, the frequency of DJ-1 mutations seems low, being 
estimated at about 1-2 % in early onset PD. The occurrence of heterozygous genomic 
rearrangements in DJ-1 emphasizes the importance of gene dosage assays for a 
sensitive screening. Gene dosage has been performed in only one study so far,246
and the other studies might have underestimated the frequencies of mutations. The 
identifi cation of larger numbers of DJ-1-related patients will allow accurate genotype-
phenotype correlation studies.
An autosomal dominant form of focal-segmental dystonia maps to 1p36 (the DYT13 
locus).247 The DYT13 critical interval overlaps for 6 cM with the PARK7 interval, and the 
DJ-1 gene is located in the region of overlap (fi gure 1). So far, linkage to this region 
has not been replicated in other dystonia families, and parkinsonian features have not 
been detected in the original DYT13-linked family. However, dystonic features such 
as laterocollis and blepharospasm are present in both the DJ-1-related families. This 
suggests that despite the differences in transmission pattern and clinical phenotypes, 
PARK7 and DYT13 might be allelic disorders; a mutational screening of the DJ-1 gene is 
therefore warranted in DYT13-linked families.
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Figure 2. Genomic structure of the DJ-1 gene and mutations identifi ed in PD. The dark and light boxes indicate 
non-coding and coding exonic sequence, respectively.  Two missense mutations observed in homozygous form 
are underlined. The Arg98Gln change is a rare, polymorphic variant observed in ~1.5% of control chromosomes 
in Caucasians.246
Pathological analysis of brains from patients with DJ-1-related forms is of great 
importance, but brain material is not currently available. Our recent fi nding that 
DJ-1 immunoreactivity co-localizes with pathological tau inclusions in different 
neurodegenerative disorders,248 suggests the involvement of this protein in the 
pathogenesis of tauopathies, and it raises the question of whether DJ-1-related
parkinsonism is also associated with tau pathology in the brain. If this would be the 
case, it would suggest the existence of a common pathological signature in DJ-1- and 
parkin-related forms, as tau pathology has been found in brains with parkin disease.210,
211, 213 It would also be interesting to investigate the expression of the DJ-1 protein in the 
brain with parkin disease and vice versa.
PARK6
This locus was fi rst identifi ed in a large Italian consanguineous family originating from 
Sicily.129 Four family members developed early-onset PD with onset ages ranging from 
32 to 48 years. A genome-wide scan provided signifi cant evidence for linkage to the 
short arm of chromosome 1, in the chromosomal region 1p36-p35. Haplotype analysis 
delineated a 12.5 cM homozygously inherited region in the affected members, fl anked 
by the markers D1S483 telomerically and D1S247 centromerically. A subsequent study 
analysed 28 smaller European AREP families, which did not carry mutations in the parkin
gene. Eight out of 28 families supported linkage to PARK6, suggesting this as a frequent 
locus.249 Of particular interest is a second consanguineous family from Central Italy, in 
which a recombination event would reduce the critical region to 9 cM. However, none 
of these families independently had enough statistical power to detect signifi cant 
linkage, and some of them also support linkage to the other recessive loci (PARK2 
and PARK7) (chapter 2.6). Considering the genetic heterogeneity of AREP and PD, the 
assignment of these families to PARK6 should therefore be considered as provisional. 
Relationships between PARK2, PARK6 and PARK7
Early onset of parkinsonism, slow disease progression, and good response to levodopa 
are unifying clinical features in different AREP forms, including parkin-related, DJ-1-
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related, and PARK6-linked families.128, 130, 250-253 This will make their differentiation diffi cult 
on clinical grounds, indicating the importance of genetic testing. In comparison 
with classical PD, the phenotype in the Dutch and Italian DJ-1-related families is 
characterized by an early onset and a slow progression (chapters 2.6 and 2.7). 
Interestingly, psychiatric disturbances (including severe anxiety in three cases, and 
psychotic episodes in one), early behavioural disturbances (one case), and dystonic 
features (including blepharospasm in two cases) have been reported in both families, 
and they might represent “red fl ags” for suspecting DJ-1 involvement.130, 251, 253 The 
presence of severe anxiety and panic attacks has indeed been noted in two further 
DJ-1-related patients identifi ed in a recent screen.245 However, a note of caution is 
warranted, as these psychiatric disturbances are non-specifi c, they are well known 
to occur in PD in general,254 and they are also described in patients with mutations in 
the parkin gene.138, 171 The analysis of larger case series is therefore needed in order to 
investigate whether psychiatric disturbances are more frequent among DJ-1-related
form than other PD forms. The average age at onset is in the early thirties for the parkin-
and DJ-1-related families, whereas the onset in PARK6-linked families might be slightly 
later (late thirties - early forties). The pathology of PARK6-linked and DJ-1-related forms 
is unknown. 
Recent positron emission tomography studies in PARK6-linked and DJ-1-related
patients showed: more uniform patterns of caudate/putamen dopaminergic terminal 
dysfunction in comparison with the one observed in classical PD; greater dopaminergic 
dysfunction than the one expected on the basis of clinical severity; a mild dysfunction 
in asymptomatic heterozygous PARK6 carriers.250, 253 These features also resemble the 
pattern observed in parkin-related disease, suggesting that these three AREP forms 
might be more similar to each other than to classical PD on pathophysiological 
grounds (chapter 2.7). 
The similarities between PARK6- and DJ-1-associated phenotypes, and the proximity of 
the two loci on chromosome 1p, raised the question of whether mutations in similar or 
functionally related genes underlie both forms. An alternative possibility is that, due to 
a large genomic rearrangement occurring in one of the linked families, linkage is found 
in seemingly different regions, while there is only one underlying, defective gene. To 
explore this possibility, a mutational analysis of the DJ-1 gene should also be performed 
in the original PARK6-linked family.
PARK9
This form has been initially described in a consanguineous family from a small community 
in the North of Jordan (Kufor-Rakeb region).255 In this kindred, fi ve siblings developed a 
multisystemic, neurodegenerative disease resembling the so-called pallido-pyramidal 
syndromes, and clinically characterized by onset below age of 20, akinetic-rigid 
parkinsonism (without tremor), pyramidal tract signs, supranuclear ophtalmoparesis, 
and cognitive deterioration. The progression is reported to be rapid, but the parkinsonian 
symptoms responded very well to levodopa therapy. Brain MRI showed progressive 
atrophy, starting from the pallidum and pyramids but later generalized. No pathology 
studies have been reported.255 A genome-wide scan in this family detected signifi cant 
evidence for linkage to the 1p36 region,131 and despite the fact that the multisystemic 
“Kufor-Rakeb syndrome” appears clinically quite different from PD, this locus has been 
designated as PARK9. Furthermore, the PARK9 critical interval overlaps with the DYT13 and 
PARK6 critical regions at the telomeric and the centromeric border, respectively (fi gure 1). 
PARK9 can therefore be allelic to one of these disorders. Identifi cation of the responsible 
genes at these loci will provide the answer to this question.
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GENOME-WIDE SCREENS IN NON-MENDELIAN PD FORMS
Families segregating PD as a monogenic trait, and large enough to be suitable for 
classical linkage mapping are very rare. Moreover, for the vast majority of cases, 
parkinsonism runs in families without a clearcut Mendelian pattern and a highly 
variable expression, suggesting a complex multifactorial etiology. In this scenario, it 
has been suggested that it might be more feasible to perform genome-wide scans in 
series of small PD families containing 2 affected relatives (sibling pairs or other relative 
pairs).256 Such families are not rare, and collecting large numbers is not diffi cult in the 
framework of multi-centric consortia. In these studies, non-parametric, model-free 
methods are often used. These methods are very robust because they do not require 
a genetic model to be specifi ed.256 The methods are based on the general principle of 
comparing the observed number of alleles shared identical-by-descent (IBD) between 
pairs of affected relatives versus the numbers expected under the null hypothesis of 
no linkage.256 For example, at a given locus, the distribution of IBD sharing by sibling 
pairs under the null hypothesis is: 0 alleles (in 25% of the pairs), 1 allele (50% pairs), and 
2 alleles (25% pairs). Any deviation from this distribution in the direction of an excess of 
allele sharing is considered as evidence of linkage, and the results can be expressed as 
LOD scores as in classical linkage analysis. As for all available methods this approach 
is not free from limitations and caveats. Since a large number of families are used, 
genetic heterogeneity infl uences greatly the outcome of such studies. Depending 
on the number and magnitude of genetic risk factors involved, and the risk allele 
frequencies, large sample sets are often needed to obtain meaningful data.256-258
The estimates of risk ratios for PD in fi rst-degree relatives of PD patients compared to 
general population range widely (from 1.3 to 9.7),259 but in several studies the fi gures 
cluster around the value of 3. Specifi c recurrence risks for siblings (Osibs) have been 
estimated only rarely.9 Assuming the contribution of a single genetic effect and Osibs
values around 3, the number of affected sibling pairs (ASPs) needed to have enough 
power to detect linkage at 0.05 genome-wide signifi cance level is estimated to be 
in the order of 200-300. However, the number of ASP needed increases sharply (to 
the order of thousands) if several genetic effects (each of smaller magnitude) are 
involved.256-258
Modelling the disease defi nition and phenotype boundaries is another critical issue 
in PD genetics. Models with narrower or broader disease defi nitions can be used. The 
statistical corrections needed to declare signifi cant linkage using multiple comparisons 
when several clinical models using the same dataset, or when subsets are analysed 
after stratifi cation of the whole dataset are still debated. Replication of positive fi ndings 
between different datasets is therefore important in order to identify genuine linkages. 
Furthermore, regions found using these approaches are usually very large (because 
ASPs are closely related so the region shared IBD is large) and therefore, follow-up 
studies to pinpoint the location of the relevant gene are diffi cult. 
The results of four genome-wide scans in families with affected relative pairs (ARP) with 
classical PD have been published so far (table 2).16, 97, 119, 260 Moreover, two of the same 
datasets have been reanalysed in search of modifi ers of PD onset age.69, 133 Comparing 
the results of these studies is not straightforward, because the studies differ in clinical 
and genetic designs, sample size, density of markers typed, and especially in statistical 
analyses. Signifi cant linkage was detected to a new region on chromosome 1p32 
(PARK10) in one scan,16 and to the parkin gene locus on 6q (PARK2) in another scan;119
moreover, the region on 1p32 was signifi cantly linked to PD onset age in another study 
(fi gure 3).133
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A list of additional regions has been generated, with values of LODs ranging from 
1 to around 2 (fi gure 3). These fi ndings represent non-signifi cant, “interesting” or 
“suggestive” linkage signals that need to be further evaluated in future studies. Several 
of these signals are non-consistent across the studies, and they might be false positive 
results. However, the consistency of fi ndings for a few regions suggests that these might 
represent additional genuine linkages, though the power of the separate studies was 
insuffi cient to achieve statistical signifi cance.
Table 2.
The genome-wide screens performed in the common forms of PD
Study Dataset Sample size Marker density Software packages
OBJECT: determinants of PD risk
De Stefano et al. sib-pairs 113 ASP (102 families) 11 cM (339 markers) GENEHUNTER 
(260) (GenePD study)
Scott et al.     families with  260 ARP (174 families) 10 cM (344 markers) VITESSE/HOMOG (par.)
(119) t 2 aff. relatives  GENEHUNTER-PLUS
Pankratz et al. sib pairs  170 ASP (160 families) 8.6 cM (400 markers) MAPMAKER-SIBS
(97)    (Parkinson Study Group)
Hicks et al.   isolated population 117 patients (51 families)  5 cM (781 markers) ALLEGRO 
(16) (Iceland)
OBJECT: determinants of PD onset age (AAO)
Li et al.  families with  see Scott et al. 119  see Scott et al. 119   SOLAR
(133) t 2 aff. relatives
De Stefano et al. sib-pairs  see De Stefano et al.260 see De Stefano et al.260   GENEHUNTER 
(69) (GenePD study)
A fi rst study (the GenePD study) performed on 113 ASPs yielded no signifi cant results, 
probably because of the limited sample size.260 A second study was performed on 
a slightly larger sample of 174 families with t1 ARPs, including 184 ASPs and 75 ARPs 
of other type (cousins, parent-child, avuncular).119 Again, in the overall dataset, no 
signifi cant linkage was found. However, within a subset of 18 families containing at least 
1 PD case with onset d 40 years (early-onset families), signifi cant evidence for linkage 
(LOD!5) was detected at the PARK2 locus (parkin). While this is not surprising, given the 
frequency of parkin mutations in early onset PD, it is noteworthy that a signal to the 
PARK2 region was not detected by the analysis on the overall dataset, highlighting the 
potential pitfalls in linkage analysis of multiple families with a genetically heterogeneous 
disease. A third study (Parkinson Study Group) analysed 182 families with ASPs.97 In 
order to reduce genetic heterogeneity, 22 families with parkin gene mutations were 
excluded from the analysis. Moreover, affection status was modelled according to 
a narrower (model I) and a broader PD defi nition (modeI II). Analyses under model I 
yielded no signifi cant LOD scores but re-analysis according to the model II (broader PD 
defi nition) increased the LODs at regions on 2q and Xq (LODs 2.5 and 2.7 respectively). 
The fi nding on chromosome 2q36-q37 was followed up in a larger dataset and now 
reached signifi cance.17
The fourth study was performed in the genetically isolated population of Iceland.16
Genetically isolated populations are increasingly recognized as a powerful framework 
for research aimed at the identifi cation of genetic factors underlying complex 
disorders.261 Since isolated populations originate from a limited number of founders, 
they are characterized by a simpler genetic make-up compared to the general 
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population; this can greatly facilitate the identifi cation of genes for complex diseases, 
such as PD. The caveat is that genetic determinants identifi ed in genetic isolates might 
not be relevant in the general population.
A signifi cant familial aggregation of PD was previously shown in Iceland.9 Using a 
population-based approach, fi fty-one families were ascertained with t1 ARPs with 
PD, yielding a total of 117 patients. Non-parametric, model-free analysis generated 
signifi cant evidence for linkage to a region on chromosome 1p32 (max LOD=4.9), and 
this locus was termed PARK10.16 In this dataset, maximizing the LODs under a variety 
of parametric models (dominant, additive, multiplicative) did not allow a particular 
mode of inheritance to be defi nitely delineated. However, the best fi tting model, which 
incorporated an additive inheritance pattern and given values of penetrances and 
at-risk allele frequency, allowed to estimate that the PARK10 gene could explain a 
sibling recurrence risk ratio ranging from 3.2 to 4.6. Given the sibling relative risks for PD 
of 6.7 observed in Iceland,9 the authors conclude that PARK10 alone can account for 
a substantial fraction of the familial aggregation of PD in this population.16 While this is 
an important signifi cant linkage fi nding, its relevance for the other populations remains 
unknown, and none of the previous three genome-wide scans had detected linkage 
to 1p32.97, 119, 260
Among the “interesting” regions detected across the four genome-wide scans, the 
most consistent appear those on chromosomes 5q, 9q, 17q, and Xq (fi gure 3). These 
regions are very large and contain many genes, including obvious candidates: the 
gene encoding synphilin-1, an alpha-synuclein interactor (on 5q)111, the gene encoding 
dopamine E-hydroxylase, and DYT1, the gene causing generalized torsion dystonia (on 
9q),262, 263 and the gene for a monogenic, X-linked dystonia-parkinsonism form (on 
Xq).264 The peak detected on 17q is close to the gene for microtubule associated 
protein tau, an important locus for neurodegeneration and a known risk factor for 
progressive supranuclear palsy and PD.265, 266 The NR4A2 gene maps more than 70 cM 
centromerically to the linkage peak detected in the study of Pankratz et al.97. Despite 
its intriguing functional links to PD,102, 107 NR4A2 is therefore not a likely candidate for the 
reported 2q36-q37 region.
All previous studies were designed to identify genetic determinants of PD risk. However, 
age at disease onset (AAO) might also be genetically controlled, and fi nding such 
genetic determinants or modifi ers of onset age might have important implications for 
developing novel therapeutic approaches aiming to delay the onset of disease. In this 
approach, the available information on AAO of patients and age at examination of 
unaffected family members can be used to model AAO as a quantitative trait locus 
(QTL), which is amenable for linkage analysis. Two groups have recently reanalysed 
their datasets using this approach.69, 133
The fi rst study on PD onset age as a QTL133 reanalysed the dataset published by Scott 
et al. 2001.119 According to these results, the estimated heritability of AAO for PD is high 
(62%), indicating that strong genetic determinants for PD onset age exist. Signifi cant 
evidence for linkage of AAO was found for markers in the region of chromosome1p32 
(LOD=3.41). This region overlaps with the PARK10 region found in the Icelandic study.16
Additional regions yielding LODs between 1.4 and 1.9 were found on chromosomes 
5q, 6p, 10q, 13q, 17p, 20p and 22q (fi gure 3). Moreover, when the PD dataset was 
analysed together with a dataset of AD families, evidence was found for the existence 
of a genetic determinant of onset age for both diseases on chromosome 10q.133
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Figure 3. Overview of results from the genome-wide screens in common forms of PD. 
The black, shaded, and grey boxes indicate regions with LOD scores values >3, >2, and >1 respectively.
Although most of the evidence came from the group of AD patients, which was 
signifi cantly larger then the group of PD patients, this fi nding is still intriguing since 
clinical, biochemical and pathological overlaps between PD and AD have been 
documented, and it is therefore conceivable that common genetic factors might 
control the pathogenesis and/or the progression in both the diseases. Moreover, 
together with the results of the Icelandic study, the detection of linkage on 1p32 
confi rms that an important genetic determinant of PD risk and/or onset age resides in 
this region.
The other study69 reanalysed the dataset of the GenePD study using age at onset as 
the phenotype of interest, and found suggestive evidence (LODs between 1.8 to 2.2) 
for linkage of AAO to chromosome 2p, 9q, 20q, and 21 (fi gure 3). The region on 2p 
coincides with PARK3, a locus for autosomal dominant, late-onset PD,61 whereas the 
region on 9q has also been detected in linkage to affection status in the GenePD and 
in another screen (fi gure 3). In addition to linkage to PARK3, evidence for association 
was also observed between a specifi c allele of D2S1394 (one of the markers within 
PARK3) and AAO.69
In addition to 2p (PARK3) and 1p32 (PARK10), mildly positive LOD scores for other 
regions like the one on 5q and 9q have been detected by different studies searching 
for linkage to disease status (genetic risk) and for linkage to AAO (fi gure 3), illustrating 
how modelling and statistical analyses can lead to detection of genetic determinants 
of AAO when studying genetic risk, and vice versa.
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With the exception of PARK3, the current results of the genome scans suggest that the 
genes implicated in the known Mendelian forms are not major loci for common forms 
of PD. However, the failure to detect signifi cant linkage, and the inconsistency of most 
peaks across different scans, suggest that most of these studies were underpowered. A 
still unknown major locus for susceptibility to common forms of PD could have escaped 
detection just due to power limitations. The results are also compatible with the 
existence of many weaker genetic risk factors, which might also differ in the different 
studies, particularly if genetically isolated populations are targeted. In the light of the 
results of screens published so far for late-onset PD, targeting a genetically isolated 
population has been more rewarding than scanning series of affected-pairs from the 
general populations.
CONCLUSIONS
Classical linkage approaches to monogenic forms of PD have been most fruitful in the 
last few years, but it is anticipated that more and more genome-wide studies will be 
performed in the coming years in the common form of the disease, using families with 
affected-pairs, and cohorts of isolated cases from genetically isolated populations. 
The technology of DNA microarrays (DNA chips) is also anticipated to contribute soon 
to the identifi cation of PD-related genes. A high level of etiological complexity likely 
exists for PD; in this scenario, genetic approaches to isolated populations or otherwise-
defi ned more homogeneous groups is convenient in order to try and dissect the 
complexity of the problem. 
This year, at the 50th anniversary of the discovery of the structure of DNA, the fi nished 
sequence of the human genome has been released. At the beginning of the post-
genomic era, there are motifs to believe that the genome-wide approach will also 
succeed in deciphering the code of PD.
REFERENCES
1. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson’s disease in Europe: A 
collaborative study of population-based cohorts. Neurologic Diseases in the Elderly 
Research Group. Neurology 2000; 54:S21-3.
2. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998; 339:1044-
53.
3. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a 
product of meperidine-analog synthesis. Science 1983; 219:979-80.
4. Mjones H. Paralysis agitans: a clinical and genetic study. Acta Psychiatr Neurol 1949; 25 
Suppl.54:1-195.
5. Martin WE, Young WI, Anderson VE. Parkinson’s disease. A genetic study. Brain 1973; 96:
495-506.
6. Lazzarini AM, Myers RH, Zimmerman TR, Jr., et al. A clinical genetic study of Parkinson’s 
disease: evidence for dominant transmission. Neurology 1994; 44:499-506.
7. Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G. Familial Parkinson’s disease: a 
clinical genetic analysis. Can J Neurol Sci 1995; 22:272-9.
8. Maher NE, Currie LJ, Lazzarini AM, et al. Segregation analysis of Parkinson disease 
revealing evidence for a major causative gene. Am J Med Genet 2002; 109:191-7.
9. Sveinbjornsdottir S, Hicks AA, Jonsson T, et al. Familial aggregation of Parkinson’s disease 
in Iceland. N Engl J Med 2000; 343:1765-70.
10. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. 
Jama 1999; 281:341-6.
Genetics of Parkinson’s disease
30
11. Dickson D, Farrer M, Lincoln S, et al. Pathology of PD in monozygotic twins with a 20-year 
discordance interval. Neurology 2001; 56:981-2.
12. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in 
sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic 
function in twins. Ann Neurol 1999; 45:577-82.
13. Maher NE, Golbe LI, Lazzarini AM, et al. Epidemiologic study of 203 sibling pairs with 
Parkinson’s disease: the GenePD study. Neurology 2002; 58:79-84.
14. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson 
disease. Neurology 2002; 58:179-85.
15. Dawson TM, Dawson VL. Rare genetic mutations shed light on the pathogenesis of 
Parkinson disease. J Clin Invest 2003; 111:145-51.
16. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for late-onset idiopathic 
Parkinson’s disease. Ann Neurol 2002; 52:549-55.
17. Pankratz N, Nichols WC, Uniacke SK, et al. Signifi cant Linkage of Parkinson Disease to 
Chromosome 2q36-37. Am J Hum Genet 2003; 72:1053-7.
18. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human 
genome. Nature 2001; 409:860-921.
19. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 
2001; 291:1304-51.
20. Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal 
dominant Parkinson’s disease. Ann Neurol 1990; 27:276-82.
21. Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson’s disease in the 
Contursi kindred. Ann Neurol 1996; 40:767-75.
22. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson’s 
disease to chromosome 4q21-q23. Science 1996; 274:1197-9.
23. Scott WK, Staijich JM, Yamaoka LH, et al. Genetic complexity and Parkinson’s disease. 
Deane Laboratory Parkinson Disease Research Group. Science 1997; 277:387-8.
24. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. Genetic complexity and Parkinson’s disease. 
Science 1997; 277:388-9.
25. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene 
identifi ed in families with Parkinson’s disease. Science 1997; 276:2045-7.
26. Athanassiadou A, Voutsinas G, Psiouri L, et al. Genetic analysis of families with Parkinson 
disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am J 
Hum Genet 1999; 65:555-8.
27. Markopoulou K, Wszolek ZK, Pfeiffer RF, Chase BA. Reduced expression of the G209A 
alpha-synuclein allele in familial Parkinsonism. Ann Neurol 1999; 46:374-81.
28. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological 
features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein 
mutation. Ann Neurol 2001; 49:313-9.
29. Papapetropoulos S, Paschalis C, Athanassiadou A, et al. Clinical phenotype in patients 
with alpha-synuclein Parkinson’s disease living in Greece in comparison with patients 
with sporadic Parkinson’s disease. J Neurol Neurosurg Psychiatry 2001; 70:662-5.
30. Bostantjopoulou S, Katsarou Z, Papadimitriou A, Veletza V, Hatzigeorgiou G, Lees A. 
Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. 
Mov Disord 2001; 16:1007-13.
31. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-
synuclein in Parkinson’s disease. Nat Genet 1998; 18:106-8.
32. Vaughan J, Durr A, Tassin J, et al. The alpha-synuclein Ala53Thr mutation is not a 
common cause of familial Parkinson’s disease: a study of 230 European cases. European 
Consortium on Genetic Susceptibility in Parkinson’s Disease. Ann Neurol 1998; 44:270-3.
33. Vaughan JR, Farrer MJ, Wszolek ZK, et al. Sequencing of the alpha-synuclein gene in a 
large series of cases of familial Parkinson’s disease fails to reveal any further mutations. 
The European Consortium on Genetic Susceptibility in Parkinson’s Disease (GSPD). Hum 
Mol Genet 1998; 7:751-3.
34. Warner TT, Schapira AH. The role of the alpha-synuclein gene mutation in patients with 
sporadic Parkinson’s disease in the United Kingdom. J Neurol Neurosurg Psychiatry 1998; 
65:378-9.
Chapter 1.1
31
35. Bennett P, Nicholl DJ. Absence of the G209A mutation in the alpha-synuclein gene in 
British families with Parkinson’s disease. Neurology 1998; 50:1183.
36. Wang WW, Khajavi M, Patel BJ, Beach J, Jankovic J, Ashizawa T. The G209A mutation in 
the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-
Greek and/or Italian populations. Arch Neurol 1998; 55:1521-3.
37. Farrer M, Wavrant-De Vrieze F, Crook R, et al. Low frequency of alpha-synuclein 
mutations in familial Parkinson’s disease. Ann Neurol 1998; 43:394-7.
38. Chan P, Tanner CM, Jiang X, Langston JW. Failure to fi nd the alpha-synuclein gene 
missense mutation (G209A) in 100 patients with younger onset Parkinson’s disease. 
Neurology 1998; 50:513-4.
39. Chan P, Jiang X, Forno LS, Di Monte DA, Tanner CM, Langston JW. Absence of mutations 
in the coding region of the alpha-synuclein gene in pathologically proven Parkinson’s 
disease. Neurology 1998; 50:1136-7.
40. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein 
in Lewy bodies. Nature 1997; 388:839-40.
41. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in 
fi lamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy 
bodies. Proc Natl Acad Sci U S A 1998; 95:6469-73.
42. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in 
glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998; 249:180-2.
43. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson’s disease, dementia 
with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 2000; 920:16-27.
44. Feany MB, Bender WW. A Drosophila model of Parkinson’s disease. Nature 2000; 404:394-
8.
45. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body 
formation in alpha-synuclein mice: implications for neurodegenerative disorders. 
Science 2000; 287:1265-9.
46. van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing 
human alpha-synuclein. J Neurosci 2000; 20:6021-9.
47. Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and 
Parkinson’s disease-associated mutant alpha-synuclein in human and transgenic mouse 
brain. J Neurosci 2000; 20:6365-73.
48. Lee MK, Stirling W, Xu Y, et al. Human alpha-synuclein-harboring familial Parkinson’s 
disease-linked Ala-53-Thr mutation causes neurodegenerative disease with alpha-
synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 2002; 99:8968-73.
49. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-
synucleinopathy with severe movement disorder in mice expressing A53T human alpha-
synuclein. Neuron 2002; 34:521-33.
50. Lakso M, Vartiainen S, Moilanen AM, et al. Dopaminergic neuronal loss and motor 
defi cits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 
2003; 86:165-172.
51. Touchman JW, Dehejia A, Chiba-Falek O, et al. Human and mouse alpha-synuclein 
genes: comparative genomic sequence analysis and identifi cation of a novel gene 
regulatory element. Genome Res 2001; 11:78-86.
52. Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat 
upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase 
reporter system. Hum Mol Genet 2001; 10:3101-9.
53. Holzmann C, Kruger R, Saecker AM, et al. Polymorphisms of the alpha-synuclein 
promoter: expression analyses and association studies in Parkinson’s disease. J Neural 
Transm 2003; 110:67-76.
54. Kruger R, Vieira-Saecker AM, Kuhn W, et al. Increased susceptibility to sporadic 
Parkinson’s disease by a certain combined alpha-synuclein/apolipoprotein E genotype. 
Ann Neurol 1999; 45:611-7.
55. Khan N, Graham E, Dixon P, et al. Parkinson’s disease is not associated with the combined 
alpha-synuclein/apolipoprotein E susceptibility genotype. Ann Neurol 2001; 49:665-8.
56. Izumi Y, Morino H, Oda M, et al. Genetic studies in Parkinson’s disease with an alpha-
synuclein/NACP gene polymorphism in Japan. Neurosci Lett 2001; 300:125-7.
Genetics of Parkinson’s disease
32
57. Pastor P, Munoz E, Ezquerra M, et al. Analysis of the coding and the 5’ fl anking regions of 
the alpha-synuclein gene in patients with Parkinson’s disease. Mov Disord 2001; 16:1115-
9.
58. Farrer M, Maraganore DM, Lockhart P, et al. alpha-Synuclein gene haplotypes are 
associated with Parkinson’s disease. Hum Mol Genet 2001; 10:1847-51.
59. Duda JE, Giasson BI, Mabon ME, et al. Concurrence of alpha-synuclein and tau brain 
pathology in the Contursi kindred. Acta Neuropathol (Berl) 2002; 104:7-11.
60. Kruger R, Kuhn W, Leenders KL, et al. Familial parkinsonism with synuclein pathology: 
clinical and PET studies of A30P mutation carriers. Neurology 2001; 56:1355-62.
61. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson’s disease 
maps to chromosome 2p13. Nat Genet 1998; 18:262-5.
62. Wszolek ZK, Cordes M, Calne DB, Munter MD, Cordes I, Pfeifer RF. [Hereditary Parkinson 
disease: report of 3 families with dominant autosomal inheritance]. Nervenarzt 1993; 64:
331-5.
63. Denson MA, Wszolek ZK, Pfeiffer RF, Wszolek EK, Paschall TM, McComb RD. Familial 
parkinsonism, dementia, and Lewy body disease: study of family G. Ann Neurol 1997; 42:
638-43.
64. Wszolek ZK, Gwinn-Hardy K, Wszolek EK, et al. Neuropathology of two members of a 
German-American kindred (Family C) with late onset parkinsonism. Acta Neuropathol 
(Berl) 2002; 103:344-50.
65. Klein C, Vieregge P, Hagenah J, et al. Search for the PARK3 founder haplotype in a large 
cohort of patients with Parkinson’s disease from northern Germany. Ann Hum Genet 
1999; 63:285-91.
66. West AB, Zimprich A, Lockhart PJ, et al. Refi nement of the PARK3 locus on chromosome 
2p13 and the analysis of 14 candidate genes. Eur J Hum Genet 2001; 9:659-66.
67. Zink M, Grim L, Wszolek ZK, Gasser T. Autosomal-dominant Parkinson’s disease linked 
to 2p13 is not caused by mutations in transforming growth factor alpha (TGF alpha). J 
Neural Transm 2001; 108:1029-34.
68. Lockhart PJ, Holtom B, Lincoln S, et al. The human siderofl exin 5 (SFXN5) gene: sequence, 
expression analysis and exclusion as a candidate for PARK3. Gene 2002; 285:229-37.
69. DeStefano AL, Lew MF, Golbe LI, et al. PARK3 infl uences age at onset in Parkinson 
disease: a genome scan in the GenePD study. Am J Hum Genet 2002; 70:1089-95.
70. Waters CH, Miller CA. Autosomal dominant Lewy body parkinsonism in a four-generation 
family. Ann Neurol 1994; 35:59-64.
71. Muenter MD, Forno LS, Hornykiewicz O, et al. Hereditary form of parkinsonism--dementia. 
Ann Neurol 1998; 43:768-81.
72. Farrer M, Gwinn-Hardy K, Muenter M, et al. A chromosome 4p haplotype segregating 
with Parkinson’s disease and postural tremor. Hum Mol Genet 1999; 8:81-5.
73. Gwinn-Hardy K, Mehta ND, Farrer M, et al. Distinctive neuropathology revealed by alpha-
synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. 
Acta Neuropathol (Berl) 2000; 99:663-72.
74. Pahwa R, Koller WC. Is there a relationship between Parkinson’s disease and essential 
tremor? Clin Neuropharmacol 1993; 16:30-5.
75. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J. The neuron-
specifi c protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989; 246:
670-3.
76. Osaka H, Wang YL, Takada K, et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and 
stabilizes monoubiquitin in neuron. Hum Mol Genet 2003; 12:1945-1958.
77. Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD. Ubiquitin carboxyl-terminal 
hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic 
of human neurodegenerative diseases. J Pathol 1990; 161:153-60.
78. Saigoh K, Wang YL, Suh JG, et al. Intragenic deletion in the gene encoding ubiquitin 
carboxy-terminal hydrolase in gad mice. Nat Genet 1999; 23:47-51.
79. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson’s disease. Nature 
1998; 395:451-2.
Chapter 1.1
33
80. Lincoln S, Vaughan J, Wood N, et al. Low frequency of pathogenic mutations in the 
ubiquitin carboxy-terminal hydrolase gene in familial Parkinson’s disease. Neuroreport 
1999; 10:427-9.
81. Harhangi BS, Farrer MJ, Lincoln S, et al. The Ile93Met mutation in the ubiquitin carboxy-
terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson’s 
disease. Neurosci Lett 1999; 270:1-4.
82. Zhang J, Hattori N, Giladi N, Mizuno Y. Failure to fi nd mutations in ubiquitin carboxy-
terminal hydrolase L1 gene in familial Parkinson’s disease. 2000; 6:199-200.
83. Hoenicka J, Vidal L, Morales B, et al. Molecular fi ndings in familial Parkinson disease in 
Spain. Arch Neurol 2002; 59:966-70.
84. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-
control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease. 
Neurology 1999; 53:1858-60.
85. Wintermeyer P, Kruger R, Kuhn W, et al. Mutation analysis and association studies of the 
UCHL1 gene in German Parkinson’s disease patients. Neuroreport 2000; 11:2079-82.
86. Zhang J, Hattori N, Leroy E, et al. Association between a polymorphism of ubiquitin 
carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson’s disease. 2000; 6:
195-197.
87. Momose Y, Murata M, Kobayashi K, et al. Association studies of multiple candidate 
genes for Parkinson’s disease using single nucleotide polymorphisms. Ann Neurol 2002; 
51:133-6.
88. Savettieri G, De Marco EV, Civitelli D, et al. Lack of association between ubiquitin 
carboxy-terminal hydrolase L1 gene polymorphism and PD. Neurology 2001; 57:560-1.
89. Levecque C, Destee A, Mouroux V, et al. No genetic association of the ubiquitin 
carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson’s disease. 
J Neural Transm 2001; 108:979-84.
90. Mellick GD, Silburn PA. The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y 
polymorphism does not confer protection against idiopathic Parkinson’s disease. 
Neurosci Lett 2000; 293:127-30.
91. Wang J, Zhao CY, Si YM, Liu ZL, Chen B, Yu L. ACT and UCH-L1 polymorphisms in 
Parkinson’s disease and age of onset. Mov Disord 2002; 17:767-71.
92. Elbaz A, Levecque C, Clavel J, et al. S18Y polymorphism in the UCH-L1 gene and 
Parkinson’s disease: evidence for an age-dependent relationship. Mov Disord 2003; 18:
130-7.
93. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT, Jr. The UCH-L1 gene encodes two opposing 
enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease 
susceptibility. Cell 2002; 111:209-18.
94. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson’s 
disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51:296-301.
95. Hasegawa K, Kowa H. Autosomal dominant familial Parkinson disease: older onset of 
age, and good response to levodopa therapy. Eur Neurol 1997; 38:39-43.
96. Scott WK, Grubber JM, Conneally PM, et al. Fine mapping of the chromosome 12 late-
onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. Am J 
Hum Genet 2000; 66:922-32.
97. Pankratz N, Nichols WC, Uniacke SK, et al. Genome screen to identify susceptibility genes 
for Parkinson disease in a sample without parkin mutations. Am J Hum Genet 2002; 71:
124-35.
98. Saucedo-Cardenas O, Kardon R, Ediger TR, Lydon JP, Conneely OM. Cloning and 
structural organization of the gene encoding the murine nuclear receptor transcription 
factor, NURR1. Gene 1997; 187:135-9.
99. Zetterstrom RH, Williams R, Perlmann T, Olson L. Cellular expression of the immediate early 
transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain 
regions including the nigrostriatal dopamine system. Brain Res Mol Brain Res 1996; 41:111-
20.
100. Zetterstrom RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron 
agenesis in Nurr1-defi cient mice. Science 1997; 276:248-50.
Genetics of Parkinson’s disease
34
101. Le W, Conneely OM, Zou L, et al. Selective agenesis of mesencephalic dopaminergic 
neurons in Nurr1-defi cient mice. Exp Neurol 1999; 159:451-8.
102. Le W, Conneely OM, He Y, Jankovic J, Appel SH. Reduced Nurr1 expression increases the 
vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem 
1999; 73:2218-21.
103. Rawal N, Periquet M, Durr A, et al. Exclusion of the Nurr1 gene in autosomal recessive 
Parkinson’s disease. J Neurol 2002; 249:1127-9.
104. Xu PY, Liang R, Jankovic J, et al. Association of homozygous 7048G7049 variant in the 
intron six of Nurr1 gene with Parkinson’s disease. Neurology 2002; 58:881-4.
105. Zheng K, Heydari B, Simon DK. A common NURR1 polymorphism associated with 
Parkinson disease and diffuse Lewy body disease. Arch Neurol 2003; 60:722-5.
106. Tan EK, Chung H, Zhao Y, et al. Genetic analysis of Nurr1 haplotypes in Parkinson’s 
disease. Neurosci Lett 2003; 347:139-42.
107. Le WD, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson 
disease. Nat Genet 2003; 33:85-9.
108. Healy DG, Sleiman P, Sweeney MG, Eunson LH, Wood NW. Exon 1 nurr1 gene mutations 
are rare in familial Parkinson’s disease. Mov Disord 2002; 17(Suppl.5):61.[abstract].
109. Zimprich A, Asmus F, Leitner P, et al. Point mutations in exon 1 of the NR4A2 gene are not 
a major cause of familial Parkinson’s disease. Neurogenetics 2003; 4:219-20.
110. Wellenbrock C, Hedrich K, Schafer N, et al. NR4A2 mutations are rare among European 
patients with familial Parkinson’s disease. Ann Neurol 2003; 54:415.
111. Engelender S, Kaminsky Z, Guo X, et al. Synphilin-1 associates with alpha-synuclein and 
promotes the formation of cytosolic inclusions. Nat Genet 1999; 22:110-4.
112. Ribeiro CS, Carneiro K, Ross CA, Menezes JR, Engelender S. Synphilin-1 is developmentally 
localized to synaptic terminals, and its association with synaptic vesicles is modulated by 
alpha-synuclein. J Biol Chem 2002; 277:23927-33.
113. Engelender S, Wanner T, Kleiderlein JJ, et al. Organization of the human synphilin-1 gene, 
a candidate for Parkinson’s disease. Mamm Genome 2000; 11:763-6.
114. Wakabayashi K, Engelender S, Yoshimoto M, Tsuji S, Ross CA, Takahashi H. Synphilin-1 is 
present in Lewy bodies in Parkinson’s disease. Ann Neurol 2000; 47:521-3.
115. Wakabayashi K, Engelender S, Tanaka Y, et al. Immunocytochemical localization of 
synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta 
Neuropathol (Berl) 2002; 103:209-14.
116. Murray IJ, Medford MA, Guan HP, Rueter SM, Trojanowski JQ, Lee VM. Synphilin in normal 
human brains and in synucleinopathies: studies with new antibodies. Acta Neuropathol 
(Berl) 2003; 105:177-84.
117. Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting 
protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 
2001; 7:1144-50.
118. Ito T, Niwa JI, Hishikawa N, Ishigaki S, Doyu M, Sobue G. Dorfi n localizes to Lewy bodies 
and ubiquitylates synphilin-1. J Biol Chem 2003; 15:15.
119. Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson disease: 
evidence for multiple genes. Jama 2001; 286:2239-44.
120. Farrer M, Destee A, Levecque C, et al. Genetic analysis of synphilin-1 in familial 
Parkinson’s disease. Neurobiol Dis 2001; 8:317-23.
121. Bandopadhyay R, de Silva R, Khan N, et al. No pathogenic mutations in the synphilin-1 
gene in Parkinson’s disease. Neurosci Lett 2001; 307:125-7.
122. Marx FP, Holzmann C, Strauss KM, et al. Identifi cation and functional characterization of 
a novel R621C mutation in the synphilin-1 gene in Parkinson’s disease. Hum Mol Genet 
2003; 12:1223-1231.
123. Gwinn-Hardy KA, Crook R, Lincoln S, et al. A kindred with Parkinson’s disease not showing 
genetic linkage to established loci. Neurology 2000; 54:504-7.
124. Racette BA, Rundle M, Wang JC, et al. A multi-incident, Old-Order Amish family with PD. 
Neurology 2002; 58:568-74.
125. Nicholl DJ, Vaughan JR, Khan NL, et al. Two large British kindreds with familial Parkinson’s 
disease: a clinico-pathological and genetic study. Brain 2002; 125:44-57.
Chapter 1.1
35
126. Grimes DA, Grimes JD, Racacho L, et al. Large French-Canadian family with Lewy body 
parkinsonism: exclusion of known loci. Mov Disord 2002; 17:1205-12.
127. Bertoli Avella AM, Giroud Benitez JL, Bonifati V, et al. Suggestive linkage to chromosome 
19 in a large Cuban family with late-onset Parkinson’s disease. Mov Disord 2003; in 
press.
128. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson’s disease 
and mutations in the parkin gene. French Parkinson’s Disease Genetics Study Group. N 
Engl J Med 2000; 342:1560-7.
129. Valente EM, Bentivoglio AR, Dixon PH, et al. Localization of a novel locus for autosomal 
recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum 
Genet 2001; 68:895-900.
130. van Duijn CM, Dekker MC, Bonifati V, et al. Park7, a novel locus for autosomal recessive 
early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001; 69:629-34.
131. Hampshire DJ, Roberts E, Crow Y, et al. Kufor-Rakeb syndrome, pallido-pyramidal 
degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J Med 
Genet 2001; 38:680-2.
132. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with 
autosomal recessive early-onset parkinsonism. Science 2003; 299:256-9.
133. Li YJ, Scott WK, Hedges DJ, et al. Age at onset in two common neurodegenerative 
diseases is genetically controlled. Am J Hum Genet 2002; 70:985-93.
134. Yamamura Y, Sobue I, Ando K, Iida M, Yanagi T. Paralysis agitans of early onset with 
marked diurnal fl uctuation of symptoms. Neurology 1973; 23:239-44.
135. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: clinical and 
pathologic study in a family. Neurology 1994; 44:437-41.
136. Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-
recessive type juvenile parkinsonism. Neurology 1996; 47:160-6.
137. Matsumine H, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for an 
autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum 
Genet 1997; 60:588-96.
138. Tassin J, Durr A, de Broucker T, et al. Chromosome 6-linked autosomal recessive early-
onset Parkinsonism: linkage in European and Algerian families, extension of the clinical 
spectrum, and evidence of a small homozygous deletion in one family. The French 
Parkinson’s Disease Genetics Study Group, and the European Consortium on Genetic 
Susceptibility in Parkinson’s Disease. Am J Hum Genet 1998; 63:88-94.
139. Jones AC, Yamamura Y, Almasy L, et al. Autosomal recessive juvenile parkinsonism maps 
to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region. Am 
J Hum Genet 1998; 63:80-7.
140. Matsumine H, Yamamura Y, Kobayashi T, Nakamura S, Kuzuhara S, Mizuno Y. Early onset 
parkinsonism with diurnal fl uctuation maps to a locus for juvenile parkinsonism. Neurology 
1998; 50:1340-5.
141. Matsumine H, Yamamura Y, Hattori N, et al. A microdeletion of D6S305 in a family of 
autosomal recessive juvenile parkinsonism (PARK2). Genomics 1998; 49:143-6.
142. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal 
recessive juvenile parkinsonism. Nature 1998; 392:605-8.
143. Sunada Y, Saito F, Matsumura K, Shimizu T. Differential expression of the parkin gene in 
the human brain and peripheral leukocytes. Neurosci Lett 1998; 254:180-2.
144. Kitada T, Asakawa S, Minoshima S, Mizuno Y, Shimizu N. Molecular cloning, gene 
expression, and identifi cation of a splicing variant of the mouse parkin gene. Mamm 
Genome 2000; 11:417-21.
145. Lucking CB, Abbas N, Durr A, et al. Homozygous deletions in parkin gene in European 
and North African families with autosomal recessive juvenile parkinsonism. The European 
Consortium on Genetic Susceptibility in Parkinson’s Disease and the French Parkinson’s 
Disease Genetics Study Group. Lancet 1998; 352:1355-6.
146. Hattori N, Kitada T, Matsumine H, et al. Molecular genetic analysis of a novel Parkin 
gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for 
variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 
1998; 44:935-41.
Genetics of Parkinson’s disease
36
147. Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH. Deletions in the 
Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson’s 
disease. Hum Genet 1998; 103:424-7.
148. Hattori N, Matsumine H, Asakawa S, et al. Point mutations (Thr240Arg and Gln311Stop) 
[correction of Thr240Arg and Ala311Stop] in the Parkin gene. Biochem Biophys Res 
Commun 1998; 249:754-8.
149. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are 
responsible for autosomal recessive parkinsonism in Europe. French Parkinson’s Disease 
Genetics Study Group and the European Consortium on Genetic Susceptibility in 
Parkinson’s Disease. Hum Mol Genet 1999; 8:567-74.
150. Nisipeanu P, Inzelberg R, Blumen SC, et al. Autosomal-recessive juvenile parkinsonism in 
a Jewish Yemenite kindred: mutation of Parkin gene. Neurology 1999; 53:1602-4.
151. Klein C, Pramstaller PP, Kis B, et al. Parkin deletions in a family with adult-onset, tremor-
dominant parkinsonism: expanding the phenotype. Ann Neurol 2000; 48:65-71.
152. Maruyama M, Ikeuchi T, Saito M, et al. Novel mutations, pseudo-dominant inheritance, 
and possible familial affects in patients with autosomal recessive juvenile parkinsonism. 
Ann Neurol 2000; 48:245-50.
153. Munoz E, Pastor P, Marti MJ, Oliva R, Tolosa E. A new mutation in the parkin gene in a 
patient with atypical autosomal recessive juvenile parkinsonism. Neurosci Lett 2000; 289:
66-8.
154. Hedrich K, Kann M, Lanthaler AJ, et al. The importance of gene dosage studies: 
mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet 2001; 
10:1649-56.
155. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin 
mutations. Ann Neurol 2001; 50:293-300.
156. Lucking CB, Bonifati V, Periquet M, Vanacore N, Brice A, Meco G. Pseudo-dominant 
inheritance and exon 2 triplication in a family with parkin gene mutations. Neurology 
2001; 57:924-7.
157. Bonifati V, Lucking CB, Fabrizio E, Periquet M, Meco G, Brice A. Three parkin gene 
mutations in a sibship with autosomal recessive early onset parkinsonism. J Neurol 
Neurosurg Psychiatry 2001; 71:531-4.
158. Pineda-Trujillo N, Carvajal-Carmona LG, Buritica O, et al. A novel Cys212Tyr founder 
mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population 
from North West Colombia. Neurosci Lett 2001; 298:87-90.
159. Terreni L, Calabrese E, Calella AM, Forloni G, Mariani C. New mutation (R42P) of the 
parkin gene in the ubiquitinlike domain associated with parkinsonism. Neurology 2001; 
56:463-6.
160. Alvarez V, Guisasola LM, Moreira VG, Lahoz CH, Coto E. Early-onset Parkinson’s disease 
associated with a new parkin mutation in a Spanish family. Neurosci Lett 2001; 313:108-
10.
161. Nisipeanu P, Inzelberg R, Abo Mouch S, et al. Parkin gene causing benign autosomal 
recessive juvenile parkinsonism. Neurology 2001; 56:1573-5.
162. Jeon BS, Kim JM, Lee DS, Hattori N, Mizuno Y. An apparently sporadic case with parkin 
gene mutation in a Korean woman. Arch Neurol 2001; 58:988-9.
163. Nichols WC, Pankratz N, Uniacke SK, et al. Linkage stratifi cation and mutation analysis 
at the Parkin locus identifi es mutation positive Parkinson’s disease families. J Med Genet 
2002; 39:489-92.
164. Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson’s 
disease for Parkin mutations. Neurology 2002; 58:1239-46.
165. West A, Periquet M, Lincoln S, et al. Complex relationship between Parkin mutations and 
Parkinson disease. Am J Med Genet 2002; 114:584-91.
166. Wu RM, Shan DE, Sun CM, et al. Clinical, 18F-dopa PET, and genetic analysis of an ethnic 
Chinese kindred with early-onset parkinsonism and parkin gene mutations. Mov Disord 
2002; 17:670-5.
167. Kann M, Jacobs H, Mohrmann K, et al. Role of parkin mutations in 111 community-based 
patients with early-onset parkinsonism. Ann Neurol 2002; 51:621-5.
Chapter 1.1
37
168. Munoz E, Tolosa E, Pastor P, et al. Relative high frequency of the c.255delA parkin gene 
mutation in Spanish patients with autosomal recessive parkinsonism. J Neurol Neurosurg 
Psychiatry 2002; 73:582-4.
169. Periquet M, Latouche M, Lohmann E, et al. Parkin mutations are frequent in patients with 
isolated early-onset parkinsonism. Brain 2003; 126:1271-1278.
170. Rawal N, Periquet M, Lohmann E, et al. New parkin mutations and atypical phenotypes 
in families with autosomal recessive parkinsonism. Neurology 2003; 60:1378-81.
171. Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case 
series. Brain 2003; 126:1279-1292.
172. Oliveira SA, Scott WK, Martin ER, et al. Parkin mutations and susceptibility alleles in late-
onset Parkinson’s disease. Ann Neurol 2003; 53:624-9.
173. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be 
attributed to parkin genotype? Ann Neurol 2003; 54:176-85.
174. Foroud T, Uniacke SK, Liu L, et al. Heterozygosity for a mutation in the parkin gene leads 
to later onset Parkinson disease. Neurology 2003; 60:796-801.
175. Gouider-Khouja N, Larnaout A, Amouri R, et al. Autosomal recessive parkinsonism linked 
to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinsonism 
Relat Disord 2003; 9:247-51.
176. Kim JS, Lee KS, Kim YI, Lee KH, Kim HT. Homozygous exon 4 deletion in parkin gene in a 
Korean family with autosomal recessive early onset parkinsonism. Yonsei Med J 2003; 44:
336-9.
177. Ujike H, Yamamoto M, Yamaguchi K, Kanzaki A, Takagi M, Kuroda S. [Two cases of 
sporadic juvenile Parkinson’s disease caused by homozygous deletion of Parkin gene]. 
No To Shinkei 1999; 51:1061-4.
178. Tassin J, Durr A, Bonnet AM, et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or 
parkin mutations? Brain 2000; 123:1112-21.
179. Kobayashi T, Wang M, Hattori N, Matsumine H, Kondo T, Mizuno Y. Exonic deletion 
mutations of the Parkin gene among sporadic patients with Parkinson’s disease. 
Parkinsonism Relat Disord 2000; 6:129-131.
180. Bia H, Shao M, Dong X, et al. Preliminary studies on parkin gene deletion at exons 1 to 6 
in Chinese patients with praecox Parkinson’s disease. Zhonghua Yi Xue Yi Chuan Xue Za 
Zhi 2000; 17:323-5.
181. Takei K, Yamamoto T, Asano Y, Iwasaki S, Shimazu K. [A case of autosomal recessive 
juvenile parkinsonism (AR-JP) with onset at the age of 6 years]. Rinsho Shinkeigaku 2000; 
40:596-9.
182. Ujike H, Yamamoto M, Kanzaki A, Okumura K, Takaki M, Kuroda S. Prevalence of 
homozygous deletions of the parkin gene in a cohort of patients with sporadic and 
familial Parkinson’s disease. Mov Disord 2001; 16:111-3.
183. Lu CS, Wu JC, Tsai CH, et al. Clinical and genetic studies on familial parkinsonism: the fi rst 
report on a parkin gene mutation in a Taiwanese family. Mov Disord 2001; 16:164-6.
184. Kuroda Y, Mitsui T, Akaike M, Azuma H, Matsumoto T. Homozygous deletion mutation 
of the parkin gene in patients with atypical parkinsonism. J Neurol Neurosurg Psychiatry 
2001; 71:231-4.
185. Pramstaller PP, Kunig G, Leenders K, et al. Parkin mutations in a patient with 
hemiparkinsonism-hemiatrophy: a clinical-genetic and PET study. Neurology 2002; 58:
808-10.
186. Xu Y, Liu Z, Wang Y, Tao E, Chen G, Chen B. [A new point mutation on exon 2 of parkin 
gene in Parkinson’s disease]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002; 19:409-11.
187. Tan LC, Tanner CM, Chen R, et al. Marked variation in clinical presentation and age of 
onset in a family with a heterozygous parkin mutation. Mov Disord 2003; 18:758-63.
188. Okuma Y, Hattori N, Mizuno Y. Sensory neuropathy in autosomal recessive juvenile 
parkinsonism (PARK2). Parkinsonism Relat Disord 2003; 9:313-4.
189. Chen R, Gosavi NS, Langston JW, Chan P. Parkin mutations are rare in patients with 
young-onset parkinsonism in a US population. Parkinsonism Relat Disord 2003; 9:309-12.
190. Inzelberg R, Hattori N, Nisipeanu P, et al. Camptocormia, axial dystonia, and parkinsonism: 
Phenotypic heterogeneity of a parkin mutation. Neurology 2003; 60:1393-4.
Genetics of Parkinson’s disease
38
191. Illarioshkin SN, Periquet M, Rawal N, et al. Mutation analysis of the parkin gene in Russian 
families with autosomal recessive juvenile parkinsonism. Mov Disord 2003; 18:914-9.
192. Asakawa S, Tsunematsu K, Takayanagi A, et al. The genomic structure and promoter 
region of the human parkin gene. Biochem Biophys Res Commun 2001; 286:863-8.
193. West A, Farrer M, Petrucelli L, Cookson M, Lockhart P, Hardy J. Identifi cation and 
characterization of the human parkin gene promoter. J Neurochem 2001; 78:1146-52.
194. Mata IF, Alvarez V, Garcia-Moreira V, et al. Single-nucleotide polymorphisms in the 
promoter region of the PARKIN gene and Parkinson’s disease. Neurosci Lett 2002; 329:
149-52.
195. West AB, Maraganore D, Crook J, et al. Functional association of the parkin gene 
promoter with idiopathic Parkinson’s disease. Hum Mol Genet 2002; 11:2787-92.
196. Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the 
nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in 
the parkin gene. Ann Neurol 2001; 49:367-76.
197. Khan NL, Brooks DJ, Pavese N, et al. Progression of nigrostriatal dysfunction in a parkin 
kindred: an [18F]dopa PET and clinical study. Brain 2002; 125:2248-56.
198. Kobayashi T, Matsumine H, Zhang J, Imamichi Y, Mizuno Y, Hattori N. Pseudo-autosomal 
dominant inheritance of PARK2: two families with parkin gene mutations. J Neurol Sci 
2003; 207:11-7.
199. Periquet M, Lucking C, Vaughan J, et al. Origin of the mutations in the parkin gene 
in Europe: exon rearrangements are independent recurrent events, whereas point 
mutations may result from Founder effects. Am J Hum Genet 2001; 68:617-26.
200. Lincoln S, Wiley J, Lynch T, et al. Parkin-proven disease: Common founders but divergent 
phenotypes. Neurology 2003; 60:1605-10.
201. Wang M, Hattori N, Matsumine H, et al. Polymorphism in the parkin gene in sporadic 
Parkinson’s disease. Ann Neurol 1999; 45:655-8.
202. Satoh J, Kuroda Y. Association of codon 167 Ser/Asn heterozygosity in the parkin gene 
with sporadic Parkinson’s disease. Neuroreport 1999; 10:2735-9.
203. Klein C, Schumacher K, Jacobs H, et al. Association studies of Parkinson’s disease and 
parkin polymorphisms. Ann Neurol 2000; 48:126-7.
204. Hu CJ, Sung SM, Liu HC, Lee CC, Tsai CH, Chang JG. Polymorphisms of the parkin gene 
in sporadic Parkinson’s disease among Chinese in Taiwan. Eur Neurol 2000; 44:90-3.
205. Oliveri RL, Zappia M, Annesi G, et al. The parkin gene is not involved in late-onset 
Parkinson’s disease. Neurology 2001; 57:359-62.
206. Mellick GD, Buchanan DD, Hattori N, et al. The parkin gene S/N167 polymorphism in 
Australian Parkinson’s disease patients and controls. 2001; 7:89-91.
207. Eerola J, Launes J, Hellstrom O, Tienari PJ. Apolipoprotein E (APOE), PARKIN and 
catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson’s 
disease in Finland. Neurosci Lett 2002; 330:296-8.
208. Peng R, Gou Y, Yuan Q, et al. Mutation screening and association analysis of the parkin 
gene in Parkinson’s disease patients from South-West China. Eur Neurol 2003; 49:85-9.
209. Oliveira SA, Scott WK, Nance MA, et al. Association study of Parkin gene polymorphisms 
with idiopathic Parkinson disease. Arch Neurol 2003; 60:975-80.
210. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile 
parkinsonism linked to chromosome 6q. Neurology 1998; 51:890-2.
211. Hayashi S, Wakabayashi K, Ishikawa A, et al. An autopsy case of autosomal-recessive 
juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 
2000; 15:884-8.
212. Yamamura Y, Hattori N, Matsumine H, Kuzuhara S, Mizuno Y. Autosomal recessive 
early-onset parkinsonism with diurnal fl uctuation: clinicopathologic characteristics and 
molecular genetic identifi cation. Brain Dev 2000; 22:S87-91.
213. van de Warrenburg BP, Lammens M, Lucking CB, et al. Clinical and pathologic 
abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001; 
56:555-7.
214. Morales B, Martinez A, Gonzalo I, et al. Steele-Richardson-Olszewski syndrome in a 
patient with a single C212Y mutation in the parkin protein. Mov Disord 2002; 17:1374-80.
Chapter 1.1
39
215. Rajput AH, Uitti RJ, Sudhakar S, Rozdilsky B. Parkinsonism and neurofi brillary tangle 
pathology in pigmented nuclei. Ann Neurol 1989; 25:602-6.
216. Broussolle E, Lucking CB, Ginovart N, Pollak P, Remy P, Durr A. [18 F]-dopa PET study in 
patients with juvenile-onset PD and parkin gene mutations. Neurology 2000; 55:877-9.
217. Portman AT, Giladi N, Leenders KL, et al. The nigrostriatal dopaminergic system in familial 
early onset parkinsonism with parkin mutations. Neurology 2001; 56:1759-62.
218. Thobois S, Ribeiro MJ, Lohmann E, et al. Young-onset Parkinson disease with and without 
parkin gene mutations: a fl uorodopa F 18 positron emission tomography study. Arch 
Neurol 2003; 60:713-8.
219. Hilker R, Klein C, Hedrich K, et al. The striatal dopaminergic defi cit is dependent on the 
number of mutant alleles in a family with mutations in the parkin gene: evidence for 
enzymatic parkin function in humans. Neurosci Lett 2002; 323:50-4.
220. Morett E, Bork P. A novel transactivation domain in parkin. Trends Biochem Sci 1999; 24:
229-31.
221. Tashiro M, Okubo S, Shimotakahara S, et al. NMR structure of ubiquitin-like domain in 
PARKIN: Gene product of familial Parkinson’s disease. J Biomol NMR 2003; 25:153-6.
222. Sakata E, Yamaguchi Y, Kurimoto E, et al. Parkin binds the Rpn10 subunit of 26S 
proteasomes through its ubiquitin-like domain. EMBO Rep 2003; 4:301-6.
223. Upadhya SC, Hegde AN. A potential proteasome-interacting motif within the ubiquitin-
like domain of parkin and other proteins. Trends Biochem Sci 2003; 28:280-3.
224. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a 
ubiquitin-protein ligase. Nat Genet 2000; 25:302-5.
225. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell 
death through its E3 ubiquitin-protein ligase activity. J Biol Chem 2000; 275:35661-4.
226. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an 
E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic 
vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 2000; 97:13354-9.
227. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative 
transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a 
substrate of Parkin. Cell 2001; 105:891-902.
228. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-
synuclein by parkin from human brain: implications for Parkinson’s disease. Science 2001; 
293:263-9.
229. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. Parkin is 
a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons 
from kainate excitotoxicity. Neuron 2003; 37:735-49.
230. Corti O, Hampe C, Koutnikova H, et al. The p38 subunit of the aminoacyl-tRNA synthetase 
complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum 
Mol Genet 2003; 12:1427-37.
231. Honbou K, Suzuki NN, Horiuchi M, et al. The crystal structure of DJ-1, a protein related to 
male fertility and Parkinson’s disease. J Biol Chem 2003; 278:31380-4.
232. Tao X, Tong L. Crystal structure of human DJ-1, a protein associated with early onset 
Parkinson’s disease. J Biol Chem 2003; 278:31372-9.
233. Wilson MA, Collins JL, Hod Y, Ringe D, Petsko GA. The 1.1-A resolution crystal structure of 
DJ-1, the protein mutated in autosomal recessive early onset Parkinson’s disease. Proc 
Natl Acad Sci U S A 2003; 100:9256-61.
234. Huai Q, Sun Y, Wang H, et al. Crystal structure of DJ-1/RS and implication on familial 
Parkinson’s disease. FEBS Lett 2003; 549:171-5.
235. Taira T, Takahashi K, Kitagawa R, Iguchi-Ariga SM, Ariga H. Molecular cloning of human 
and mouse DJ-1 genes and identifi cation of Sp1-dependent activation of the human 
DJ-1 promoter. Gene 2001; 263:285-92.
236. Mitsumoto A, Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species 
elicited by endotoxin. Free Radic Res 2001; 35:885-93.
237. Mitsumoto A, Nakagawa Y, Takeuchi A, Okawa K, Iwamatsu A, Takanezawa Y. Oxidized 
forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to 
sublethal levels of paraquat. Free Radic Res 2001; 35:301-10.
Genetics of Parkinson’s disease
40
238. de Nobel H, Lawrie L, Brul S, et al. Parallel and comparative analysis of the proteome 
and transcriptome of sorbic acid-stressed Saccharomyces cerevisiae. Yeast 2001; 18:
1413-28.
239. Trotter EW, Kao CM, Berenfeld L, Botstein D, Petsko GA, Gray JV. Misfolded proteins 
are competent to mediate a subset of the responses to heat shock in Saccharomyces 
cerevisiae. J Biol Chem 2002; 277:44817-25.
240. Giasson BI, Ischiropoulos H, Lee VM, Trojanowski JQ. The relationship between oxidative/
nitrative stress and pathological inclusions in Alzheimer’s and Parkinson’s diseases. Free 
Radic Biol Med 2002; 32:1264-75.
241. Zoghbi HY, Botas J. Mouse and fl y models of neurodegeneration. Trends Genet 2002; 18:
463-71.
242. Hyun DH, Lee M, Hattori N, et al. Effect of wild-type or mutant Parkin on oxidative 
damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 2002; 277:
28572-7.
243. Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, Masliah E. alpha-Synuclein 
protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-
signaling pathway in neuronal cells. J Biol Chem 2002; 277:11465-72.
244. Hague S, Rogaeva E, Hernandez D, et al. Early-onset Parkinson’s disease caused by a 
compound heterozygous DJ-1 mutation. Ann Neurol 2003; 54:271-4.
245. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 
mutations in Parkinson’s disease. Ann Neurol 2003; 54:283-6.
246. Hedrich K, Djarmati A, Schäfer N, et al. DJ-1 mutations are less frequent than parkin 
mutations in early-onset Parkinson’s disease. Submitted to Neurology.
247. Valente EM, Bentivoglio AR, Cassetta E, et al. DYT13, a novel primary torsion dystonia 
locus, maps to chromosome 1p36.13--36.32 in an Italian family with cranial-cervical or 
upper limb onset. Ann Neurol 2001; 49:362-6.
248. Rizzu P, Hinkle DA, Zhucareva V, et al. DJ-1 co-localizes with pathological tau inclusions: 
a possible link between Parkinsonism and dementia. Ann Neurol in press.
249. Valente EM, Brancati F, Ferraris A, et al. PARK6-linked parkinsonism occurs in several 
European families. Ann Neurol 2002; 51:14-8.
250. Khan NL, Valente EM, Bentivoglio AR, et al. Clinical and subclinical dopaminergic 
dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002; 52:
849-53.
251. Bonifati V, Breedveld GJ, Squitieri F, et al. Localization of autosomal recessive early-onset 
parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann Neurol 
2002; 51:253-6.
252. Bentivoglio AR, Cortelli P, Valente EM, et al. Phenotypic characterisation of autosomal 
recessive PARK6-linked parkinsonism in three unrelated Italian families. Mov Disord 2001; 
16:999-1006.
253. Dekker M, Bonifati V, Van Swieten J, et al. Clinical features and neuroimaging of PARK7-
linked parkinsonism. Mov Disord 2003; 18:751-7.
254. Anderson KE, Weiner WJ. Psychiatric symptoms in Parkinson’s disease. Curr Neurol 
Neurosci Rep 2002; 2:303-9.
255. Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal 
degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. 
Acta Neurol Scand 1994; 89:347-52.
256. Risch N. Evolving methods in genetic epidemiology. II. Genetic linkage from an 
epidemiologic perspective. Epidemiol Rev 1997; 19:24-32.
257. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 
1996; 273:1516-7.
258. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405:
847-56.
259. Foltynie T, Sawcer S, Brayne C, Barker RA. The genetic basis of Parkinson’s disease. J 
Neurol Neurosurg Psychiatry 2002; 73:363-70.
260. DeStefano AL, Golbe LI, Mark MH, et al. Genome-wide scan for Parkinson’s disease: the 
GenePD Study. Neurology 2001; 57:1124-6.
Chapter 1.1
41
261. Heutink P, Oostra BA. Gene fi nding in genetically isolated populations. Hum Mol Genet 
2002; 11:2507-15.
262. Craig SP, Buckle VJ, Lamouroux A, Mallet J, Craig IW. Localization of the human 
dopamine beta hydroxylase (DBH) gene to chromosome 9q34. Cytogenet Cell Genet 
1988; 48:48-50.
263. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) 
encodes an ATP-binding protein. Nat Genet 1997; 17:40-8.
264. Wilhelmsen KC, Weeks DE, Nygaard TG, et al. Genetic mapping of Lubag (X-linked 
dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X 
chromosome. Ann Neurol 1991; 29:124-31.
265. Heutink P. Untangling tau-related dementia. Hum Mol Genet 2000; 9:979-86.
266. Martin ER, Scott WK, Nance MA, et al. Association of single-nucleotide polymorphisms of 
the tau gene with late-onset Parkinson disease. Jama 2001; 286:2245-50.
Genetics of Parkinson’s disease

43
Pathogenesis of Parkinson’s disease – the contribution of 
α-synuclein and parkin 
This chapter reviews the available data on the pathogenesis of PD forms caused by 
mutations in D-synuclein and parkin, and discusses the implications of this growing body 
of knowledge for the understanding of the mechanisms underlying the common forms 
of the disease. 
THE CONTRIBUTION OF α-SYNUCLEIN
There is no doubt that the fi rst monogenic form of PD (PARK1) has led to a landmark 
discovery: D-synuclein is a key player in the pathogenesis of both autosomal dominant 
PD and idiopathic PD. While missense variants (A53T, A30P) of this protein are a very rare 
cause of autosomal dominant PD,1, 2 wild type D-synuclein is one of the major components 
of the Lewy bodies in all forms of PD, and other synucleinopathies.3, 4 In the last three years, 
several transgenic animal models have been generated that over-express wild type 
or mutant human D-synuclein. These models display varying degrees of biochemical, 
pathological and clinical abnormalities reminiscent of PD, and further support the 
contention that D-synuclein is primarily implicated in the pathogenesis of PD in general.5-7
D-Synuclein is a 140 amino acid protein, which has been highly conserved in evolution; 
it is abundant in neurons and enriched in the presynaptic compartment.8 Although 
its exact function remains unknown, an involvement in synaptic plasticity,8 and in 
regulation of size9 and turnover10 of synaptic vesicles has been suggested. Mice 
in which the D-synuclein gene has been knocked out possess a normal number of 
dopaminergic neurons and synapses, but show mild reduction in striatal dopamine 
levels, and abnormalities in the amphetamine-induced responses, suggesting a role 
for D-synuclein in the regulation of the dopaminergic neurotransmission.11 D-Synuclein
KO mice do not develop PD-like pathology, in keeping with the role of this protein in 
PD being due to a “gain of function” rather than a “loss of function”. However, the 
possibility that loss of the normal function of D-synuclein might contribute to the disease 
progression cannot be excluded, and the expression of A53T and A30P alleles appears 
decreased in advanced disease stages.12, 13
The D-synuclein protein contains a N-terminal amphipathic region, a central region, 
which includes the amyloidogenic peptide NAC (Non-AE Component of Alzheimer’s 
disease amyloid), and a C-terminal acidic region. Six imperfect repeats of 11 amino 
acids, containing the KTKEGV consensus motif, are present within the fi rst 95 amino 
acids. These repeats confer a variation in hydrophobicity, which is typical of the 
amphipathic D-helix of the lipid-binding domain in apolipoproteins.8, 14 And indeed, 
D-synuclein shows homology with fatty acid binding proteins,8, 15 but also with the 14-3-3 
family of molecular chaperones,16 and it displays inhibitory activity on phospholipases.17
D-Synuclein is natively unfolded, and its secondary structure is critically dependent from 
interaction with lipid membranes, which markedly increase the alpha-helix content.18
Biochemical studies have shown that D-synuclein displays a concentration-dependent 
property to form oligomeric species (also called protofi brils) and amyloid E-sheet fi brils in
vitro.19, 20 Oligomers are believed to represent the precursors of higher order aggregates 
(fi brils) in vivo, which are therefore assembled in the fi lamentous structures seen in Lewy 
bodies and Lewy neurites. In different neurodegenerative diseases, the oligomers, and 
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not the mature fi brils, are suggested to be the real neurotoxic molecules.21-25 In support 
of this view, increased oligomerization, not fi brillization, is the shared property of the two 
known PD-linked mutations.26, 27
It is therefore critical to understand the factors governing the formation, and controlling 
the steady state levels of oligomers in the common forms of the disease. Several 
biophysical and biochemical studies investigated D-synuclein aggregation, but 
only recently, the oligomerization process has been specifi cally addressed and the 
factors involved are beginning to be characterized. It is possible that small amounts of 
D-synuclein oligomers are normally formed in the neuron as well, and evidence for the 
existence of oligomers in normal conditions has indeed been obtained recently.28
Factors enhancing D-synuclein fi brillization in vitro include heavy metals and pesticides 
(implicated in PD on the basis of epidemiological studies),29-31 oxidative stress,32 and 
heparin33, but how these factors relate to the formation of oligomers is unknown. On the 
other hand, it is known that molecular crowding,34 interaction with calcium, possibly via 
calmodulin35, 36 interaction with lipid membranes37 and polyunsaturated fatty acids28, 38
promote and/or enhance oligomerization, whereas saturated fatty acids decrease the 
oligomerization.28
Furthermore, studies in cell culture and animal models have shown that mitochondrial 
inhibitors like rotenone and paraquat,39-41 oxidative42, 43 and nitrative44 conditions, and 
proteasomal inhibition,45 are all associated with increased D-synuclein fi brillization with 
formation of intracellular aggregates. 
Post-translational modifi cations of D-synuclein, including transglutaminase mediated 
cross-linking,46 phosphorylation,47, nitration,48 and mono- and diubiquitylation49 likely 
contribute to the formation and/or stabilization of aggregates. On the other hand, 
magnesium31, E-synuclein and J-synuclein50 appear to inhibit the fi brillization of 
D-synuclein. E-Synuclein markedly decreased formation of D-synuclein inclusions and 
prevented neurodegeneration in D-synuclein/E-synuclein double transgenic mouse.51
Intrinsic biophysical properties of D-synuclein are probably conferring a high neurotoxic 
potential to this protein, in analogy to other critical proteins which are pivotal in other 
neurodegenerative diseases, like tau and E-amyloid for AD, or PrP for prion disease. 
Recent evidence suggests that interactions between tau and D-synuclein can 
synergistically promote the polymerization of both proteins,52 in keeping with reports of 
co-localization of D-synuclein and tau epitopes in Lewy bodies.53, 54
The regulation of D-synuclein neuronal levels is likely subject to tight control, and a 
major hypothesis is that the primary abnormality in PD is an abnormally increased 
D-synuclein expression, perhaps giving rise to an excess of oligomers. The factors 
controlling the expression of D-synuclein in human neurons remain largely unexplored 
and this appears a very promising area for future studies. The expression of D-synuclein
might be regulated by the transcription factors engrailed-1 and engrailed-2,55 by nerve 
growth factor,56 and by steroid hormones.57
Studies of the human D-synuclein promoter in cell systems suggest that high- and 
low-expression alleles exist,58 but clear evidence of overrepresentation of the high-
expression alleles in PD is lacking so far. Intriguingly, increased expression of D-synuclein
and decreased expression of β-synuclein has been reported in brains from patients 
with diffuse Lewy body disease, suggesting that an imbalance between expression of 
the different synucleins might be pathogenic,59 and that smaller peptides mimicking 
E-synuclein effects might have therapeutic potential in PD.60 However, another study 
did not fi nd changes in D-synuclein expression in PD brain.61
The other possibility is that in PD there is a primary decrease in the clearance of D-synuclein
and/or its oligomers. Direct interaction between D-synuclein and a proteasomal 
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subunit has been reported.62, 63 However, whether D-synuclein is degraded by the 
proteasome or by different systems remains controversial, with evidence in favour,64,
65 including ubiquitin-independent proteasomal processing,66 and evidence against 
it.65, 67 Other studies suggest that calpain (a cysteine protease),68 and the lysosomes44,
65 are also involved in cleavage and degradation of D-synuclein. Intriguingly, reduced 
activity of the proteasome subunits have been found in PD brains,69 and two other 
genes implicated in monogenic PD (parkin and UCH-L1) suggest an involvement of 
the ubiquitin-proteasome pathway. Last, proteasomal subunits, ubiquitylated proteins, 
and molecular chaperones are present in Lewy bodies, further implicating the protein 
clearance system in the pathogenesis.7 However, a defi nite link between D-synuclein
and the proteasome remains to be proven, and it is not certain whether D-synuclein
(or a modifi ed form) is a parkin substrate in vivo. Other pathways might be crucial for 
D-synuclein degradation and for PD pathogenesis. This is another very important area 
for future investigation.
How is α-synuclein neurotoxic? 
Apart from the questions of how an abnormal oligomerization of D-synuclein is 
determined in PD, another central problem is how monomeric or oligomeric D-
synuclein exerts its toxicity. This remains unclear, but several possibilities have been 
suggested, including a direct inhibition of the proteasome system,63, 70, 71 an impairment 
of mitochondrial function72 and derangement in cellular traffi cking73. As a further 
mechanism, it has been proposed that D-synuclein oligomers can form pore-like 
structures similar to bacterial toxins, which are able to damage synaptic vesicles.74, 75
Mutant PD-linked D-synuclein oligomers would have even greater potential to damage 
vesicles.76 In the case of the dopaminergic neuron, the release of dopamine in the 
presynaptic cytosol would lead to oxidative stress. 
Any kind of selective interaction between D-synuclein and dopamine has the 
potential to explain the relative selectivity of the PD neurodegenerative process for 
the dopaminergic neurons. In this regard, it is interesting that in a neuronal culture 
system, the toxicity of D-synuclein requires endogenous dopamine production, as 
it is abolished by tyrosine hydroxylase inhibition, and it seems mediated by reactive 
oxygen species.77
And indeed, D-synuclein and dopamine might be linked at many levels. For example, 
overexpression of D-synuclein inhibits the activity of tyrosine hydroxylase, the rate-
limiting enzyme in the dopamine synthetic pathway,78 as well as the expression of 
genes involved in the dopamine biosynthesis, possibly by down-regulating NR4A2.79
This could represent a protective response against the toxicity of excessive D-synuclein
levels. Intriguingly, in the last report, both PD-linked D-synuclein mutants were unable 
to down-regulate the expression of dopamine-synthetic enzymes, suggesting that 
defective down-regulation of the dopamine synthetic pathway is pathogenic.79
Any links between D-synuclein and NR4A2 pathways is very interesting because 
NR4A2 mutations have been described in families with PD. These mutations appear 
associated with decreased expression of NR4A2 and its controlled genes,80 but effects 
on D-synuclein expression are also possible and these remain unexplored.
Other studies suggest that D-synuclein interacts with, and enhances the activity of the 
dopamine transporter,81 and it inhibits the monoamine vesicular transporter.82 Together 
with a direct damage to vesicles by pore-like oligomers, these effects would converge 
to the common endpoint of increasing the cytosolic levels of free dopamine, leading 
to oxidative stress. Moreover, the oxidative metabolite dopamine quinone can form 
adducts with the same D-synuclein, and these adducts inhibit the conversion of 
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D-synuclein oligomers to higher aggregates, further reinforcing the oligomer-mediated 
toxicity.83 Interestingly, oxidative modifi cations,84 including formation of dityrosine cross-
links,27, 85 as well as nitrative modifi cations,86 have been independently reported to 
promote/stabilize D-synuclein oligomers and inhibit the formation of fi brils.
The links between D-synuclein and dopaminergic neurons are also highlighted by 
evidence that D-synuclein overexpression might enhance the toxicity of MPTP,87
whereas D-synuclein KO mice are resistant to the toxicity of MPTP,88, 89 a selective 
dopaminergic neurotoxin, which inhibits mitochondrial complex I, but also leads to 
dopamine redistribution from vesicles to cytosol and dopamine-mediated oxidative 
stress.90
Several studies in cell culture systems have linked the overexpression of wild type 
and especially mutant D-synuclein to mitochondrial dysfunction,72 oxidative stress,72,
91-93 susceptibility to dopamine-mediated toxicity,94, 95 proteasomal inhibition,71, 93 and 
apoptosis.71, 93 It is of interest that in other cell systems, D-synuclein exerted protection 
against oxidative stress96 or anti-apoptotic properties,97 and protected mice from 
paraquat-induced neurodegeneration.98 These fi ndings illustrate the complexity of the 
D-synuclein pathways and its possible functions, as well as the possible confounding 
effects of the different cell types, levels of expressions, and different experimental 
paradigms. More importantly, many reciprocal infl uences are known between 
protein misfolding, oligomerization, proteasome inhibition, activation of unfolded 
protein response, oxidative stress, and mitochondria damage, leading to many 
possible vicious cycles, and ultimately to neuronal cell death. Furthermore, all of these 
mechanisms have been implicated in the pathogenesis of common PD, but it is diffi cult 
to disentangle the primary and secondary events. 
The role of Lewy bodies
The role of the highly ordered, fi lamentous inclusion bodies (Lewy bodies) is controversial, 
as they might be neurotoxic, inert, or even protective for the neuron. The presence of 
ubiquitylated proteins, proteasomal subunits, and molecular chaperones in the Lewy 
bodies, as well as in other aggregates found in neurodegenerative diseases, implicates 
the protein clearance system in the pathogenesis.
Lewy bodies are observed in the surviving, and otherwise healthy neurons. They 
can function to eliminate toxic soluble species (oligomers) by sequestering them in 
insoluble non-toxic form. This could be a compensatory mechanism in situations where 
the protein quality control system (proteasome, chaperones and other systems) is 
insuffi cient or overloaded by misfolded, or toxic proteins. This view is supported by 
the fact that Lewy bodies, as well as other neurodegenerative disease-associated 
inclusion bodies, resembles the so-called aggresomes.99
Aggresomes are microtubule-dependent inclusion bodies to which aggregated 
proteins are specifi cally and actively delivered. They are usually single, perinuclear 
structures, located close to the centrosome (the microtubule organizing centre). 
They contain molecular chaperones, proteasomal subunits, and a peripheral cage-
shaped ring of intermediate fi laments (typically vimentin). Aggresomes are believed 
to be part of the cell repertoire of responses to protein misfolding and aggregation, as 
they can sequester oligomers or smaller aggregates of toxic proteins, accumulating 
them perhaps for more effi cient disposal via autophagy.100 Lewy bodies display 
many similarities to aggresomes, including the morphology, presence of chaperones, 
proteasomal subunits, and other aggresomal markers like J-tubulin and pericentrin.101,
102 Last, studies in an inducible mice model of Huntington’s disease (HD) indicate 
Chapter 1.2
47
that formation of intranuclear inclusions in HD are reversible, suggesting that a 
continuous infl ux of misfolded proteins is needed to maintain the inclusions also in other 
neurodegenerative diseases.103
The role of molecular chaperones
Our knowledge about the role of molecular chaperones in neurodegeneration is 
gaining momentum. These proteins function in assisting the proper folding of nascent 
polypeptides, and refolding of damaged proteins; they are also involved in targeting 
and/or delivering of protein to the proteasomal system for degradation.104 Studies 
in transgenic animal models and cell systems provided convincing evidence that 
manipulation of the chaperone and of the ubiquitin systems infl uences markedly 
the pathogenesis. In rodent and fl y models of different neurodegenerative diseases 
(including SCA1, SCA3, HD, and D-synuclein), the overexpression of chaperones 
reduces, whereas interference on the chaperones aggravates neurotoxicity.105-109
Interestingly, these effects are not accompanied by visible modifi cation of aggregates.7
On the contrary, interference with the ubiquitylation (namely by inactivating an 
ubiquitin ligase) enhances pathogenesis but also markedly reduces the formation of 
aggregates.110
Taken as a whole, these studies strongly support the contention that inclusions are 
not primarily pathogenic, and they might actually be neuroprotective. However, the 
presence of molecular chaperones, proteasomal subunits, cytoskeletal components, 
and many other proteins in the Lewy bodies, suggests that the inclusions could also be 
detrimental for the cell by sequestering these and other important components. Lewy 
bodies could therefore have a “dual” role, being neuroprotective and neurotoxic, 
perhaps depending from the disease stage, or the age of the brain. The absence of 
Lewy bodies in PARK2 is associated with an accelerated loss of nigral neurons and 
onset of symptoms, but with slower progression of disease, in keeping with such a dual 
role of the inclusions. 
PATHOGENESIS OF PARKIN DISEASE
The discovery of parkin mutations in PARK2 has provided a second landmark 
contribution to the understanding of PD.111, 112 The results of large and comprehensive 
studies indicate that mutations in this gene are found in about half of the families with 
early-onset PD compatible with recessive inheritance, and in about 20% of the sporadic 
cases with early onset PD (chapters 2.1, 2.4).113, 114 The fact that parkin mutations are a 
frequent cause of early onset PD supports the contention that the parkin protein is 
another key player in PD in general.
The function of the parkin protein
The parkin protein is widely expressed in neurons but also in glial cells.115, 116 In studies 
using different techniques and different cell types, the parkin protein was localized 
at the level of the Golgi complex and cytosol,117 with endoplasmic reticulum and 
large cytosolic vesicles,115 in association with actin fi laments,118 synaptic vesicles,119,
120 postsynaptic densities and lipid drafts,121 the nuclear matrix,122 and the outer 
mitochondrial membrane.123
Parkin possesses ubiquitin-ligase activity.124-126 Covalent attachment of the ubiquitin 
(Ub) polypeptide (ubiquitylation) tags proteins for proteasomal degradation, and this 
is a fundamental mechanism for the protein quality control system.127 The Ub system 
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involves a series of enzymatic steps: a fi rst ubiquitin-activating enzyme (E1) uses ATP to 
confer Ub a high-energy state. Then Ub is transferred to an Ub-conjugating enzyme (E2) 
which in cooperation with an Ub-ligase (E3) transfers the ubiquitin to the fi nal substrate. 
Only one E1 gene is known in the human genome, whereas there are a few E2 and 
hundreds of E3 genes. Most of the substrate specifi city of the ubiquitylation process 
appears therefore contributed by the E3s. In some instances, a fourth enzyme (E4) 
enhances the formation of the poli-ubiquitin chain, which is a preferential signal for 
proteasomal degradation.127 Parkin interacts through its RING-IBR-RING domains with 
different E2 enzymes, including the cytosolic UbcH7 and UbcH8,124-126 and with the 
endoplasmic reticulum associated UBC6 and UBC7.128 Parkin also ubiquitylates itself 
and promotes its own proteasomal degradation.126, 129
Parkin, a protein with many interactors
PARK2 is in most cases a classical recessive disease, suggesting that the loss of parkin 
function is pathogenic. Moreover, several disease-causing missense mutations in parkin 
abolish the Ub-ligase activity.124, 126, 130 To the extent that loss of this E3 function is the 
culprit in parkin disease, an accumulation of non-ubiquitylated substrates is important in 
the pathogenesis. The identifi cation of parkin substrates is therefore of great interest.
Yeast two-hybrid screens and other approaches have provided several putative 
candidates, including: CDCrel-1, a synaptic vesicle associated protein;126 synphilin-1, 
an D-synuclein-interacting protein;130 the putative G protein-coupled transmembrane 
PAEL-receptor (parkin-associated endothelin receptor-like receptor),128 DSp22, a new 
brain-specifi c glycosylated form of D-synuclein,131 CASK, a postsynaptic protein,121
cyclin-E, a protein linked to cell cycle regulation and neuronal apoptosis,132 p38, 
a component of the tRNA-aminoacyl synthetase complex,133 and lastly, D- and E-
tubulins.134
CDCrel-1 and the septins
The CDCrel-1 protein (sept-5) belongs to a family of proteins (septins) classically 
involved in cytokinesis, exocytosis and cellular morphogenesis.135 CDCrel-1 is 
predominantly expressed in the nervous system where it may regulate synaptic vesicle 
dynamics. Whether abnormal metabolism of sept-5 might affect the dopaminergic 
neurotransmission, remains unknown. Moreover, there are other fi ndings linking septins 
to neurodegeneration: sept-4 is present in Lewy bodies and interacts with D-synuclein,136
and sept-1, sept-2 and sept-4 are present in neurofi brillary tangles.137 Last, sept-4 is 
localized to mitochondria and signals in a pro-apoptotic pathway.138
CASK and the postsynaptic compartment
On the basis of the presence of a PDZ (postsynaptic density 95, disc large, zona
occludens) binding motif at its C-terminus, parkin was shown to bind the PDZ protein 
CASK (calcium/calmodulin-dependent serine protein kinase), and to co-localize 
with CASK at the synapse and post-synaptic densities and lipid drafts in brain.121 A 
protein complex formed by CASK, Velis and Mint, is implicated in the transport of the 
NR2B subunit of the NMDA (N-methyl D-aspartate) receptor, which is critical for the 
postsynaptic plasticity.139 Indeed, other components involved in the scaffolding or 
signalling of the NMDA receptor (including PSD-95, the NR2B subunit, the calmodulin-
dependent kinase II (CaMKII), and homer 1a) were co-immunoprecipitated with parkin, 
suggesting that they might associate via CASK.121 Since parkin does not ubiquitylate 
CASK, it is possible that CASK serves to scaffold parkin at postsynaptic complexes, in 
order to target the ubiquitylation of other synaptic proteins.121 The CDCrel-1 protein 
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and CASK are once again bringing the attention to the synapse, as D-synuclein did, 
suggesting synaptic derangement as alternative common pathway in PD. There is 
increasing evidence that ubiquitylation is important for synaptic function.140
PAEL receptor and the endoplasmic reticulum stress
The function of the PAEL receptor is unknown, but when overexpressed, PAEL becomes 
unfolded and induces endoplasmic reticulum (ER) stress and the unfolded protein 
response (UPR).128 The UPR is a complex adaptive cellular pathway, which can be 
triggered by perturbations in redox state, calcium levels, elevated protein synthesis, 
altered glycosylation, proteasomal inhibition, and other causes of misfolded protein 
overload in the ER.141 The UPR includes the coordinated transcriptional and post-
transcriptional regulation of many genes, leading to increased activity of chaperones, 
increased protein degradation via the ubiquitin-proteasome system, and decreased 
protein synthesis.141 In case of failure of these responses to counteract misfolded protein 
overload, a prolonged activation of UPR leads to cell death by several redundant 
pathways for caspase activation, including mitochondrial-dependent and direct 
activation.141
Expression profi ling in cell systems exposed to toxins which induce dopaminergic 
neuronal loss and experimental parkinsonism (6-OH-dopamine, MPTP, and rotenone) 
revealed strong induction of the UPR, lending further support to the contention that 
UPR is involved in the mechanisms of neuronal cell death in PD.142, 143 A link between 
parkin and the UPR was established in a study which showed that parkin expression 
is induced during the UPR, and that parkin suppresses the UPR–induced cell death 
through its E3 activity.125 This suggested that parkin is involved in the UPR response by 
ubiquitylation and proteasomal degradation of unfolded substrates. A note of caution 
is warranted here, as parkin expression showed no changes144 or a mild up-regulation145
during the UPR in other cell culture studies, and parkin overexpression failed to protect 
from UPR-induced death in another cell system.123
However, subsequent studies showed that parkin overexpression promotes the 
ubiquitylation and degradation of PAEL and protects from the PAEL-induced toxicity 
in cell culture as well as in fl y models engineered to express human PAEL.120, 128 Parkin-
mediated ubiquitylation of PAEL is promoted by CHIP (carboxyl terminus of the Hsc70-
intacting protein), which acts by promoting the dissociation of the chaperone Hsp70 
from the parkin-PAEL complex, as well as by directly enhancing the E3 activity of parkin, 
thereby serving as a E4-like protein.146
Finally, there is evidence of PAEL accumulation in the brain of patients with parkin 
disease,128 suggesting that PAEL is a substrate for parkin mediated degradation in vivo,
and that the UPR is implicated in the pathogenesis of parkin disease.120 The fact that 
PAEL is highly expressed in nigral neurons provides a fi rst possible explanation for regional 
selectivity of pathology in parkin disease.128 However, the panneural expression of PAEL 
in Drosophila is associated with age-related, selective degeneration of dopaminergic 
neurons,120 suggesting that other factors, which are specifi c of the dopaminergic 
neurons, determine the selectivity of the pathology.
α-synuclein, synphilin-1 and parkin
Parkin was co-immunoprecipitated with a new O-glycosylated form of D-synuclein
(DSp22) from normal brain lysates, but not with the native D-synuclein abundant form. 
Moreover, wild type parkin (but not disease-linked parkin mutants) ubiquitylate DSp22
in vitro, and the levels of DSp22 increase in brain of parkin patients.131 These fi ndings 
suggest that DSp22 is a substrate of parkin and identifi es a novel pathway, which is 
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potentially involved in the genesis of Lewy bodies and in the pathogenesis of classical 
PD. The accumulation of DSp22 in the brain might lead to neurodegeneration in parkin 
disease.131 However, the biological relevance of the DSp22 isoform remains unclear. 
Another study confi rmed that parkin does not interact with, nor does it ubiquitylate 
the native D-synuclein isoform, but the DSp22 species was not detected in neuronal 
as well as non-neuronal cultures.130 In this last study, parkin was shown to interact 
with and ubiquitylate the D-synuclein-interacting protein synphilin-1. Co-expression of 
parkin, D-synuclein and synphilin-1 in cell cultures results in ubiquitylation of proteins in 
Lewy body-like cytoplasmic inclusions. Disease-linked mutations in parkin impair the 
ubiquitylation of synphilin-1 and of the cytoplasmic inclusions.130
The reported interaction between parkin and D-synuclein, either direct via DSp22,131
or indirect via synphilin-1,130 is intriguing because it would link parkin to D-synuclein,
another protein which is central in the pathogenesis of PD. The link between these two 
proteins has been confi rmed in recent studies, which showed that parkin overexpression 
protects from D-synuclein-induced neurotoxicity in cell culture147 and in Drosophila.120
The last report fi rmly indicates parkin as a potent modifi er of the D-synuclein-induced
neurodegeneration in Drosophila, once again suggesting that parkin is implicated in 
the pathogenesis of PD in general.
Parkin and the tubulins
In a recent study, parkin was shown to bind D- and E-tubulins, and microtubules; 
moreover, parkin was able to ubiquitylate and to promote the degradation of D- and 
E-tubulins. This suggests that parkin is a microtubule-associated protein, and it plays a 
protective role in controlling the levels of neurotoxic misfolded tubulins, which originate 
during the dynamic process of microtubule polymerization and depolymerization.134
Cyclin-E, p38 and apoptosis
Two of the latest proposed parkin substrates, cyclin-E and p38 suggest additional and 
intriguing links between parkin activity and protection of neurons from apoptosis. 
According to a recent study, parkin functions in a multiprotein ubiquitin ligase complex, 
which includes hSel-10 (a F-box/WD repeat protein also termed hCdc4 or Archipelago) 
and Cullin-1. HSel-10 targets the parkin E3 activity to its interactor cyclin-E.132
Cyclin E has been implicated in the regulation of cell cycle entry into S phase, but 
evidence suggests a role for cyclins including cyclin-E in the regulation of apoptosis in 
postmitotic neurons, and particularly in the response to excitotoxicity.148-150 Interestingly, 
cyclin levels are increased in PD and other neurodegenerative diseases, and cyclin 
E seems also increased in the brain of patients with parkin disease.132 Moreover, 
glutamate excitotoxicity has been implicated in the pathogenesis of neuronal loss in 
PD.151 In keeping with this evidence, parkin overexpression protected, whereas parkin
knock down sensitised neuronal cultures to kainate-mediated apoptosis (a model of 
excitotoxicity), also displaying a relative selectivity for dopaminergic neurons.132 These 
results suggest a role for parkin in another pathway of brain neuronal survival, which is 
potentially implicated in both parkin disease and common PD. 
The last putative parkin substrate to be discussed is p38, a key scaffold subunit of the 
aminoacyl-tRNA synthetase complex.133 Parkin is able to interact, ubiquitylate and 
promote the degradation of p38 in cell cultures, and to protect dopaminergic neurons 
from toxicity associated with p38 overexpression. Moreover, p38 overexpression 
leads to formation of aggresome-like inclusions also containing parkin, and p38 
immunoreactivity was found in Lewy bodies in classical PD.133 These fi ndings suggest 
that p38 plays a role in the pathogenesis of parkin disease and of common PD. In 
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addition to their role in protein translation, several components of the aminoacyl-
tRNA synthetase complex might have non canonical functions including cytokine 
generation and control of apoptosis,152 suggesting a further putative pathway linking 
parkin dysfunction to neuronal death.
The links between parkin and apoptosis are supported by fi ndings in the Drosophila 
parkin knock out model.153 These fl ies show reduced longevity, male sterility, locomotor 
defects and mild, age-related structural changes in a particular cluster of dopaminergic 
brain neurons (the dorsomedial cluster), which is also particularly sensitive to toxicity in 
the D-synuclein transgenic fl y.153 The male sterility is due to mitochondrial defects in 
spermatogenesis, and the locomotor defects are caused by a mitochondrial myopathy 
leading to apoptotic cell death.153 This model failed to reproduce dopaminergic 
neuronal loss typical of human parkin disease. However, its fi ndings are important in 
the light of mitochondrial defects observed in classical PD.154 Reduced male fertility 
and muscle dysfunctions have not been reported in human parkin disease, but none 
of these aspects has been specifi cally addressed in patients, and this would certainly 
be of interest for future investigations. Intriguingly, the DJ-1 gene homologue has also 
been linked to male infertility in rodents,155, 156 suggesting the possibility that parkin and 
DJ-1 function is required in a common pathway during spermatogenesis.
Recently, parkin function has been linked to protection from mitochondria-dependent 
cell death in a cell culture model.123 Last, oxidative stress and nitric oxide production 
has been observed as a result of overexpression of disease-linked parkin mutations in 
cell cultures,157 and the observed accumulation of iron in the substantia nigra of parkin 
patients also supports a role for oxidative stress in the pathogenesis.158
Parkin as a multifunctional neuroprotective agent
Whether the accumulation of one or several of the putative parkin substrates is 
neurotoxic remains unclear. Evidence for accumulation of the proposed parkin 
substrates in the brain of patients with parkin disease is so far limited to single reports,128,
131, 132 and they remain to be confi rmed in other studies on human brain as well as in 
animal models of parkin disease. Whatever the initial mechanism is, the fi nal endpoint 
in parkin disease appears to share evidences of mitochondrial derangement, oxidative 
stress, and apoptosis,123, 153, 157 suggesting further links to the pathogenesis of classical 
PD.
Taken as a whole, the available evidence delineates parkin as a multifunctional 
neuroprotective protein, which is active against stress induced by several misfolded 
proteins (D-synuclein, PAEL, D- and E-tubulins, and other proteins, including expanded 
polyglutamine proteins159), as well as against excitotoxicity, and cell death pathways 
linked to cyclic E or p38.  The interaction between parkin and the chaperone Hsp70,146
now confi rmed by an independent group,159 could mediate the interaction with a 
variety of misfolded proteins, explaining the apparent broad substrate specifi city 
of parkin.159 The parkin ubiquitin-ligase activity could protect cells in several ways, 
including tagging the unfolded substrates for proteasomal degradation, promoting 
formation of aggresome-like inclusions to sequester excess of substrates in inert forms, 
and perhaps by signalling in other ubiquitin-mediated pathways related to cell death. 
The relation between parkin and Lewy bodies
The presence of D-synuclein,160 parkin161, 162 and synphilin-1163 in Lewy bodies suggests 
that the Ub-ligase activity of parkin is important for the formation of these inclusions. 
This could explain the absence of Lewy bodies in the patients with parkin disease. The 
recent description of a case of heterozygous carrier of parkin mutations and Lewy 
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bodies is in agreement with this view,164 as one of these mutants possesses residual E3 
activity according to another report.130
The absence of Lewy bodies in parkin disease (PARK2) is associated with a rather 
selective, severe loss of dopaminergic neurons, an early onset but a slower progression 
of symptoms in comparison with common, Lewy body PD. It is tempting to speculate 
that in common PD the formation of Lewy bodies is initially able to counteract the 
toxicity of soluble species, slowing down the neurodegenerative process and the loss 
of dopaminergic neurons, so delaying the onset of symptoms. However, after decades 
of overload of misfolded or toxic proteins, this system eventually collapses, and the 
aggregates begin to add to the toxicity of soluble species, so contributing to the more 
aggressive course, and to the loss of dopaminergic as well as non-dopaminergic 
neurons, as seen in late-onset PD.
The ubiquitin-proteasome system in parkin disease and PD
While the link between parkin and ubiquitylation is convincingly established, much 
less so is the implication of the proteasomal degradation. The ubiquitin-like domain 
(Ub-L) of parkin shares a motif with other Ub-L-containing proteins, which are known 
to interact with the proteasome.165 This suggests that parkin might also interact with 
the proteasome, linking this structure with the ubiquitylation machinery. And indeed, 
recent evidence suggests that parkin is able to bind proteasomal subunits, such as 
Rpt6159 and Rpn10.166
However, it is increasingly being recognized that, in addition to the proteasomal 
degradation, ubiquitin conjugation is a signalling system which regulates a broad 
range of cellular processes, including gene transcription, endocytosis, and protein 
sorting.127, 167 Ubiquitylation is therefore regarded as a form of post-translational protein 
modifi cation pathway like phosphorylation. Much of the previous functional work 
has explored the physiological and pathological role of parkin assuming a link to the 
ubiquitin-proteasome system. However, it is possible that this is not the whole story, 
and parkin might be linked to neurodegeneration via a different ubiquitin-mediated 
pathway.
A primary involvement of the ubiquitin system in neurodegeneration is also supported 
by the association of a single mutation and a polymorphism in UCH-L1 with PD (chapter 
1.1),168 and a mutation in mahoganoid, encoding a ubiquitin ligase, in a spongiform 
neurodegenerative disease in mice.169 UCH-L1hydrolyses ubiquityl-peptide conjugates 
in vitro.170 Although its physiological role remained debated, this protein was deemed 
important for the recycling of free ubiquitin molecules from the ubiquityl-peptides 
fragments produced by the proteasome. This contention is not supported by recent 
evidence, which implicates a different enzyme, POH1, a subunit of the proteasomal 
regulatory complex, in a rate-limiting de-ubiquitylating reaction taking place before 
the proteasomal degradation.171 The UCH-L1 protein displays a second, dimerization 
dependent, ubiquitin ligase activity for D-synuclein in vitro.172 This ligation uses K63 as 
opposed to K48 chemistry, and it is therefore unlinked to proteasomal degradation. 
Whether this reaction takes place in vivo and whether it is implicated in PD pathogenesis 
remains unknown. Last, very recently it has been discovered that UCH-L1 binds mono-
ubiquitin in neurons and stabilizes the mono-ubiquitin levels in vivo by preventing the 
degradation of ubiquitin.173 Interestingly, the PD-associated mutation (I93M) has no 
effects on this activity, and therefore, if really pathogenic, it acts by another (likely 
gain-of-function) mechanism.
Chapter 1.2
53
Mutations in proteasomal subunits have not been linked to human neurodegeneration. 
Evidence of proteasomal abnormalities has not been reported so far in PD animal 
models either. It is likely that major defects in this system are not compatible with life. 
For example, loss of the function of the POH1 homologue Rpn11 is lethal in yeasts. 
However, mild decreases in proteasomal activity could be compatible with life and 
could predispose to neurodegeneration. 
The available evidence for an involvement of the proteasome system in PD is indirect.
Reduced proteasomal activity has been reported in post-mortem studies on PD brains,69
while another group detected no abnormalities.174 Overexpression of D-synuclein and 
other proteins in cell systems leads to proteasomal inhibition with or without aggregate 
formation.63, 70, 71, 147 Catecholaminergic neurons seem particularly vulnerable to 
proteasomal inhibition in vitro, suggesting a possible explanation of the selectivity of D-
synuclein-associated degeneration.147 Direct injection of a proteasomal inhibitor in the 
substantia nigra in rats induced neuronal degeneration and formation of inclusions.175
However, whether the effects observed in post-mortem studies and overexpressing cell 
models are relevant for in vivo conditions remains unclear, and whether a systemic 
proteasomal inhibition can produce selective dopaminergic neurotoxicity remains to 
be demonstrated. 
The presence of ubiquitylated proteins, molecular chaperones, and proteasomal 
components in the Lewy bodies is perhaps the strongest evidence implicating the 
protein clearance system in disease pathogenesis. Moreover, the morphological 
and biochemical similarities between Lewy bodies and aggresomes101, 102 once again 
points to defective or overloaded proteasomal activity, as aggresome formation 
is considered a cell response to insuffi cient proteasomal-mediated clearance of 
misfolded or toxic proteins.100
In common PD the proteasome could be primarily defective, for example as a 
consequence of mutations in its subunits, or it could be inhibited by D-synuclein
oligomers or other toxic species, or lastly, it could become insuffi cient due to chronic 
overload of misfolded and other damaged proteins. In the case of the proteasomal 
defect, as for the oxidative stress, the mitochondrial dysfunction, and other 
abnormalities proposed in the pathogenesis, it is important to distinguish processes that 
are central and determinant in the cascade leading to neurodegeneration from other 
collateral effects. Moreover, it is critical to understand why the pathological process in 
PD affects the dopaminergic neurons with relative selectivity. 
TOWARD A UNIFYING THEORY OF PATHOGENESIS
It is possible to reconcile evidences from different research lines assuming that PD (as 
well as other common neurodegenerative diseases) is a disorder of the protein quality 
control (PQC) system, which is associated with neuronal accumulation of misfolded 
proteins and presence of protein aggregates. Major arms in the PQC system are the 
molecular chaperones,104 the endoplasmic reticulum associated unfolded protein 
response pathway,141 the ubiquitin-proteasome system,127 and other ubiquitin-like 
protein conjugation systems, including sumoylation.176 Studies of the monogenic 
forms of PD implicate the different components of this system, delineating a coherent 
pathogenetic framework, which could be at the roots of the common forms of the 
disease as well.
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Scope of this thesis
Parkinson’s disease (PD) is etiologically heterogeneous, and several monogenic forms 
have been identifi ed (chapter 1.1). Although the monogenic forms so far known 
explain a very small fraction of PD cases at the population level, they are promoting 
the understanding of the molecular events and the metabolic pathways involved in 
the common forms of PD as well (chapter 1.2). This thesis aims to study the molecular 
genetics and the phenotypical aspects of autosomal recessive, early-onset forms of 
PD.
Mutations in a novel gene termed parkin were fi rst identifi ed in families with autosomal 
recessive early-onset parkinsonism in Japan. In order to accurately assess the frequency 
of involvement of parkin and to characterize the associated mutational spectrum, we 
analysed this gene in a large number of European families in which early-onset PD was 
compatible with a recessive model of inheritance, as well as in a large series of isolated 
cases with early-onset PD (chapter 2.1). Mutations were found in almost 50% of families 
and 20% of isolated cases, delineating parkin as a major gene for early onset, recessive 
PD. To illustrate further the high frequency of the mutations in this gene, we described 
two families with early-onset PD due to parkin gene mutations, and showing pseudo-
dominant inheritance or allelic heterogeneity in the same sibship (chapters 2.2, 2.3).
Last, we collected a large series of patients with PD due to parkin gene mutations to 
perform genotype-phenotype correlation studies. The results are presented in chapter
2.4.
In order to identify novel genes causing autosomal recessive, early-onset PD, we 
undertook a genome-wide linkage mapping study in a large consanguineous family 
originating from a genetically isolated community of the South West of the Netherlands. 
This study led us to the identifi cation of PARK7, a novel locus for autosomal recessive, 
early-onset PD, on the short arm of chromosome 1 (chapter 2.5). In order to identify 
further families linked to PARK7, we performed linkage analysis of candidate regions in 
an independent dataset of families with early onset PD. This study, presented in chapter
2.6, yielded conclusive evidence for linkage to PARK7 in a second family from central 
Italy. We also undertook detailed clinical and neuroimaging studies in the Dutch family 
linked to PARK7, to characterise further the phenotypical spectrum associated with this 
form. The results are shown in chapter 2.7.
In order to identify the gene defective at the PARK7 locus, we performed fi ne mapping 
and positional cloning studies, which led to the discovery of pathogenic mutations in 
the DJ-1 gene in the two families defi nitely linked to PARK7 (chapter 2.8). The function 
of the protein encoded by DJ-1 is mostly unknown, and none has previously linked this 
gene to brain function or disease. We reviewed the literature in order to provide clues 
to a possible function and formulate hypotheses linking DJ-1 to neurodegeneration 
(chapter 2.9). The discovery of the gene defect in another form of Mendelian PD 
opens a novel window on the mechanisms underlying human neurodegeneration. 
More importantly, this discovery might promote our understanding of the pathogenesis 
of the common forms of PD.
Chapter 1.3
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disease and mutations in the parkin gene
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ABSTRACT
Background Mutations in the parkin gene have
recently been identified in patients with early-onset
Parkinson’s disease, but the frequency of the muta-
tions and the associated phenotype have not been
assessed in a large series of patients.
Methods We studied 73 families in which at least
one of the affected family members was affected at
or before the age of 45 years and had parents who
were not affected, as well as 100 patients with isolated
Parkinson’s disease that began at or before the age
of 45 years. All subjects were screened for mutations
in the parkin gene with use of a semiquantitative
polymerase-chain-reaction assay that simultaneously
amplified several exons. We sequenced the coding
exons in a subgroup of patients. We also compared
the clinical features of patients with parkin mutations
and those without mutations.
Results Among the families with early-onset Par-
kinson’s disease, 36 (49 percent) had parkin mutations.
The age at onset ranged from 7 to 58 years. Among
the patients with isolated Parkinson’s disease, muta-
tions were detected in 10 of 13 patients (77 percent)
with an age at onset of 20 years or younger, but in
only 2 of 64 patients (3 percent) with an age at onset
of more than 30 years. The mean (±SD) age at onset
in the patients with parkin mutations was younger
than that in those without mutations (32±11 vs. 42±
11 years, P<0.001), and they were more likely to have
symmetric involvement and dystonia at onset, to have
hyperreflexia at onset or later, to have a good response
to levodopa therapy, and to have levodopa-induced
dyskinesias during treatment. Nineteen different re-
arrangements of exons (deletions and multiplications)
and 16 different point mutations were detected.
Conclusions Mutations in the parkin gene are a
major cause of early-onset autosomal recessive famil-
ial Parkinson’s disease and isolated juvenile-onset Par-
kinson’s disease (at or before the age of 20 years). Ac-
curate diagnosis of these cases cannot be based only
on the clinical manifestations of the disease. (N Engl
J Med 2000;342:1560-7.)
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ARKINSON’S disease is one of the most fre-
quent neurodegenerative disorders, with a
prevalence of 1 to 2 percent among persons
older than 65 years of age.1 It is character-
ized by resting tremor, rigidity, and bradykinesia, all
of which respond well to treatment with levodopa.
The pathological hallmarks are the presence of Lewy
bodies (cytoplasmic eosinophilic hyaline inclusions)
and massive loss of dopaminergic neurons in the pars
compacta of the substantia nigra.2 The cause of the
disease is still unknown, but the existence of genet-
ic susceptibility factors is strongly suspected.3,4 Two
genes (a-synuclein5 and ubiquitin carboxy-terminal
hydrolase L1 [UCH-L1]6) and two gene loci (on
chromosomes 2p13 and 4p14–16.3, respectively7,8)
have been implicated in the pathogenesis of autoso-
mal dominant Parkinson’s disease, but they seem to
account for the cases in only a few families. In con-
trast, mutations in the gene designated parkin have
recently been identified in several families with au-
tosomal recessive early-onset parkinsonism.9-14 How-
ever, the frequency of mutations in this gene in fa-
milial and isolated cases of early-onset parkinsonism
has not yet been assessed in large series of patients.
The phenotype associated with mutations in the
parkin gene has not been clearly established, making
the selection of patients for genetic testing difficult.
In Japanese patients with parkin mutations, the dis-
ease is characterized by an early onset, dystonia at
P
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onset, hyperreflexia, early complications resulting from
levodopa treatment, and slow progression.9-11 In con-
trast, the clinical characteristics of some European
and North African patients with parkin mutations
were indistinguishable from those of patients with
idiopathic Parkinson’s disease, with an age at onset
of up to 58 years.13,14 The number of families analyzed
so far is small, however, and the correlations between
genotype and phenotype are uncertain. Brain tissue
from the patients studied did not contain Lewy bod-
ies, suggesting that the pathologic process might dif-
fer from that of idiopathic Parkinson’s disease.15,16
We performed a clinical and molecular study of 73
families with early-onset autosomal recessive Parkin-
son’s disease, including 152 affected family mem-
bers, and 100 patients with early-onset isolated Par-
kinson’s disease. They were screened for mutations
in the parkin gene by a semiquantitative polymerase-
chain-reaction (PCR) assay designed to detect exon
rearrangements (deletions and multiplications) and
by genomic sequencing. Correlations between gen-
otype and phenotype were assessed both in patients
with parkin mutations and in those without such
mutations.
METHODS
Patients and Families
We studied 73 families (152 patients with Parkinson’s disease
and 53 unaffected relatives) that met the following criteria: symp-
toms of parkinsonism in affected family members that were re-
duced by at least 30 percent by treatment with levodopa (the re-
sponse could not be assessed in 3 untreated patients); a mode of
inheritance compatible with autosomal recessive transmission (af-
fected siblings without affected parents); an age at onset of 45 years
or younger in at least one of the affected siblings; and the absence
of extensor plantar reflexes, ophthalmoplegia, early dementia, or
early autonomic failure in the family members we examined. Twen-
ty of the families originated from Italy, 14 from France, 12 from
Great Britain, 10 from the Netherlands, 9 from Germany, 2 from
Portugal, and 1 each from Spain, Algeria, Morocco, Argentina, In-
dia, and Vietnam. Eight of the families were consanguineous, and
12 have been described previously.13,14 In addition, we studied 100
patients with isolated Parkinson’s disease with an age at onset of
45 years or younger, most of whom were European, and 8 of whom
were from consanguineous marriages. These 100 patients were se-
lected according to the same clinical criteria used for the patients
with familial disease but who had no family history of Parkinson’s
disease. Eight of these 100 patients had never received treatment.
The enrollment of the subjects was random. For each subject,
we obtained clinical information from the subject or the subject’s
records and peripheral blood for DNA analysis. DNA was extracted
from peripheral-blood leukocytes according to standard procedures.
The study was approved by ethics committees in the countries of
all the participating investigators, and written informed consent
was obtained from all the study subjects.
Molecular Analysis
Screening for mutations in the parkin gene was performed in
all index patients (except those known to be homozygous or to have
compound heterozygosity for such mutations13,14) with the use of
a semiquantitative PCR assay for the detection of rearrangements of
parkin exons. Exons 2 through 12 were amplified simultaneously in
three groups by PCR (multiplex PCR): group 1 consisted of exons
4, 7, 8, and 11; group 2 consisted of exons 5, 6, 8, and 10; and
group 3 consisted of exons 2, 3, 9, and 12 and an external control,
C328, a 328-bp sequence of the transthyretin gene on chromosome
18. The primers used were the same as those described by Kitada et
al.9 except for the primer for exon 3, for which exonic primers were
used: 5'AATTGTGACCTGGATCAGC3' (Ex3iFor) as the forward
primer and 5'CTGGACTTCCAGCTGGTGGTGAG3' (Ex3iRev)
as the reverse primer. The C328 forward primer was 5'ACGTT-
CCTGATAATGGGATC3' (TTRForHex), and the reverse primer
was 5'CCTCTCTCTACCAAGTGAGG3' (TTR328Rev). All for-
ward primers were fluorescently labeled with HEX-phosphorami-
tide. The PCR products (2.5 μl) were analyzed by 5 percent de-
naturing polyacrylamide-gel electrophoresis with an automated
sequencer (model ABI 377) and GeneScan version 3.1 and Gen-
otyper version 1.1.1 software (all from Applied Biosystems). All
reactions were performed at least twice. The DNA from a patient
known to have a heterozygous deletion of exons 8 and 9 was al-
ways processed in parallel as an internal control.
We calculated the ratios of all the peak heights in a given reac-
tion and then compared the ratios with the ratios measured in a
specimen from a normal subject. This comparison yielded the fol-
lowing rules: values of 0.6 or less were interpreted as indicating
a heterozygous deletion of an exon; values of 0.8 to 1.2 were in-
terpreted as normal; values of 1.3 to 1.7 were interpreted as indi-
cating a heterozygous duplication of an exon; values of 1.8 to 2.3
were interpreted as indicating a homozygous duplication or heter-
ozygous triplication of an exon; and values of more than 2.6 were
interpreted as indicating a homozygous triplication of an exon. An
exon rearrangement was confirmed only if all the ratios concern-
ing this exon were abnormal. The consequence of the rearrange-
ments at the protein level (a frame shift vs. an in-frame rearrange-
ment) was deduced from the exon sequences published by Kitada
et al.9 (DNA Data Bank of Japan accession number AB009973).
Each PCR reaction involved, in a total volume of 25 μl, 40 ng
of DNA, with 3 mM magnesium chloride, 0.2 mM of each deox-
ynucleoside triphosphate, and 1 U of Taq polymerase. Denatur-
ation for 5 minutes at 95°C was followed by 23 cycles consisting
of 30 seconds of denaturation at 95°C, 45 seconds of annealing
at 53°C, and 2.5 minutes of extension at 68°C, with a final period
of extension at 68°C for 5 minutes. Primer concentrations were
chosen to yield — within the exponential phase of the PCR (data
not shown) — similar peak heights in each multiplex reaction and
ranged from 0.4 to 1.9 μM. Deletions and insertions of bases
were deduced from the size of the PCR products.
In the case of 54 index patients with familial disease and 91 in-
dex patients with isolated disease, exon rearrangements or dele-
tions or insertions of bases were not found on both chromosomes
and thus did not account for the phenotype. Therefore, the entire
coding region of the parkin gene (including exon–intron bound-
aries) was sequenced as described previously14 in 53 index patients
with familial disease and 50 patients with isolated disease.
Whether the parkin variants we identified cosegregated with
the disease was assessed by genotyping of all available members,
affected or not, of the respective families. In addition, 114 chro-
mosomes from mostly European, unrelated controls who had no
movement disorders were analyzed for the point mutations and the
rearrangements of the exons represented in multiplex group 3.
The techniques used were restriction assays, polyacrylamide-gel
electrophoresis, and the semiquantitative PCR assay. For two point
mutations — the substitution of A for G at nucleotide 939 of
complementary DNA (cDNA) and the substitution of T for C at
nucleotide 1101 of cDNA — mismatched reverse primers were
used in order to create a restriction site that depended on the point
mutation being looked for: 5'GGCAGGGAGTAGCCAAGTTG-
AGGAT3' for digestion with AlwI and 5'AGCCCCGCTCCACA-
GCCAGCGC3' for digestion with BstUI (in each primer, the un-
derlined nucleotide differs from the wild-type sequence).
Statistical Analysis
Means (±SD) were compared with the nonparametric Mann–
Whitney U test. Frequencies were compared with the chi-square
test, with Yates’ correction when appropriate.
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RESULTS
Frequency of Mutations in the parkin Gene
Twenty-five families (56 patients) with autosomal
recessive Parkinson’s disease had homozygous or com-
pound heterozygous mutations on each allele of the
parkin gene (Table 1). In addition, 11 families (27
patients) with a mutation in one allele were consid-
ered to have parkin-related disease, on the basis of the
assumption that the second mutation was not de-
tected by the methods used in this study. Thus, mu-
tations in the parkin gene were detected in 36 of 73
families (49 percent), including 12 previously de-
scribed families.13,14 Among the 100 patients with iso-
lated Parkinson’s disease, 18 (18 percent) had parkin
mutations. The frequency of mutations among con-
sanguineous patients with isolated Parkinson’s disease,
a pattern that is suggestive of autosomal recessive in-
heritance, was similar to that among consanguine-
ous patients with familial disease (50 percent vs. 62
percent). The frequency of mutations in the patients
with isolated Parkinson’s disease decreased significant-
ly with increasing age at onset: mutations were de-
tected in 10 of 13 patients (77 percent) with an age
at onset of disease of 20 years or younger, but only
in 2 of 64 patients (3 percent) with an age at onset
of 31 to 45 years (Table 2). Sequencing of the parkin
gene in 22 of the 64 patients with isolated Parkinson’s
disease who were older than 30 years at the onset of
symptoms revealed a point mutation in only 1 patient.
In 14 families in which the affected family members
had parkin mutations on both chromosomes, none
of 28 unaffected siblings had two parkin mutations,
indicating the high penetrance of the mutations.
Clinical Studies
The 36 families with Parkinson’s disease and par-
kin mutations and the 18 patients with isolated Par-
kinson’s disease and parkin mutations came from a
variety of regions: France (in 15 cases), Italy (in 13),
Great Britain (in 7), the Netherlands (in 3), Spain
(in 3), Germany (in 3), Portugal (in 2), Algeria (in
2) and Lebanon, India, Pakistan, Vietnam, Japan, and
Argentina (in 1 case each).
As a group, the 100 patients with parkin muta-
tions had a mean (±SD) age at onset of 32±11 years
(range, 7 to 58); the age at onset was not known for
1 patient (Table 3). Among the patients with an age
at onset of 45 years or younger, the onset of the dis-
ease was earlier in the 18 patients with isolated Par-
kinson’s disease and parkin mutations than in the
75 patients with familial Parkinson’s disease and mu-
tations (mean age, 21±9 vs. 32±9 years; median, 20
vs. 33 years; P<0.001). This difference was not due
to selection bias, because the mean ages at onset were
similar in the two groups when all initially included
patients with an age at onset of 45 years or younger
were compared, whether or not they had parkin mu-
tations (age at onset in 118 patients with familial dis-
ease, 34±9 years; in 100 patients with isolated disease,
32±9 years). The mean age at onset was significant-
ly younger in the patients with parkin mutations
than in those without mutations, both in the total
sample (Table 3) and in the group with familial cas-
es alone (34±10 years for 82 patients with familial
disease and mutations and 43±12 years for 65 pa-
tients with familial disease but without mutations;
P<0.001).
The initial manifestations of the disease in most
patients with parkin mutations were tremor (65 per-
*Early onset was defined as an onset at or before 45 years of age (in at
least one of the affected siblings in affected families).
†The parkin gene was not sequenced in one family.
‡The parkin gene was not sequenced in 41 patients in whom the onset
of disease was after 30 years of age.
TABLE 1. FREQUENCY OF MUTATIONS IN THE PARKIN GENE 
IN 73 FAMILIES WITH AUTOSOMAL RECESSIVE EARLY-ONSET 
PARKINSON’S DISEASE AND 100 PATIENTS WITH ISOLATED 
EARLY-ONSET PARKINSON’S DISEASE.*
NO. OF MUTATIONS
FAMILIES WITH AUTOSOMAL
RECESSIVE DISEASE
(N=73)
PATIENTS WITH ISOLATED 
CASES (N=100)
NO. OF 
FAMILIES
NO. OF 
CONSANGUINEOUS 
FAMILIES
NO. OF 
PATIENTS
NO. OF 
CONSANGUINEOUS 
PATIENTS
Two 25 5 14 4 
One 11† 0 4 0 
None identified 37 3 82‡ 4
Total no. with 
mutations (%)
36 (49) 5 (62) 18 (18) 4 (50)
*P=0.003 for the comparison with patients with an age at onset of 21
to 30 years.
†P=0.005 for the comparison with patients with an age at onset of 31
to 40 years.
‡The parkin gene was not sequenced in 35 patients.
§The parkin gene was not sequenced in six patients.
TABLE 2. FREQUENCY OF MUTATIONS IN THE PARKIN GENE IN 100 
PATIENTS WITH ISOLATED EARLY-ONSET PARKINSON’S DISEASE, 
ACCORDING TO THE AGE AT ONSET.
AGE AT ONSET
PATIENTS WITH HOMOZYGOUS
OR HETEROZYGOUS
MUTATIONS
CONSANGUINEOUS PATIENTS
WITH HOMOZYGOUS OR
HETEROZYGOUS MUTATIONS
no. of patients/total no. (%)
«20 yr 10/13 (77)* 2/3 (67)
21–30 yr 6/23 (26)† 2/2 (100)
31–40 yr 1/49 (2)‡ 0/2
41–45 yr 1/15 (7)§ 0/1
Total no. of 
patients (%)
18/100 (18) 4/8 (50)
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*Plus–minus values are means ±SD. Among the patients with parkin mutations, 83 had familial
disease and 18 had isolated disease. Among the patients without parkin mutations, 57 had familial
disease and 28 had isolated disease.
†The motor scale of the Unified Parkinson’s Disease Rating Scale (UPDRS)17 assesses 14 motor
functions of patients with Parkinson’s disease. Some of the functions were tested separately for each
side of the body, the arms and legs, the face, and the trunk, resulting in 27 subtests. Each subtest
was scored on a scale from 0 (no impairment) to 4 (severe impairment), resulting in a total score
ranging from 0 to 108.
‡The Hoehn and Yahr stages are used to describe the degree of functional disability of patients
with Parkinson’s disease. Stage 1 indicates mild unilateral symptoms, stage 2 bilateral or axial symp-
toms, stage 3 impairment of postural reflexes, stage 4 strongly disabling disease (the patient is able
to stand and walk unassisted but is markedly incapacitated), and stage 5 severely disabling disease (the
patient cannot stand or walk without assistance and is therefore confined to a wheelchair or bed).18
§The Mini–Mental State examination assesses orientation; short-term memory; attention span; and
naming, copying, reading, writing, spatial, and constructive capacities with respect to 30 tasks, all
scored as either 1 (succeeded) or 0 (failed). The maximal score is 30; dementia was considered to be
present if the score was below 24.
TABLE 3. CHARACTERISTICS OF PATIENTS WITH PARKINSON’S DISEASE ACCORDING TO
THE PRESENCE OR ABSENCE OF MUTATIONS IN THE PARKIN GENE.*
CHARACTERISTIC
PATIENTS WITH PARKIN 
MUTATIONS 
(N=101)
PATIENTS WITHOUT 
PARKIN MUTATIONS 
(N=85) P VALUE
Sex (F/M) 49/52 31/54
Age at onset (yr) 32±11 42±11 <0.001
Duration of disease (yr) 17±11 13±11 0.002
Clinical signs at onset (%)
Micrography
Bradykinesia
Tremor
Dystonia
Asymmetric signs
30
63
65
42
89
47
65
75
22
98
0.02
0.02
0.02
Clinical signs at examination
Bradykinesia (%)
Rigidity (%)
Resting tremor (%)
Postural tremor (%)
Urinary urgency (%)
Hyperreflexia (%)
No progression or slow rate of progression (%)
95
92
74
54
11
44
88
98
99
80
47
25
21
72
0.01
0.04
Motor scale of UPDRS score†
Without treatment
During treatment
41±22
23±18
43±16
26±15
Hoen–Yahr assessment without treatment‡
Mean stage
Interval from onset to stage 2 (yr)
Interval from onset to stage 3 (yr)
Interval from onset to stage 4 (yr)
Interval from onset to stage 5 (yr)
3.2±1.0
11±9
19±10
26±8
40±19
3.1±0.8
5±3
17±8
33±2
44
Mini–Mental State Examination score§
Clinical signs during treatment
Percent improvement with levodopa
Daily dose of levodopa (mg)
Duration of levodopa treatment
Months
Years
29±3
72±20
500±340
123±102
10
28±2
64±17
600±400
111±99
9
0.03
Levodopa-induced dyskinesia
Percentage of patients
Months of treatment
77
64±65
63
60±55
0.04
Levodopa-induced fluctuations in symptoms
Percentage of patients
Months of treatment
79
64±61
65
61±54
Dystonia
Percentage of patients
Months of treatment
58
65±72
45
54±40
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cent) and bradykinesia (63 percent) (Table 3). The pa-
tients with parkin mutations had significantly higher
frequencies of dystonia and symmetric symptoms at
onset and of hyperreflexia at onset or later, as well as
a better response to levodopa despite having had the
disease for a longer period (Table 3) than those with
no parkin mutations. Dystonia began in the lower
limbs in 28 of 31 patients with mutations, but 2 pa-
tients first had torticollis and 1 had right-arm dysto-
nia. Dyskinesia as a result of levodopa treatment was
significantly more common in patients with muta-
tions than in those with no mutations, but such dys-
kinesia occurred in both groups, on average, after
nearly 5 years of treatment (range, 1 month to 20
years). There were no significant differences between
the 24 patients with at least one missense mutation
and the 52 patients with two truncating mutations;
the 25 patients with single heterozygous truncating
mutations were not assigned to either group, since
the nature of the suspected second mutation was un-
known.
Nineteen different homozygous and heterozygous
exon rearrangements were found in 35 index pa-
tients, including 4 from previously described fami-
lies with homozygous deletions of exons (Table 4
and Fig. 1A).13,14 In addition to identifying the sus-
pected deletions of an exon, our approach provided
evidence of four duplications of an exon and one
triplication of an exon. The results were highly re-
producible and confirmed by cosegregation analysis.
Rearrangements of exons 2, 3, 9, and 12 were not
found in the controls.
Sixteen different exonic point mutations were found
in 28 index patients, including 8 from previously de-
scribed families14 (Table 4 and Fig. 1B). In addition,
an intronic deletion of 5 bp (IVS8 ¡21 to ¡17del)
was detected. All point mutations cosegregated with
the disease, and none were found in any control. The
amino acids modified by mutations were conserved
in the parkin orthologues in rats20 and mice (Gene
Bank accession numbers AF210434 and AB019558,
respectively). However, in two patients from one fam-
ily, the homozygous point mutation Arg334Cys was
associated with the homozygous intronic 5-bp dele-
tion and the heterozygous Asp280Asn mutation, so
that the pathogenicity of the latter two mutations
cannot be ascertained.
Many of the exon rearrangements were found re-
peatedly among the index patients, particularly dele-
tions of exon 3 (in 10 patients), exon 2 (in 4), exon
4 (in 4), and exons 3 and 4 (in 4) (Fig. 1A). Six point
mutations were found in more than one index pa-
tient: the deletion of A at nucleotide 255 of cDNA
(in six index patients), the deletion of A and G at nu-
cleotide 202 to 203 of cDNA (in five), Arg275Trp
(in five), the insertion of G and T between nucleo-
tide 321 and nucleotide 322 of cDNA (in two),
Lys211Asn (in two), and Gly430Asp (in two) (Fig. 1).
DISCUSSION
We detected mutations in the parkin gene in al-
most half the families with autosomal recessive Par-
kinson’s disease in which at least one affected mem-
ber was 45 years of age or younger at the onset of
symptoms. The frequency of such mutations was low-
er in a group of patients with isolated early-onset Par-
kinson’s disease.
On average, patients with parkin mutations began
to have symptoms in their early 30s, but the age at
onset ranged widely, from 7 to 58 years. The fact
that the onset occurred at an earlier age in patients
with isolated Parkinson’s disease and parkin muta-
tions than in those with familial Parkinson’s disease
and parkin mutations suggests that among patients
who are older than 30 years at the onset of isolated
Parkinson’s disease, the disease is mainly due to caus-
es other than parkin mutations.
Can patients with parkin mutations be distin-
guished clinically from patients with early-onset Par-
kinson’s disease from other causes? As a group, those
with parkin mutations had an earlier onset of dis-
ease, were more likely to have dystonia and symmetric
signs at onset, as well as hyperreflexia at onset or later,
and were more likely to have a better response to le-
vodopa, but were also more likely to have dyskinesia
during treatment, than were patients without parkin
mutations. These signs were less frequent, however,
than in previous reports11,21 and could not be used
specifically to identify patients with mutations. Fur-
thermore, the clinical manifestations of the parkin
mutations were independent of the age at onset.
In addition, patients with late-onset disease who
have mutations can be difficult to distinguish from
those with idiopathic Parkinson’s disease. In general,
however, the disease progressed slowly in the patients
with mutations. Despite having had symptoms for
*NA denotes not applicable.
†The parkin gene was not sequenced in one index patient.
TABLE 4. FREQUENCY OF HOMOZYGOUS, COMPOUND 
HETEROZYGOUS, AND SINGLE HETEROZYGOUS MUTATIONS 
AMONG 45 INDEX PATIENTS WITH FAMILIAL OR ISOLATED 
PARKINSON’S DISEASE, ACCORDING TO THE TYPE OF MUTATION.
TYPE OF MUTATION
EXON 
REARRANGEMENT
POINT 
MUTATION
EXON 
REARRANGEMENT 
PLUS A POINT 
MUTATION*
TOTAL 
NO. (%)
no. of index patients 
(no. of consanguineous index patients)
Homozygous 9 (6) 10 (3) NA 19 (35)
Compound hetero-
zygous
8 3 9 20 (37)
Single heterozygous 9† 6 NA 15 (28)
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Figure 1. Mutations in the parkin Gene.
Panel A shows the exon rearrangements identified. Deletions are indicated above the sequence, and duplications (dup) and triplica-
tions (trip) are indicated below the sequence. Their deduced effect on the protein is represented by a dotted line for in-frame re-
arrangements and by a solid line for frame-shift rearrangements. The number of index patients with the rearrangement and the type
of mutation — heterozygous (h) or homozygous (H) — are indicated above each mutation. Panel B shows the point mutations result-
ing in truncation of the sequence of 12 exons or in a missense mutation. The hatched regions indicate the ubiquitin-like domain and
the RING–IBR–RING finger motif.19 The 6 truncating mutations are indicated above the sequence, and the 10 missense mutations
are indicated below the sequence. For mutations identified in more than one index patient, the number of index patients with the
mutation is given in parentheses. The nucleotide change and the restriction enzymes used to screen family members and unrelated
control subjects without movement disorders are given in parentheses below the mutation (mm denotes the mismatch primer used
for the PCR, and PAGE polyacrylamide-gel electrophoresis). Mutations that were not based on published sequences14 are underlined.
Nucleotides prefaced by a small c indicate the numbers in the complementary DNA sequences described by Kitada et al.9 The ATG
of the initiator methionine codon begins at nucleotide 102. The putative site of phosphorylation (P) and an N-myristoylation site (M)
affected by the Thr415Asn and Trp453Stop mutations, respectively, are indicated. UTR denotes untranslated region.
Truncating mutations
Missense mutations
c.255delA (6)
Cys268Stop
(c.905T>A, Dde I)
c.1142–1143delGA
(PAGE)
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5' UTR 3' UTR
1
P
111098765432 12
M
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B
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many years, the majority of patients with parkin mu-
tations had good responses to low doses of levodopa.
Although levodopa-induced dyskinesia was reported
to develop early,9,11,21 the mean delay in our patients
was about 5 years, with a maximum of 20 years. This
time frame was similar to that for the patients with-
out parkin mutations.
Finally, dementia was rare among the patients with
mutations. This might be explained by a less wide-
spread neuronal loss in patients with mutations, in
whom the substantia nigra and, to a lesser extent,
the locus caeruleus are selectively affected, as com-
pared with patients with idiopathic Parkinson’s dis-
ease.15,16 However, the low frequency of dementia in
the patients with mutations could also be due to a
younger mean age at examination or to the exclusion
of patients who had dementia early in the course of
the disease.
There were no clinical differences between patients
with missense mutations and those with truncating
mutations. This finding was surprising, since missense
mutations might be expected to interfere less with
the function of the parkin protein than truncating
mutations and therefore to result in a milder pheno-
type. We therefore assume that the 10 conserved ami-
no acids that were affected by the missense mutations
are of crucial importance for the function of the pro-
tein or that their modification results in decreased
protein synthesis or more rapid degradation.22 In ad-
dition, the wide range of clinical signs, even within
single families with mutations (e.g., variation of up
to 20 years in the age at onset) suggests that addi-
tional factors contribute to the phenotype.
The chief histopathological differences between
patients with parkin mutations and those with idio-
pathic Parkinson’s disease that have been detected so
far are the absence of Lewy bodies and the restric-
tion of neuronal cell loss to the substantia nigra and
the locus caeruleus in the patients with parkin mu-
tations.16 Thus, parkin gene mutations are responsi-
ble for the death of selective cells, the mechanism of
which might differ from that in idiopathic Parkin-
son’s disease.
The PCR-based technique that we used revealed
numerous rearrangements of exons, including those
identified in eight families in which no mutations were
found by direct sequencing.14 In combination with
genomic sequencing, this technique greatly improves
the sensitivity of the molecular diagnosis in patients
with parkin gene mutations. The various combina-
tions of exon deletions, the exon multiplications,
and the newly identified point mutations increase
the already wide variety of disease-related mutations
identified in the parkin gene. The position of the
mutations indicates functionally important protein re-
gions such as the RING–IBR–RING domain, as does
conservation of the corresponding amino acids in
mice and rats.20
The presence of both deletions and multiplications
of some exons (e.g., exon 2 and 3) suggests that a
mechanism such as unequal recombination might be
involved. The observation that 13 of the mutations
were found repeatedly in as many as 10 families raises
the possibility of a founder effect. However, many of
the mutations were found in families from different
European countries, suggesting that these alterations
are recurrent. The point mutations that accounted for
the disease in approximately 40 percent of our patients
seem to be less frequent among Japanese patients.11
Finally, the identification of 15 index patients with
single heterozygous mutations indicates that other
mutations remain to be discovered, perhaps in non-
coding regions of the parkin gene.
In conclusion, mutations of the parkin gene are
frequent among patients with autosomal recessive Par-
kinson’s disease. Although dystonia at the onset of
disease, hyperreflexia, and a slow rate of disease pro-
gression are characteristic features of patients with
parkin mutations, there are no specific clinical signs
that distinguish these patients from patients with oth-
er causes of Parkinson’s disease. The wide spectrum
of mutations in the parkin gene renders molecular
diagnosis difficult, but the relatively simple semiquan-
titative PCR method that we used detected approx-
imately 70 percent of the mutations found in this se-
ries of patients.
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SHORT REPORT
Three parkin gene mutations in a sibship with
autosomal recessive early onset parkinsonism
V Bonifati, C B Lücking, E Fabrizio, M Periquet, G Meco, A Brice
Abstract
The objective was to describe a family
with autosomal recessive, early onset par-
kinsonism, with aVected siblings carrying
three diVerent exon rearrangements in
the parkin gene.
The living aVected siblings were person-
ally examined. Molecular genetic analyses
included exon dosage of the parkin gene
using a semiquantitative multiplex
polymerase chain reaction (PCR) proto-
col and haplotype analysis.
The index case was a compound heterozy-
gote with a deletion of exon 5 and a dupli-
cation of exon 3. His aVected sister was a
compound heterozygote for a deletion of
exon 5 and a deletion of exons 3–9. Haplo-
type analysis confirmed the presence of
three mutant alleles at the parkin locus.
The phenotype was early onset parkinson-
ism with marked response to levodopa,
and a very slow, prolonged course.
In conclusion, the frequency of mutations
in the parkin gene in certain populations
might be high enough to cause allelic
heterogeneity in the same sibship.
(J Neurol Neurosurg Psychiatry 2001;71:531–534)
Keywords: early onset parkinsonism; parkin gene; exon
rearrangements
Mutations in the parkin gene are a frequent
cause of autosomal recessive, early onset
parkinsonism. Various mutations, including
exon rearrangements (deletions and multipli-
cations) and point mutations (truncating and
missense) have been identified.1–10 The muta-
tional screening is probably still incomplete, as
only one mutant allele has so far been detected
in 15 out of 54 European families with parkin
mutations, even after exon dosage and se-
quence analysis have been performed.7 The
parkin protein has recently been shown to pos-
sess ubiquitin ligase activity, which is lost when
mutated.11
The finding of a pedigree with parkin muta-
tion in aVected persons from two diVerent
generations raised the question of a possible
dominant negative eVect of some parkin muta-
tions.9 A pseudodominant transmission is an
alternative explanation which cannot be ruled
out until mutational screenings in parkin
become more sensitive. To date, a pseudo-
dominant transmission of parkin related dis-
ease has been reported in a single Japanese
family segregating three mutant alleles in
diVerent sibships (two alleles carrying an exon
4 deletion, and the third allele carrying the
Cys431Phe point mutation in exon 12).10
We describe a sibship with early onset, slowly
progressive parkinsonism whose members are
compound heterozygotes for three diVerent
exon rearrangements in the parkin gene.
Family report
There is no known consanguinity between the
parents of the patients, who originated from
diVerent regions in Italy.
The index case (RM611, born 1922) first
noticed slowness of movements in the right leg
at the age of 35. The clinical course was very
slow. He was diagnosed with Parkinson’s
disease and treated with levodopa from 1970,
with marked response. Owing to motor fluc-
tuations and levodopa induced dyskinesias,
since 1994 levodopa has been replaced by oral
dopamine agonist monotherapy (0.5 mg lisu-
ride four times/day), with a satisfactory re-
sponse for years.
Our examination in 1998 (at age 76, after 40
years of disease course) showed a flexed
posture, axial akinesia and gait diYculties;
moderate generalised rigidity, and mild diVuse
bradykinesia in all four limbs, although more
severe in the upper limbs and on the left side.
Tremor was absent and the tendon reflexes
were normal. Dysarthria and hypomimia were
mild, and a Meyerson’s sign was present. Cog-
nition was normal and there was no severe
autonomic disturbance. His on state Hoehn
and Yahr stage was III. Brain MRI was normal.
He was still treated with oral lisuride (0.5 mg
four times/day) and deprenyl (5 mg/day).
The sister (RM612, born 1909) first experi-
enced resting tremor in the upper limbs at the
age of 31. Tremor was bilateral, although more
severe on the right side. When bradykinesia
and rigidity developed later, she was diagnosed
with Parkinson’s disease. The disease was
slowly progressive, aVecting both sides of the
body, although more severely on the right side.
In the late 1960s, after more than 25 years, the
symptoms had worsened to the extent that she
underwent stereotactic left thalamotomy,
which satisfactorily controlled the contralateral
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tremor. She was treated with levodopa from
1970, with good response. After several years
she developed motor fluctuations and levodopa
induced dyskinesias. We were able to examine
her at the age of 89, after 58 years of disease
course, a few months before her death; she had
a severe akinetic rigid syndrome, with Hoehn
and Yahr stage IV in the on, and V in the oV
states, respectively. Only mild resting tremor
was evident in both upper limbs. Tendon
reflexes were brisk. She also had a memory
deficit, visual hallucinations, and frank confu-
sional episodes, which were reported to have
been present during the past 3 years. At the
Figure 1 Exon rearrangements detected in the parkin gene. (A) Electropherograms showing fluorescently labelled
multiplex PCR products (see methods). The peak height reflects the quantity of template exon DNA. Het del=heterozygous
exon deletion, indicated by half of the expected peak height; hom del=homozygous exon deletion, indicated by no
amplification product; het dupl=heterozygous duplication, indicated by 1.5 times the expected peak height. (B) Schematic
representation of the exon rearrangements at the genomic level. Exons 2–12 within the pair of homologous chromosomes are
depicted as boxes, introns as solid lines. As the size of the introns is not known, double slashes separate the exons. Exon
deletions are indicated as dotted lines. The in tandem position of the duplicated exon 3 is hypothetical.
RM 611
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B
RM 612
Control
het del
ex 8 ex 7 ex 4 ex 11 ex 8 ex 7 ex 4 ex 11 ex 8 ex 7 ex 4 ex 11
RM 611
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het del
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Wild type (2 copies of each exon)
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(1 copy = 1/2 of expected peak height)
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time of our examination she was still receiving
levodopa (375 mg/day), amantadine (200
mg/day), and biperiden (5 mg/day). Brain
imaging was not available, and pathological
studies could not be performed.
Another sister (born 1913) was diagnosed
with Parkinson’s disease with onset at the age
of 31. She died in 1969, after 25 years of
disease course. Very limited information is
available on the parental and previous genera-
tions. The father of the patients died at the age
of 54, whereas the mother of the patients died
at the age of 67, with no reported evidence of
parkinsonism.
Molecular genetic studies
DNA was extracted using standard techniques
from peripheral blood leucocytes after in-
formed written consent. Exon rearrangements
of the parkin gene were detected using a semi-
quantitative multiplex polymerase chain reac-
tion (PCR) protocol described elsewhere.7
Exons 2–12 were amplified simultaneously in
three combinations by multiplex PCR using
HEX labelled forward primers. A 328 base pair
sequence of the transthyretin gene on chromo-
some 18 (C328) was also amplified as an inter-
nal control.7 The PCR products were analyzed
on an ABI377 automated sequencer with the
Genescan 3.1 and Genotyper 1.1.1 software
(Applied Biosystems). All possible peak height
ratios were calculated between the peaks in
given multiplex reactions. The peak height
ratios of the family members were compared
with a normal control.DiVerences of a factor of
0.5 were interpreted as indicating a hetero-
zygous deletion, and those of a factor of 1.5 as
indicating a heterozygous exon duplication. All
reactions were carried out at least in duplicate.
This method has been validated by cosegrega-
tion studies in several families.7
The consequences of exon rearrangements
at the level of parkin protein were predicted
according to the published exonic sequences
(Genome database accession number
AB009973).
Haplotypes of the parkin gene region were
constructed manually using the following
DNA repeat markers: D6S1581, D6S959,
D6S1579, D6S1599, D6S305, D6S411,
AFMa155td9, AFMb281wf1, D6S1550,
D6S1035 (intragenic markers underlined).
They were amplified with the primers specified
in the Genome database, except for D6S1599
which was amplified using “forward” 5'-GGG
TGTGCTTGGATTCCTTCATG-3' and
“reverse” 5'-TAGCATGTGGACTGCATAT
CAAC-3'. PCR conditions were 95°C for 30
seconds, 55°C for 30 seconds and 72°C for 45
seconds in 35 cycles. The PCR products were
analysed on an ABI377 automated sequencer
(Applied Biosystems), and marker alleles were
assigned in increasing order.
Molecular findings
The index case is a carrier of heterozygous
deletion of exon 5 and heterozygous duplica-
tion of exon 3. His sister carries a heterozygous
deletion of exon 5, and a heterozygous deletion
of exons 3 to 9 (fig 1).
At the level of the parkin protein, the exon 5
and exon 3–9 deletions lead to in-frame
rearrangements. By contrast, assuming that the
duplicated exons 3 are in tandem (fig 1 B), the
mutation introduces a frameshift rearrange-
ment and a complete loss of function of the
parkin protein.
Reconstructed haplotypes using intragenic
and flanking polymorphic markers are shown
in figure 2. As expected, the two sibs only share
one haplotype, the one associated with exon 5
deletion. In addition, for the intragenic markers
D6S305, D6S411, and AFMa155td9 patient
RM612 was an obligate hemizygote, because
the deletion of exons 3–9 encompasses intron
7, where these markers are located (fig 1 B).
For the remaining intragenic markers
D6S1599 (located in intron 2), and
AFMb281wf1 and D6S1550 (both located in
intron 9), it was not possible to determine
whether patient RM612 was homozygote or
hemizygote because parental genotypes were
not available.
Discussion
The young onset, very slow disease progression
and good response to levodopa in this family
suggested the involvement of parkin gene
mutations.7 In addition, the prolonged satisfac-
tory response to dopamine agonist mono-
therapy in case RM611 is of interest. A
sustained response to combined therapy with
bromocriptine and biperiden has been re-
ported in a patient with parkin mutations.8
Further studies are warranted to characterise
the response to dopaminergic stimulation in
patients with parkin mutations.
Dementia is not considered as part of the
phenotype in patients with parkin muta-
tions.7 12 In the largest series so far analyzed,
this may have been due to the young age of
patients at the examination or exclusion from
screening of cases with early dementia.7 Patient
RM612 is the first described with marked cog-
nitive disturbances, which might be ascribed
either to the extremely long course of parkin
Figure 2 Haplotype analysis. Six intragenic (the intronic position is given in parenthesis)
and four flanking markers were analyzed. The haplotype associated with the exon 5
deletion is boxed. The alleles for markers D6S1581 and D6S959 were not attributable to
either haplotype and are indicated in italics.
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disease, or to a coincidental Alzheimer-type
pathology. However, they more likely represent
side eVects of the antiparkinsonian drugs in an
old subject who also underwent stereotactic
thalamotomy.
The presence of three diVerent mutations
indicate that one of the parents was also a
compound heterozygous carrier of parkin
mutations. Neither the father nor mother was
known to be aVected when they died at the ages
of 54 and 67, respectively. This finding may
represent a case of as yet undescribed non-
penetrance of parkin mutations, or more likely
reflect the age dependent penetrance of the
disease. Parkin related disease displays wide
intrafamilial variability of ages at onset,5–7 and
the latest age at onset reported so far in patients
with proved parkin mutations is 64 years.9
Moreover, owing to the mild severity of symp-
toms in the first years from onset, the disease of
one parent might not have been recognised.
Mistaken paternity could be another explana-
tion, but is unlikely because one would have to
assume that both biological fathers were
heterozygous carriers of diVerent parkin muta-
tions.
Both scenarios therefore suggest that muta-
tions in the parkin gene are frequent enough in
some populations to lead to allelic heterogen-
eity in the same sibship, as described here, or to
pseudodominant transmission, as recently re-
ported.10
Owing to the presence of three mutant alle-
les, linkage and haplotype analyses could have
led to an erroneous exclusion in this family of
the parkin locus. Therefore, parkin gene muta-
tion in patients with levodopa responsive
parkinsonism, onset before the age of 40 and
slow disease progression should be tested by
direct analyses.
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Pseudo-dominant
inheritance and exon
2 triplication in a
family with parkin
gene mutations
Article abstract—The authors report an Italian family with pseudo-
dominant inheritance of parkinsonism attributable to parkin gene mutations.
The father (disease onset at age 57 years) was homozygous for a triplication
of exon 2 that is so far unique. The unaffected mother was heterozygous for
deletions of exons 3 and 4, and the son (onset at age 31 years) was a com-
pound heterozygote carrying both mutations. Thus, pseudo-dominant inheri-
tance of parkin gene mutations has to be considered in early-onset
parkinsonism, and sensitive screening techniques, such as semiquantitative
multiplex PCR, should be applied.
NEUROLOGY 2001;57:924–927
C.B. Lücking, MD; V. Bonifati, MD; M. Periquet; N. Vanacore, MD; A. Brice, MD; and G. Meco, MD
Parkin gene mutations cause autosomal recessive
early-onset parkinsonism. To date, many mutations
of different types have been described.1-7 The associ-
ated phenotypes vary widely and include late-onset
PD6,7 as well as phenotypes resembling Dopa-
responsive dystonia.8 Although transmission is re-
ported to be autosomal recessive (implicating loss of
function of the parkin protein as pathogenic mecha-
nism), questions have been raised concerning possi-
ble dominant negative effects of a subgroup of parkin
mutations for which patients in two generations
were heterozygous.7 However, in families with ap-
parently dominant inheritance, pseudo-dominant
transmission has to be considered. This has been
described only once in a family in Japan,9 a country
where the frequency of parkin gene mutations might
be particularly high.
Here we report the molecular and clinical findings
in an Italian family with pseudo-dominant inheri-
tance of parkinsonism due to parkin gene mutations.
Patients and methods. The proband (RM 330) of our
pedigree (figures 1 through 3) was screened for parkin
gene mutations6 because of early onset (at age 31 years)
and slow progression of parkinsonism. The affected father
(RM 347), whose neurologic signs (onset at age 57 years)
were initially thought to result from small vascular lesions
detected on brain CT scan, was genotyped subsequently.
DNA was extracted from peripheral blood leukocytes by
use of standard techniques after informed written consent.
Rearrangements of exons 2 through 12 of the parkin gene
were detected by semiquantitative multiplex PCR, as de-
scribed.6 In brief, we first calculated, for each case and
each control, the ratios of the peak heights of each exon to
every other exon in a given exon combination (PCR done in
duplicate). Then, each ratio of the controls was divided by
the respective ratio of the cases, yielding normalized ratios
(NR) for the cases. The NR thus could be compared among
three independent experiments for exon combination A
(figure 1), allowing calculation of mean normalized ratios
(MNR). Deviations of the NR/MNR from 1 were inter-
preted as exon rearrangement. Haplotypes of the parkin
gene region were constructed manually by using the micro-
satellite markers D6S1581, D6S959, D6S1579, D6S1599,
D6S305, D6S411, AFMa155td9, AFMb281wf1, D6S1550,
D6S1035, amplified with the primers specified in the
Genome database (GDB), except for D6S1599, which was
amplified by using “Forward” 5'-GGGTGTGCTTGGATTCC-
TTCATG-3' and “Reverse” 5'-TAGCATGTGGACTGCATAT-
CAAC-3'. PCR conditions were 95 °C for 30 seconds, 55 °C for
30 seconds, and 72 °C for 45 seconds in 35 cycles. PCR
products were analyzed on an ABI377 automated se-
quencer using GeneScan 3.1 and Genotyper 1.1.1 software
(Applied Biosystems, Weiterstadt, Germany), and marker
allele numbers were assigned in increasing order from the
smallest to the largest PCR product.
Results. Molecular findings. In 15 different controls
tested for exon combination A, the NR varied between 0.83
and 1.2; mean, 1.0  0.09 (SD of the ratio with the highest
SD). On this basis, confirmatory Southern blot was not
performed, because this technique—using parkin exons as
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probe—was considered less reliable. Figures 1 and 2 show
representative PCR profiles and a schematic presentation
of the parkin gene alleles. In RM 330, the peaks for exons
3 (MNR: 0.52 to 0.55  0.08) and 4 (NR: 0.45 to 0.5) were
half the expected size (theoretical value [TV]: 0.5), consis-
tent with heterozygous deletions, whereas the peak for
exon 2 was twice the expected size (MNR: 1.9 to 2.0  0.1;
TV: 2.0), consistent with four copies of exon 2. RM 330 was
heterozygous for all but one intragenic markers (figure 3).
RM 347 was homozygous for eight consecutive markers,
with a peak for exon 2 that was three times higher than
expected (MNR: 2.8 to 3.0  0.3; TV: 3.0). Thus, the PCR
profile would be explained by the presence of a homozy-
gous triplication of exon 2 in RM 347 (six copies of the
exon), and the combination of a heterozygous triplication of
exon 2 and a heterozygous deletion of exons 3 and 4 in RM
330. The deletion was transmitted from RM 399 (NR, exon
3: 0.5 to 0.63; NR, exon 4: 0.51 to 0.57). The deletion
included D6S1599, because RM 330 did not receive a ma-
ternal allele (figure 3), indicating the large size of the
deletion (72 kb, figure 2).
Clinical findings. The index patient (RM 330) first no-
ticed symmetric resting and postural tremor in the upper
limbs and generalized slowness of movement at age 31
years. Two years later, our examination showed mild par-
kinsonian signs (hypomimia, resting and postural tremors,
and bradykinesia) and brisk tendon reflexes. The Hoehn–
Yahr stage was II. The cognitive status was normal, but he
was very anxious. He remained untreated.
His father (RM 347) noticed resting tremor and motor
slowness in his left leg at age 57 years. A year later, brain
CT performed in another hospital was reported to be nor-
mal. A “pyramidal-extrapyramidal syndrome, and arterial
hypertension” were diagnosed, and he was successfully
Figure 1. Multiplex PCR detection of
exon rearrangements in the parkin
gene. The exons indicated at the bot-
tom were amplified in two multiplex
combinations (A and B) with fluores-
cently labeled forward primers and an-
alyzed on an automated sequencer
(ABI 377) with GeneScan 3.1 and
Genotyper 1.1.1 software (Applied Bio-
systems). The size of the PCR products
in bp is indicated at the top. The elec-
trophoregrams of the index case (RM
330) and his parents (RM 347, RM
399) are aligned with the control. Peak
heights represent the quantity of PCR
product that reflects the quantity of
template exon DNA. Peak heights of
heterozygous deletions (het del) are
half the expected height. Peak heights
of the heterozygous triplication (het
tripl) are 2 times the expected height and of the homozygous triplication (hom tripl) are 3 times the expected height. C328
is a sequence of the transthyretin gene (chromosome 18) serving as reference PCR product.
Figure 2. Schematic representation of
exons in the family and the control. Ex-
ons within the pair of homologous chro-
mosomes are depicted as boxes, introns
as solid lines. As the size of the introns
is not known, the lines are of arbitrary
length. Exon 2 and the marker
D6S1599 are positioned according to
the PAC clone HS292F10 (116 kb, se-
quenced by the Sanger Center) with the
distances specified in kilobases (kb). Exon
deletions are indicated as dotted lines.
The sequential localization of the tripli-
cated exon 2 is hypothetical. The type of
exon rearrangements and the factors by
which the peak heights differ from the
control are given below each pair of ho-
mologous chromosomes.
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treated with the anticholinergic drug trihexyphenidyl (1
mg three times daily). At age 59 years, after transient left
hemiparesthesia, a CT scan indicated a small ischemic lesion
in the right thalamus. His clinical condition remained stable
for 8 years under anticholinergic therapy; then the parkinso-
nian symptoms worsened. At the time of our first examina-
tion (age 69 years, with the same dosage of trihexyphenidyl),
he had a flexed posture, generalized rigidity and bradykine-
sia, more severe on the left side, resting tremor in the left leg,
and gait difficulties caused by postural disturbances and mo-
tor blocks. The Hoehn–Yahr stage was III. He also had brisk
tendon reflexes at all four limbs, and Babinski sign in the left
foot. The brain CT showed mild, diffuse cerebral atrophy, and
small ischemic lesions in right thalamus, left caudate nu-
cleus, and left pons. Levodopa was then added (100 mg three
times daily). It improved bradykinesia, gait, and especially
resting tremor. There was no known consanguinity between
the parents of the father. However, they came from the same
very small Italian village.
The mother (RM 399) was healthy at age 67 years.
Discussion. This is the first European family with
established pseudo-dominant transmission of par-
kinsonism caused by parkin gene mutations, and the
second family worldwide.9 Three of the four parkin
gene alleles in this family harbored mutations. Auto-
somal dominant transmission in families with par-
kin gene mutations should therefore only be
considered after complete exploration of the parkin
gene. However, even with a combination of exon dos-
age and genomic sequencing, approximately 15% of
mutant alleles remain undetected and might be lo-
cated in promoter or intronic regions of the gene.6
Whereas the proband showed early-onset and
slowly progressive parkinsonism, a phenotype usu-
ally associated with parkin gene mutations, disease
onset was later in the father and was complicated by
vascular brain lesions. However, later onset of
parkin-related disease has been described, and the
clinical picture can be indistinguishable from idio-
pathic PD.5-7 Although ages at onset might vary con-
siderably within the same sibship,5 they only differed
for more than 20 years in less than 10% of our series
of 39 sibpairs with parkin gene mutations (unpub-
lished observation). Thus, in this family, the differ-
ence in age at onset might be attributable to the fact
that father and son have only one disease-causing
allele in common, and the dissimilar mutations
might be more or less deleterious. However, addi-
tional genetic or environmental modifying factors are
not excluded.
The deletion of exons 3 and 4 is thought to cause a
frameshift in the mRNA (as deduced from the pub-
lished cDNA sequence1), resulting in a seriously
truncated parkin protein. In contrast, the mecha-
nisms by which the so far unique exon 2 triplication
leads to loss of parkin function needs further examina-
tion. We were never able to amplify a corresponding
reverse transcription (RT)-PCR product (Periquet et
al., manuscript in preparation), indicating the result-
ing mRNA might be unstable. Interestingly, exon 2 has
been found to be both triplicated or deleted in different
families,6 suggesting that unequal crossing-over after
misalignment of repeated sequences might give rise to
both of these mutations.
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How Much Phenotypic Variation Can Be
Attributed to parkin Genotype?
Ebba Lohmann, MD,1 Magali Periquet, BS,1 Vincenzo Bonifati, MD,2 Nick W. Wood, MD, PhD, FRCP,3
Giuseppe De Michele, MD,4 Anne-Marie Bonnet, MD,5 Vale´rie Fraix, MD,6 Emmanuel Broussolle, MD,7
Martin W. I. M. Horstink, MD,8 Marie Vidailhet, MD,1,9 Patrice Verpillat, MD, PhD,1,10
Thomas Gasser, MD,11 David Nicholl, MRCP,12 He´lio Teive, MD,13 Salmo Raskin, MD,14
Olivier Rascol, MD, PhD,15 Alain Deste´e, MD,16 Merle Ruberg, MD,1 Francesca Gasparini, MD,1
Giuseppe Meco, MD,2 Yves Agid, MD, PhD,1,5 Alexandra Durr, MD, PhD,1,17 Alexis Brice, MD,1,5,17
and The French Parkinson’s Disease Genetics Study Group and the European Consortium on
Genetic Susceptibility in Parkinson’s Disease
To establish phenotype–genotype correlations in early-onset parkinsonism, we have compared the phenotype of a large
series of 146 patients with and 250 patients without parkin mutations. Although no single sign distinguished the groups,
patients with mutations had significantly earlier and more symmetrical onset, dystonia more often at onset and hyper-
reflexia, slower progression of the disease, and a tendency toward a greater response to levodopa despite lower doses.
After forward stepwise multiple logistic regression analysis, dystonia at onset and brisk reflexes were not longer signif-
icantly different but were correlated with age at onset rather than the presence of the parkin mutation. Age at onset in
carriers of parkin mutations varied as did the rate of progression of the disease: the younger the age at onset the slower
the evolution. The genotype influenced the phenotype: carriers of at least one missense mutation had a higher United
Parkinson’s Disease Rating Scale motor score than those carrying two truncating mutations. The localization of the
mutations was also important because missense mutations in functional domains of parkin resulted in earlier onset.
Patients with a single heterozygous mutation had significantly later and more asymmetrical onset and more frequent
levodopa-induced fluctuations and dystonia than patients with two mutations.
Ann Neurol 2003;54:176–185
In the last few years, five genes and four loci have been
identified in families with Parkinson’s disease (PD).
Mutations in the alpha-synuclein gene on chromosome
4q,1 the UCH-L1 gene on chromosome 4p,2 and the
NR4A2 gene mapped to chromosome 2q22-233 are au-
tosomal dominant, whereas mutations in the parkin
gene on chromosome 6q4 and the DJ-1 gene on chro-
mosome 1p5 are autosomal recessive. Four other loci
have been localized on chromosomes 2p13,6 4p14-16,7
1p35-36,8 and 12p11-q13.9 Other susceptibility fac-
tors, such as the Icelandic 1p32 locus,10 the polymor-
phic variant S18Y of the UCH-L1 gene,11 or the A0
allele of the tau gene,12 have been reported. Whereas
mutations in alpha-synuclein and UCH-L1 have been
found in only a few families,1,2,13 mutations in the par-
kin gene have been described in many patients with
autosomal recessive juvenile parkinsonism (ARJP).4,14–16
Pathological studies have shown several differences be-
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tween ARJP with parkin mutations and idiopathic PD:
in four cases there was an absence of Lewy bodies and a
severe generalized loss of dopaminergic neurons from the
substantia nigra pars compacta.17–19 One of these four
brains showed additional involvement of the substantia
nigra pars reticulata,19 the second showed additional
neurofibrillary tangles and argyrophilic astrocytes in ce-
rebral cortex and brainstem nuclei,18 the third showed
neuronal loss in parts of the spinocerebellar system,17
and the fourth case, with a single heterozygous muta-
tion, showed additional tau aggregates consistent with
progressive supranuclear palsy.20 Only one case, carry-
ing compound heterozygous mutations of the parkin
gene, has been described as having Lewy bodies.21 The
parkin gene, which contains 12 exons, spans more than
1.5Mb and encodes a protein of 465 amino acids with
similarity to ubiquitin at the amino terminus (UBL do-
main) and a RING-in between ring (IBR)–RING mo-
tif at the carboxy terminus. Like many other proteins
with a RING-finger domain, parkin has E3 ubiquitin
ligase activity, linking parkin-associated PD to a defect
in the ubiquitin-proteasome system.22 Because muta-
tions in parkin are associated with recessively inherited
parkinsonism, they presumably result in reduction or
loss of its E3 ligase activity.22–25 This might interfere
with the ubiquitin-mediated proteolysis of certain sub-
strates, the accumulation of which might lead to neu-
ronal death. Why dopaminergic neurons in the sub-
stantia nigra are particularly vulnerable to the loss of
parkin function remains to be determined.
Many different parkin mutations have been found
in familial as well as in sporadic cases of different or-
igins. They are reported to be associated with pheno-
types including typical early-onset parkinsonism, but
also late-onset PD14,26,27 and phenotypes resem-
bling Dopa-responsive dystonia,28 hemiparkinsonism-
hemiatrophy,29 forms with cerebellar ataxia,17,30 pyra-
midal tract dysfunction,30 or peripheral neuropathy.31
However, no clinical correlations have been established
so far between a given phenotype and specific muta-
tions in the parkin gene. In addition, in some families
the disease is associated with heterozygous parkin mu-
tations that appear to be transmitted dominantly.21,26
This suggests that carriers of some single parkin muta-
tions might be at risk for developing PD.32–34 This
differs from the pseudodominant inheritance described
in rare families in which all patients carry two muta-
tions.35–37
The aim of our study was to compare large series of
patients with and without parkin mutations and to as-
sess the influence of the number and the nature of the
mutations on the phenotype of the patients.
Patients and Methods
Patients
Five hundred patients with isolated or familial parkinsonism
with ages at onset of up to 55 years (in at least one affected
family member for the familial cases) were included as in our
previous studies,14,38,39 even though mutations in the parkin
gene also have been reported in patients with onset up to 72
years of age.27 The diagnostic criteria for PD in our study
were at least two of the Parkinsonian triad of signs (brady-
kinesia, rigidity, rest tremor) and at least 30% improvement
after L-dopa therapy in familial or isolated cases. Exclusion
criteria were the existence of extensor plantar reflexes, oph-
thalmoplegia, early dementia, or early autonomic failure. A
standardized form was used to assess the history of the dis-
ease and of the family, the clinical signs and the response to
treatment. The response to treatment was calculated only in
patients who had United Parkinson’s Disease Rating Scale
III assessment both “on” and “off” treatment. The percent-
age of improvement was obtained by comparing the “off”
and “on” values. Quality control of clinical information was
performed by one clinician.
One hundred and four patients were excluded because
clinical information was incomplete. Among the remaining
396 patients, there were 210 cases from 76 families, includ-
ing 207 compatible with autosomal recessive inheritance and
3 families with pseudodominant inheritance, two of which
have been reported already.36,37 The other 186 had no
known family histories of PD in first or second-degree rela-
tives, but in 15 cases there was consanguinity. The families
were mostly of European descent (n  329), including pa-
tients from France (n  165), Italy (n  73), the Nether-
lands (n  26), United Kingdom (n  26), Germany (n 
20), Portugal (n  11), Spain (n  4), and Eastern Europe
(n  4). There were also patients from North Africa (n 
27), South America (n  15), and North America (n  2),
Asia (n  9), Russia (n  6), Middle East (n  1) and Near
East (n  3), and Turkey (n  4). Most families were white
(91%).
Molecular Analysis
All index cases were screened for exon rearrangements in the
parkin gene with a semiquantitative multiplex polymerase
chain reaction assay, in which several exons of the parkin
gene were coamplified together in the same reaction. To
identify the mutations, we analyzed the polymerase chain re-
action products on denaturing polyacrylamide gels on an
ABI 377 automated sequencer with the GENESCAN 3.1
and GENOTYPER 1.1.1 softwares. The ratios between the
heights of the peaks of each of the exons amplified in a given
reaction were calculated and then compared with the ratios
for nonrearranged exons in the control sample from a normal
subject (for detailed description of this method, see Lu¨cking
and Brice40). The consequences of the exon rearrangements
at the protein level (in-frame or frameshift) were deduced
from published exon sequences (DNA Data Bank of Japan,
accession no. AB009973). In the patients in whom the assay
detected only one or no mutations, the entire coding se-
quence was analyzed by sequencing as previously described.41
To establish phenotype–genotype correlations, we consid-
ered all exon rearrangements, nonsense mutations, and small
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insertions/deletions resulting in frameshifts to be truncating
mutations. Although all of the truncating mutations do not
have the same consequences on the protein, they all affect
one of the functional domains of the parkin protein. All
other mutations resulting in single amino acid changes were
classified as missense mutations. In addition, patients were
considered to carry a single parkin mutation only when one
unambiguous parkin mutation was detected; this excludes all
patients with rearrangements of consecutive exons where it
cannot be concluded whether there are multiple exon rear-
rangements on a single allele or two different mutations, one
on each allele. Patients with single heterozygous mutations
were genotyped for the 258 parkin promoter single nucle-
otide polymorphism (SNP) according to West and col-
leagues.42
Statistical Analyses
Comparisons were first made between parkin carriers and pa-
tients without parkin mutations. Then, comparisons were
made among subgroups of carriers of parkin mutations. Be-
cause age at onset younger than 40 years usually defines
early-onset parkinsonism, we compared patients with age at
onset younger than 40 years with those with age at onset 40
years or older. Patients with one or two missense mutations
were compared with those carrying two truncating muta-
tions. Patients who carried at least one missense mutation
outside of the known functional domains were compared
with those carrying two missense mutations within func-
tional domains, such as the UBL and the RING-IBR-RING
domains. Finally, patients with only one detected mutation
in the parkin gene, as defined above, were compared with
those with two known mutations. We used the 2 test or the
Fisher’s exact test when appropriate for comparison of pro-
portions and analysis of variance for comparison of means.
Forward stepwise multiple logistic regression analysis was
performed to sort out the independent variables of items that
defined significantly between patients with and without par-
kin mutations (Hoehn and Yahr “off” was not included in
this analysis because the available data were unevenly distrib-
uted among groups and the sample size was too small in the
last step of the analysis). No corrections were applied for
multiple testing.
Results
Forty-five of 396 patients are reported for the first time
including five isolated cases without parkin mutation
and 40 cases with family histories including 18 carriers
of parkin mutations. The remaining patients have been
reported previously.14,34,38,39 The proportion of pa-
tients with parkin mutations from families with auto-
somal recessive parkinsonism decreased significantly as
a function of age at onset, ranging from 82% before
age 20 years to 28% between 46 and 55 years (Fig,
p  0.01). This decrease already has been shown in iso-
lated cases in which the difference was even greater.14,38
The clinical comparison between parkin carriers and
noncarriers is shown in Table 1. The groups differed in
four respects: (1) mean age at onset in patients with
parkin mutation (31.4  11.9 years) was earlier
(38.1  11.2 years, p  0.001). The range was similar,
Fig. Frequency of familial parkin cases according to the age at onset. (unfilled bars) patients with parkin mutations; (filled bars)
patients without parkin mutations. (asterisk) Ages at onset: 56, 58, 68, 68, and 70 years.
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however, in both groups (7–70 vs 12—76 years); (2)
dystonia and symmetry at onset and brisk reflexes at
examination were more frequent in parkin carriers; (3)
despite longer mean durations of disease (16.7  10.4
vs 11.8  9.2 years, p  0.001) and L-dopa treatment
(11.5  8.3 vs 8.7  7.7 years, p  0.005), the daily
dose of L-dopa was lower (497  312 vs 610 
405mg, p  0.05), and the percentage of improvement
tended to be greater (62  20 vs 55  23%, not sig-
nificant) in patients with parkin mutations; (4) the
mean rate of progression, assessed by the Hoehn and
Yahr score “off” (without treatment) adjusted for dis-
ease duration was lower in the parkin group (0.23 
0.27, n  57 vs 0.40  0.40, n  87, p  0.01)
independent of age at onset. The gender of patients
had no influence of the phenotype.
The regression analysis showed that age at onset
(p  0.01), disease duration (p  0.01), asymmetry at
onset (p  0.05), and daily dose of L-dopa (p  0.05)
are significant independent variables. Interestingly, dys-
tonia at onset as well as brisk reflexes were no longer
independent after forward stepwise multiple logistic re-
gression analysis. However, there was a significant cor-
relation between age at onset and dystonia at onset
(p  0.01).
Age at onset was highly variable among parkin car-
riers, ranging from 7 to 70 years. We therefore ana-
lyzed the clinical features according to the age at onset
(40 vs 40 years). The rate of progression was
greater in the group with age at onset after 39 (0.5 
0.62, n  8 vs 019  0.12, n  49, p  0.01). Pre-
senting signs were also different because dystonia at on-
set was more frequent in the early-onset than in the
late-onset group (30/95 vs 2/22, p  0.05). There
were no significant differences according to the age at
onset for other clinical features.
To explain the differences in age at onset, we inves-
tigated the possible influence of the nature and the lo-
calization of the mutation in the parkin gene. We first
compared patients with at least one missense with
those with two truncating mutations (Table 2), reason-
ing that missense mutations usually have less functional
consequences than truncating mutations in autosomal
recessive disorders.43 Patients carrying at least one mis-
sense mutation had higher United Parkinson’s Disease
Rating Scale motor score without treatment than pa-
tients carrying two truncating mutations (51.1  20.7
vs 31.3  16.5, p  0.01) after similar disease dura-
tions. There were no other differences between the
groups. This suggests that missense mutation carriers
have a more severe disease than those carrying two
truncating mutations.
We then compared phenotypes of patients with mis-
sense mutations according to their location with regard
to functional domains (Table 3). Patients carrying two
missense mutations within the functional domains
(RING-IBR-RING and UBL domains) developed
symptoms earlier than patients with one mutation out-
side the functional domains (29.9  13.2 vs 39.5 
8.6 years, p  0.05). The latter therefore were signif-
icantly older at examination (59.2  9.7 vs 45.5 
13.1 years, p  0.05).
Because several observations supported the hypothe-
sis that the presence of a single parkin mutation might
represent a risk factor for PD,21,26,32–34 we compared
patients with only a single parkin mutation to those
carrying two mutations (Table 4). Patients with a sin-
gle mutation showed symptoms later than those with
Table 1. Phenotype of 396 Patients with and without Parkin Mutations
Characteristic
Parkin
(n  146)
No. of
Patients
Non-Parkin
(n  250)
No. of
Patients
Gender ratio (M:F) 74:72 146 138:112 250
Age, yr (range) 48.6 12.8 (16–89) 140 49.9 12.6 (17–80) 250
Age at onset, yra (range) 31.4 11.9 (7–70) 146 38.1 11.2 (12–76) 250
Disease duration, yra (range) 16.7 10.4 (1–58) 140 11.8 9.2 (1–54) 250
Signs at onset
Asymmetrya 87% 137 96% 231
Dystoniaa 27% 117 10% 204
Clinical signs at examination
Rigidity 92% 143 96% 233
Bradykinesia 94% 144 97% 231
Rest tremor 73% 141 74% 235
Hoehn & Yahr “off”a (range) 3.3 1.1 (1.5–5) 57 2.9 1.2 (1–5) 87
Treatment
Daily dose of L-dopa, mga (range) 497  312 (62–1500) 118 610  405 (50–3,000) 192
Duration of treatment, yra (range) 11.5 8.3 (0.2–40) 115 8.7 7.7 (0.08–55) 182
Other signs
Brisk reflexesa 33% 112 19% 190
aTwo-tailed p  0.05.
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two mutations (37.3  11.3 vs 30.5  10.7 years, p 
0.05). L-Dopa–induced fluctuations and dystonia were
more frequent in the latter (94% vs 69%, p  0.05,
and 70% vs 40%, p  0.05, respectively) and clinical
signs were more frequently asymmetrical at onset (100
vs 82%, p  0.05). One of 34 relatives of patients
with known parkin mutations carrying heterozygous
R275W mutations had PD with onset at age 68 years.
Among these relatives, there were 16 siblings with a
mean age at examination of 41  7.9 years (ranging
from 28 to 50 years) and 18 parents with a mean age
at examination of 71.1  6.9 years (ranging from 63
to 84 years). None of these individuals were examined
at an age younger than the age at onset of their affected
relatives. Recently, a genetic association was described
between idiopathic PD and the 258 T/G promoter
SNP of the parkin gene.34 The 258G allele, associ-
ated with reduced parkin expression in in vitro exper-
iments, is also suspected to contribute to early-onset
parkinsonism.34 To determine whether the status of
heterozygous parkin mutation carrier could be respon-
sible for parkinsonism in conjunction with a parkin
polymorphism, we genotyped the 258 T/G parkin
promoter SNP by polymerase chain reaction restriction
in the 23 patients with a single parkin mutation. The
258 G allele was observed in 45.6% of alleles inher-
ited by heterozygous parkin carriers compared with
14% of Northern European controls (p  0.001).34
Because some mutations were recurrent, we com-
pared seven groups of patients with the same genotype.
No specific clinical pattern could be associated with
any of the genotypes. Mean disease durations were sig-
nificantly different, but not ages at onset or at exami-
nation, which were highly variable (Table 5). Patients
homozygous for the exon 3 deletion had ages at onset
that differed by as much as 34 years. Patients carrying
the R275W missense mutation tended to have an ear-
lier age at onset than those from all other groups with
two truncating mutations (p  0.09). This suggests
that the R275W mutation, located within the RING-
IBR-RING domain, could have a more deleterious ef-
fect than truncating mutations. Unfortunately, the dis-
ease durations in patients with this mutation were very
short, precluding the assessment of the severity of dis-
ease progression.
Atypical manifestations in parkin patients are re-
Table 2. Comparison of Parkin Patients with At Least One Missense Mutation and Parkin Patients with
Two Truncating Mutations
Characteristic
At Least One Missense
Mutation (n  42)
No. of
Patients
Two Truncating Mutations
(n  76)
No. of
Patients
Gender ratio (M:F) 23:19 42 38:38 76
Age, yr (range) 49.8 13.6 (16–75) 42 48.6 12.9 (21–89) 70
Age at onset, yr (range) 32.9 12.7 (9–68) 42 30.2  10.0 (7–58) 76
Disease duration, yr (range) 16.9 11.2 (1–42) 42 17.4  10.8 (2–58) 70
Clinical signs at examination
UPDRS III “off”a 51.1 20.7 (25–87) 15 31.3 16.5 (4–62) 23
Treatment
Daily dose of L-dopa, mg (range) 538  354 (150–1,400) 35 453  286 (62–1,500) 60
Dyskinesia 76% 37 75% 65
aTwo-tailed p  0.01.
UPDRS  United Parkinson’s Disease Rating Scale.
Table 3. Comparison of Parkin Patients with and without Mutations in Functional Domains (UBL and RING-IBR-RING)
Characteristic
Mutation in Functional
Domains (n  29)
No. of
Patients
Mutation outside the
Functional Domains
(n  13)
No. of
Patients
Gender ratio (M:F) 17:12 29 6:7 13
Age, yra (range) 45.5 13.1 (16–70) 29 59.2 9.7 (44–75) 13
Age at onset, yra (range) 29.9 13.2 (9–68) 29 39.5  8.6 (18–55) 13
Disease duration, yr (range) 15.7 10.5 (2–40) 29 19.7  12.5 (1–42) 13
Clinical signs at examination
Hoehn and Yahr “on” (range) 2.3 0.7 (1–4) 24 2.6  0.9 (1–4) 12
Treatment
Daily dose of L-dopa, mg (range) 523  309 (150–1,400) 25 577  466 (150–1,400) 10
aTwo-tailed p  0.05.
UBL  ubiquitin at the amino terminus; IBR  in between ring.
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ported in Table 6. In nine patients from different fam-
ilies, psychiatric disorders were evident and included
psychosis, panic attacks, depression, disturbed sexual
behavioral and obsessive-compulsive behaviors. Four
patients had abnormal magnetic resonance imaging
findings, but no evident pattern could be seen. A single
patient had axonal polyneuropathy.
Discussion
We report the first evidence to our knowledge of phe-
notype–genotype correlations in patients with parkin
mutations in a large cohort of 396 patients. Our pre-
vious studies had shown that parkin mutations ac-
counted for 49% (36/73 families) of ARJP and 14%
(20/146 patients) of isolated cases with an age at onset
younger than 45 years.14,38 The relative frequencies of
parkin mutations in ARJP or isolated cases with age at
onset at 55 years or younger found in this study are
similar to those in our previous report: 61% (54/89
families) and 19% (35/186 patients), respectively.
However, in familial cases with ages at onset 20 years
or younger, greater than 80% of the patients have par-
kin mutations, whereas only 28% of those between the
age of 46 and 55 are parkin carriers. This confirms that
parkin mutations are much more frequent in early-
onset patients.
There is no individual sign or symptom that distin-
guished between parkin carriers and noncarriers with
early-onset parkinsonism. However, patients with par-
kin mutations tended to have earlier and more sym-
metrical onset, slower progression of the disease, and
greater response to L-dopa despite lower doses. Never-
theless, our parkin carriers did not present all of the
signs associated with ARJP previously reported: coarse
tremor, foot dystonia, and diurnal fluctuations were
absent.44 They have, however, consistently slower dis-
ease progression and a marked response to L-dopa, but
they do not have more complications from treatment,
such as dyskinesias and fluctuations, than patients
without parkin mutations, as reported in several previ-
ous studies.44–46 The younger the age at onset, the
more frequently dystonia is observed at onset. Thus,
dystonia does not represent a specific sign of carriers of
parkin but rather is associated with young onset par-
kinsonism regardless of the genetic origin. Age at onset
among patients carrying parkin mutations varies (range,
7–70 years), as does the rate of progression of the dis-
ease: the younger the age at onset the slower the dis-
ease. In addition, atypical signs also were observed,
such as psychiatric manifestations, cerebellar signs, neu-
ropathy, and abnormal findings on brain magnetic res-
onance imaging, enlarging the spectrum of the disease
(see Table 6). Behavioral disorders in parkin disease
have been mentioned previously, but only in a few re-
ports.31,47,48 We did not find a homogenous psychiat-
ric pattern in our parkin patients, and, because psychi-
atric manifestations are frequent in the general
population and delirium and hypersexuality can be
triggered by antiparkinsonism drugs, it cannot yet be
concluded whether they are part of the phenotype or if
they occurred by chance in several patients. Systematic
psychiatric evaluation of parkin patients and their rel-
atives will be required to resolve this question. Addi-
tional neurological manifestations, such as axonal neu-
ropathy or cerebellar ataxia, were observed in several of
our cases. Cerebellar signs,17,30 pyramidal tract dys-
function30 and peripheral neuropathy31 have been re-
ported previously, but not the presence of abnormali-
ties on brain magnetic resonance imaging.
Mutations in the parkin gene are polymorphous and
often private. To date, 79 different parkin mutations
have been described: 45 point mutations including 20
truncating, 22 missense, and 3 splice mutations, as well
as 34 exon rearrangements including 24 deletions and
10 multiplications.4,14,15,21,25–27,32–35,37,41,47–58 The
large spectrum of parkin gene defects, which differ in
their predicted consequences on the function of the
protein, raises the question of their role in the variabil-
Table 4. Comparison of Parkin Patients with a Single Mutation and Parkin Patients with Two Mutations
Characteristic Single (n  23)
No. of
Patients Two (n  109)
No. of
Patients
Gender ratio (M:F) 10:13 23 55:54 109
Age, yr 51.5 9.2 (31–70) 23 48.3 13.3 (16–89) 103
Age at onset, (yr)a (range) 37.3 11.3 (18–68) 23 30.5 10.3 (7–58) 109
Disease duration, yr (range) 14.2 8.2 (2–37) 23 17.2 10.9 (1–58) 103
Signs at onset
Asymmetrya 100% 23 82% 100
Treatment
Daily dose of L-dopa, mg (range) 461  283 (125–1400) 22 476  310 (62–1500) 84
Dyskinesia 82% 22 74% 92
Fluctuationa 94% 17 69% 83
Dystoniaa 70% 17 40% 70
aTwo-tailed p  0.05.
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ity of the phenotype. We indeed have found some dif-
ferences. Despite the fact that the age at onset is similar
in patients with at least one missense mutation and
those with two truncating mutations, the phenotype is
significantly more severe in the former. Although mis-
sense mutations usually have less functional conse-
quences than truncating mutations in autosomal reces-
sive disorders,43 the consequences of several types of
mutations is very difficult to predict (eg, missense mu-
tations might have effects on splicing and therefore
they can have more drastic consequences at the protein
level).59 Furthermore, the location of the mutation
within the gene plays a role in the phenotype because
mutations in functional domains resulted in onset of
the disease approximately 9 years earlier than muta-
tions in domains not known to be essential for parkin
function. However, the influence of the nature and po-
sition of the mutation on the phenotype appears to be
of limited importance, because no evident pattern
emerged from comparison of patients with the same
genotype. Furthermore, for most genotypes, there was
great variability (up to 34 years) in age at onset despite
the presence of the same mutations. The number of
cases in each of the seven genotype groups was too low
for a specific clinical pattern to emerge, but it appears
that the mean age at onset of the patients who carry
both the R275W mutation and a truncating mutation
tended to be earlier than in those with two truncating
mutations. This result suggests that the R275W muta-
tion does not result in a simple loss of function as pos-
tulated for missense mutations. The R275W mutation
might have dominant negative effect, which would ac-
count for the greater severity of the phenotype. How-
ever, this hypothesis is not supported by the fact that
four heterozygous relatives (aged 28–70 years) are not
affected by PD. Another explanation is that that
R275W might confer a partial loss of function which,
in conjunction with an additional, still unknown, pre-
disposing factor is more deleterious than complete ab-
lation of the gene. However, this discussion remains
speculative, and the results must be confirmed by an-
alyzing more patients.
Single mutations were detected in several patients36,37
despite thorough molecular analyses of the gene includ-
ing the promoter region.34 Furthermore, families with
apparently true autosomal dominant inheritance21,26 or
decreased striatal F-DOPA uptake in asymptomatic car-
riers of heterozygous parkin mutations60 have been de-
scribed. This prompted us to compare the phenotype in
parkin carriers as a function of the number of mutations
detected. Patients with a single parkin mutation were
characterized by later and more asymmetrical onset and
more frequent fluctuations and dystonias than patients
with two characterized mutations. Their age at onset ex-
tends up to 68 years, 10 years later than in our series of
patients with two parkin mutations. This suggests that
the presence of a single parkin mutation might represent
a risk factor for later onset PD. This result should be
interpreted with caution, however, because the size and
the complexity of the parkin gene may cause some mu-
tations to escape detecting by our current screening tech-
niques.34
However, note that among the 34 heterozygous car-
riers who were relatives of patients with two identified
mutations only one was affected with onset at age 68
years. This may be coincidental or may suggest reduced
penetrance or a slightly higher risk of developing PD
in heterozygous carriers, even though the age at exam-
ination was earlier in siblings than parents, and they
may develop symptoms in the future. In contrast, all
their relatives with two mutations were affected. This
observation indicates that being carrier of a single
parkin mutation is not sufficient to produce the phe-
notype in all individuals and that other genetic or en-
vironmental factors are probably necessary in combina-
tion with the mutation. In this regard, note that the
frequency of the 258 G allele of the parkin promoter
SNP was significantly higher in our patients who carry
a single heterozygous mutation than in European con-
trols. These findings are consistent with a previous
study34 and suggest that the 258 G allele also may
contribute to early-onset parkinsonism, particularly in
individuals who also carry a heterozygous parkin mu-
tation.
Table 5. Comparison of Parkin Patients with the Same Genotype
Characteristic
ex3del/ex3del
(n  8)
ex3-4del/ex3-4del
(n  4)
ex2del/ex3del
(n  6)
Gender ratio (M:F) 3:5 3:1 3:3
Age, yr (range) 46.9 9.8 (35–59) 52.5 6 (44–58) 49  6.8 (42–59)
Age at onset, yr (range) 35.4 10.6 (21–55) 37  10.6 (23–47) 33.2 10.4 (14–42)
Duration of disease, yr (range)a 11.5 5.3 (4–17) 15.5 6.2 (7–21) 15.8 10.6 (3–33)
aSignificant differences among the groups (p  0.05).
ex  exon, del  deletion.
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Conclusion
There were significant clinical differences between pa-
tients with and without parkin mutations: parkin car-
riers tended to have earlier onset, more dystonia at on-
set, and brisk reflexes. They also took lower doses of
L-dopa despite longer durations but did not have more
Table 6. Parkin Patients with Atypical or Additional Features
Patient First Mutation Second Mutation
Age at
Onset
(yr)
Age at
Examination
(yr) Atypical Features
FPD-171-3 Exon 6 duplication c255delA 26 29 Obsessive-compulsive behavior
and depression
FPD-192-6 Exon 3 deletion Exon 7 duplication 27 53 Psychosis
SPD-70 c255delA c255delA 19 30 Delirium
SPD-92 Exon 3 to 6 deletion R275W 16 46 Panic attacks
SPD-169 Exon 2 deletion Exon 3 deletion 29 42 Verbal aggressiveness
BHAM-3 Exon 5 to 6 deletion Exon 5 to 6 deletion 29 59 Hypersexuality, behavioral
changes
BHAM-18 Exon 3, 4, 5 deletiona ? 18 53 Hypersexuality and depression
UK-4720 c202-203delAG c202-203delAG 29 53 Psychosis
SAL-711-4 Exon 3 deletion Exon 3 deletion 33 50 Depression, anxiety, hysterical
episodes, and conversional
symptoms. Cerebral MRI:
T2 periventricular white
matter hyperintensities
SAL-711-5 Exon 3 deletion Exon 3 deletion 40 55 Cerebral MRI: important di-
latation of the lateral ven-
tricles and T2 hyperintensi-
ties in the frontal white
matter
SAL-711-6 Exon 3 deletion Exon 3 deletion 28 41 Axonal polyneuropathy
FPD 235-7 Exon 3 to 6 deletion c255delA 27 55 Presenting sign: resting tremor
in both legs that increased
markedly when standing
and was absent when walk-
ing
IT-48-97 Exon 3 to 4 deletion Exon 3 to 4 deletion 43 58 Orthostatic tremor diagnosed
before PD. Cerebral corti-
cal atrophy at MRI, T2
hyperintensities in the up-
per pons and midbrain.
JMP-28 Exon 3 deletion Exon 3 deletion 28 34 Cerebellar signs (nystagmus,
slight left limb dysmetria).
Cerebral MRI: bilateral
sickle-shaped abnormal sig-
nals (decreased in T1-, in-
creased in T2-weighted im-
ages) in the cerebellum.
aThe phase of transmission was not known for this patient, and we could not determine if the deletion was present on one or both alleles.
MRI  magnetic resonance imaging; PD  Parkinson’s disease.
Table 5. (Continued)
c255delA/c255delA
(n  4)
c202-203delA/c202-203delA
(n  2)
ex3-4del/c255delA
(n  2)
ex3del/R275W
(n  3)
3:1 1:1 0:2 1:2
48.8 16 (30–62) 48 7.1 (43–53) 33  17 (21–45) 25.3 8.3 (16–32)
28.5 13.1 (17–45) 26 4.2 (23–29) 26.5 17.7 (14–39) 21.3 8.1 (12–27)
20.3 7.9 (11–29) 22 2.8 (20–24) 6.5 0.7 (6–7) 4  1 (3–5)
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complications from treatment than noncarriers. There
were no clinical signs that permit identification of a
patient with parkin mutations, but parkin carriers rep-
resented a specific subgroup of early-onset parkinson-
ism. The phenotype differs with the genotype: patients
with missense mutations had a more severe disease
than those with truncating mutations, suggesting that
missense mutations result in more than a loss of func-
tion. A dominant negative effect, as suggested for the
R275W mutation, would produce a more severe clini-
cal course. Not unexpectedly, missense mutations in
functional domains resulted in an earlier onset than
mutations in other regions of the protein. Finally, pa-
tients with two detected mutations had earlier onset
than those with only one detected mutation, although
the interpretation of this result is subject to caution. It
is not yet clear whether the second mutation was not
detected by the techniques used or whether the pres-
ence of a single mutation constitutes a real risk factor
for PD.
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Appendix
The French Parkinson’s Disease Genetics Study Group in-
cludes Y. Agid, A. M. Bonnet, M. Borg, A. Brice, E. Brous-
solle, P. Damier, A. Deste´e, A. Du¨rr, F. Durif, J. Feingold,
G. Fe´nelon, E. Lohmann, M. Martinez, C. Penet, P. Pollak,
O. Rascol, F. Tison, C. Tranchant, M. Ve´rin, F. Viallet, M.
Vidailhet, and J. M. Warter. The European Consortium on
Genetic Susceptibility in Parkinson’s Disease includes N. W.
Wood, J. R. Vaughan (UK); A. Brice, A. Du¨rr, M. Martinez,
Y. Agid (France); T. Gasser, B. Mu¨ller-Myhsok (Germany);
M. Breteler, S. Harhangi, B. Oostra (Netherlands); V. Boni-
fati, M. DeMari, G. De Michele, E. Fabrizio, A. Filla, G.
Meco (Italy).
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PARK7, a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism,
on Chromosome 1p36
C. M. van Duijn,1 M. C. J. Dekker,1 V. Bonifati,1,3 R. J. Galjaard1, J. J. Houwing-Duistermaat,1
P. J. L. M. Snijders,1 L. Testers,1 G. J. Breedveld,1 M. Horstink,4 L. A. Sandkuijl,1
J. C. van Swieten,2 B. A. Oostra,1 and P. Heutink1
1Genetic-Epidemiologic Unit, Departments of Epidemiology and Biostatistics and Clinical Genetics, and 2Department of Neurology, Erasmus
Medical Center Rotterdam, Rotterdam; 3Department of Neurological Sciences, La Sapienza University, Rome; and 4Department of Neurology,
University Hospital Nijmegen, The Netherlands
Although the role of genetic factors in the origin of Parkinson disease has long been disputed, several genes involved
in autosomal dominant and recessive forms of the disease have been localized. Mutations associated with early-
onset autosomal recessive parkinsonism have been identified in the Parkin gene, and recently a second gene, PARK6,
involved in early-onset recessive parkinsonism was localized on chromosome 1p35-36. We identified a family
segregating early-onset parkinsonism with multiple consanguinity loops in a genetically isolated population. Ho-
mozygosity mapping resulted in significant evidence for linkage on chromosome 1p36. Multipoint linkage analysis
using MAPMAKER-HOMOZ generated a maximum LOD-score of 4.3, with nine markers spanning a disease
haplotype of 16 cM. On the basis of several recombination events, the region defining the disease haplotype can
be clearly separated, by 
25 cM, from the more centromeric PARK6 locus on chromosome 1p35-36. Therefore,
we conclude that we have identified on chromosome 1 a second locus, PARK7, involved in autosomal recessive,
early-onset parkinsonism.
Parkinson disease (PD [MIM 168600]) is a neurodege-
nerative disorder characterized by bradykinesia, resting
tremor, muscular rigidity, and postural instability. The
cerebral pathology includes loss of dopaminergic neu-
rons, in particular at the substantia nigra and cytoplas-
matic eosinophilic inclusions (i.e., Lewy bodies). The
role of genetic factors in the origin of PD has long been
disputed. However, several families segregating the dis-
ease as a dominant or recessive trait have been identified.
At present, four genes implicated in autosomal dominant
forms of parkinsonism have been identified or localized,
including the a-synuclein gene (Polymeropoulos et al.
1997), the ubiquitin carboxy-terminal hydrolase-L1
gene (Leroy et al. 1998), and two yet-unidentified
genes—PARK3 on chromosome 2p13 (Gasser et al.
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1998) and PARK4 on chromosome 4p14-16.3 (Farrer
et al. 1999). Until now, most mutations have been found
in the Parkin gene (Kitada et al. 1998) and have been
found to lead to a recessive form of juvenile parkinson-
ism (ARJP [MIM 600116]). The onset age may vary
from 20 to 65 years, but in most patients the onset is
at age !40 years (Lu¨cking et al. 2000). Parkin mutations
are estimated to explain up to 50% of familial patients
with ARJP (Lu¨cking et al. 2000). Recently, a new locus,
PARK6 (MIM 605909), involved in autosomal recessive
early-onset parkinsonism was localized on chromosome
1p35-36 in a single Italian family (Valente et al. 2001).
In the present report, we describe a family segregating
early-onset parkinsonism with multiple consanguinity
loops that we identified in a genetically isolated popu-
lation. We report the findings of a genome search using
homozygosity mapping in an effort to localize the gene
involved in the disease.
Patients were from a genetically isolated community
in the southwestern region of The Netherlands. The
study is part of a larger research program named “Ge-
netic Research In Isolated Populations” (GRIP). The iso-
lated population was founded ∼1750, by ∼150 individ-
Chapter 2.5
104
630 Am. J. Hum. Genet. 69:629–634, 2001
Figure 1 Pedigree of family with autosomal recessive early-onset parkinsonism, and haplotypes of marker loci spanning the linked region
on chromosome 1p36. To protect patient confidentiality, a diamond symbol has been used to mask the sex of all family members. Individuals
VI-2, VI-3, and VII-1–VII-7 were examined clinically. Black symbols indicate definitely affected individuals; black bars denote the disease-
associated haplotype.
uals. The scientific protocol of GRIP has been approved
by the Medical Ethical Committee of the Erasmus Med-
ical Center Rotterdam. From the population, initially
three patients (VII-2, VII-3 and VII-7) diagnosed with
early-onset parkinsonism were ascertained, including
two affected siblings and one apparently sporadic pa-
tient (fig. 1). The patients and their first-degree relatives
were personally examined by the research physician, a
neurologist, and a clinical geneticist. Clinical diagnosis
of parkinsonism required the presence of at least two of
the three cardinal signs (i.e., resting tremor, bradykine-
sia, and muscular rigidity) and absence of atypical fea-
tures and of signs of involvement of other neurological
systems (pyramidal, cerebellar, or autonomic). The ex-
trapyramidal signs were evaluated by Hoehn-Yahr stag-
ing (HY) (Hoehn and Yahr 1967) and the Unified Par-
kinson’s Disease Rating Scale (UPDRS; maximum of
motor subscalep 108) (Fahn et al. 1987). Furthermore,
structural and functional brain-imaging studies were
performed. The clinical examinations of available rela-
tives revealed a fourth affected individual (VII-6), who
was not known to have the diagnosis of parkinsonism.
The clinical details of the four affected subjects are
reported in table 1. Onset of symptoms was at age 40
years in three subjects (VII-2, VII-3, and VII-7). The
fourth affected individual (VII-6), who was age 40 years
at the time of the clinical examination, was newly di-
agnosed with parkinsonism and could not indicate the
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Table 1
Clinical Phenotype of Four Patients with Parkinsonism
PATIENT
AGE AT
(years) SYMPTOMa
THERAPY HY UPDRS OTHER CHARACTERISTICS
Time of
Study Onsetb RT PT B R P AS
VII-2 50 40 X X X X Untreated II 29 Psychotic episodes
VII-3 48 31 X X X X X X Pergolide III 57 Neurotic signs, blepharospasm
VII-6 40 NA X X X X Untreated III 22 Neurotic signs
VII-7 38 27 X X X X X L-dopa/IDD, entacapone III 42 Wearing-off, dyskinesias, off dystonia
a RT p resting tremor; PT p postural tremor; B p bradykinesia; R p muscular rigidity; P p loss of postural reflexes; AS p asymmetric
onset of symptoms.
b NA p not available.
age at onset of the disease. None of the patients exhibited
atypical features or signs of involvement of additional
neurological systems. The parkinsonian signs responded
well to therapy with L-dopa or dopamine agonists in
two patients (VII-3 and VII-7); at the time of clinical
examination, the two other patients still had not been
treated with antiparkinsonian drugs. One patient (VII-
7) showed motor fluctuations of “wearing-off” type, L-
dopa–induced dyskinesias in the “on” phase, and “off”-
phase dystonia (i.e., laterocollis). Mild blepharospasm
was present in patient VII-3, who receives dopamine-
agonist therapy. Tendon reflexes in lower limbs were
brisk in three of the patients (VII-3, VII-6, and VII-7).
Babinski sign was absent. Two of the patients also
showed neurotic signs, and one had suffered from psy-
chotic episodes. In all patients, the progression of disease
was slow. Structural brain images were unremarkable,
in agreement with the diagnosis of idiopathic parkin-
sonism. Brain single-positron–emission computed to-
mography with dopamine-transporter tracer, performed
in patients VII-2 and VII-3, showed severe abnormalities
consistent with presynaptic dysfunction of nigrostriatal
dopaminergic systems. Autopsy data are not available.
At the time of clinical examination, the ages of unaf-
fected individuals VII-1, VII-4 and VII-5 were 54, 50,
and 46 years, respectively.
The genealogical history of the isolate has been com-
puterized as far back as 1750. Although the patients
were not aware of consanguinity in their family, the ped-
igree of each of the two sibships showed multiple con-
sanguinity loops (fig. 1). The pedigree is drawn on the
basis of the two shortest consanguinity loops for both
parent pairs (VI-1/V-2 and VI-2/VI-3), which links the
two sibships to a common ancestor six generations ago.
However, other connections between the sibships exist,
including a second loop linking VI-1 and V-2 to a com-
mon ancestor, who is also related to VI-2.
The pedigree structure is consistent with an autosomal
recessive mode of inheritance, and the kindred therefore
was considered to be suitable for homozygositymapping
(Lander and Botstein 1987). For all patients and avail-
able first-degree relatives, genomic DNA was isolated
from peripheral blood, according to the method de-
scribed by Miller et al. (1988). For the systematic ge-
nome scan, short tandem-repeat polymorphisms
(STRPs) from the ABI PRISM Linkage Mapping Set
MD-10 (Applied Biosystems) were used. Additional
markers for fine-mapping and the PARK6 region were
obtained from the Ge´ne´thon and Marshfield (Center for
Medical Genetics, Marshfield Medical Research Foun-
dation) genetic-marker sets. Marker order and distances
were obtained from the Marshfield (Center for Medical
Genetics, Marshfield Medical Research Foundation) in-
tegrated linkage map. Markers were amplified from ge-
nomic DNA, according to methods specified by theman-
ufacturers. PCR products were pooled and loaded onto
an ABI377 automated sequencer (filter set D; 5% de-
naturing FMC LongRanger acrylamide gel), and data
were analyzed by ABI GENESCAN3.1 and ABI GENO-
TYPER2.1 software.
In the initial screens, only three definitely affected in-
dividuals (VII-2, VII-3, and VII-7) were genotyped. We
first tested for linkage of our family to known PD loci
(Polymeropoulos et al. 1997; Gasser et al. 1998; Kitada
et al. 1998; Leroy et al. 1998; Farrer et al. 1999), using
STRPs from the ABI PRISM Linkage Mapping Set MD-
10. At chromosome 4q22, the markers D4S414 and
D4S1572 were assessed; at chromosome 4p14, markers
D4S419 and D4S405; at chromosome 4p14-16.3, mark-
ers D4S419 and D4S1592; at chromosome 6q25.2-q27,
markers D6S1581 and D6S264; and, at chromosome
2p13, markers D2S337 and D2S2368. The analysis of
the markers flanking the known PD genes did not show
evidence for homozygosity, indicating that the disease in
the family cannot be explained by one of these known
genes (data not shown). We then performed a systematic
genome screen. LOD scores were generated by the pro-
gram MAPMAKER-HOMOZ (Kruglyak et al. 1995),
under the assumptions of equal recombination for males
and females, autosomal recessive inheritance, and gene
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Table 2
Genotypes of Affected Individuals, for
Markers of the PARK6 Region
MARKERa
GENOTYPE OF
AFFECTED INDIVIDUAL
VII-2 VII-3 VII-6 VII-7
D1S199 2 5 3 5 2 5 3 4
D1S483 1 1 1 2 1 1 2 2
D1S478 3 5 1 3 3 5 2 3
D1S2828 4 1 4 5 4 1 4 3
D1S2732 2 4 2 3 2 4 1 4
D1S2702 2 4 2 3 2 4 4 1
D1S2734 5 4 5 5 5 4 4 1
D1S2885 4 1 4 2 4 1 1 3
D1S247 4 2 1 6 4 2 3 5
SOURCE.—Valente et al. (2001).
a Order is according to the Marshfield
(Center for Medical Genetics, Marshfield
Medical Research Foundation) integrated
linkage map.
frequency .004. In the initial genome screen, the family
structure used in the analysis is depicted in figure 1, and
allele frequencies were estimated on the basis of theDNA
of 51 spouses of patients participating in the various
studies in GRIP. The three individuals included in the
initial screen (VII-2, VII-3, and VII-7) were homozygous
for six markers, located on chromosomes 1, 5, 11, 17,
and 21. Only for the chromosome 1 region, two adjacent
markers (D1S468 and D1S214) were found to be ho-
mozygous in all patients, leading to a maximum LOD
score of 2.8.
The newly diagnosed patient (VII-6) was identified
after this initial screen and was typed, together with
unaffected first-degree relatives (VI-2, VI-3, VII-1, VII-
4, and VII-5), only for the five regions at which the first
three patients were homozygous.
Homozygosity remained only for markers on chro-
mosomes 1, 5, and 17. On chromosomes 5 and 17, ho-
mozygosity was found with very-frequent (34% and
42%, respectively) alleles of the markers D5S1981 and
D17S944. For closely linked (i.e., !10 cM distant) mark-
ers, all four patients were heterozygous, indicating that
the observed alleles for these markers could be identical
by state (IBS). In contrast, the population frequency of
the homozygous allele at D1S468 was 9%. The chances
that the homozygous allele in our distantly related pa-
tients is IBS are very small. In addition, all four patients
were homozygous for the flanking marker D1S214, in-
dicating that the alleles were most likely identical by
descent. We therefore saturated the region surrounding
D1S468 and D1S214 with 13 additional markers and
found that all patients were homozygous for 9 of the
markers studied, whereas the unaffected parents and two
unaffected siblings were all either heterozygous or non-
carriers of the disease haplotype (fig. 1). When LOD
scores for the disease haplotype were calculated, equal
allele frequencies for eachmarker were assumed, because
population allele frequencies were not available. Pene-
trance was assumed to be 100% by age 40 years. The
most conservative analysis—that is, under the assump-
tion that there is a second-degree relationship between
the parents of the sibships—resulted in a maximummul-
tipoint LOD score of 4.3. Subsequent haplotype analysis
showed homozygosity of all four patients, for a region
of ∼16 cM on the sex-averaged linkage map. The first
recombination events were observed for marker D1S243
on the telomeric side in individual VII-6 and for marker
D1S244 on the centromeric side in individual VII-3.
Because of Valente et al.’s (2001) recent report of link-
age of an early-onset autosomal recessive form of par-
kinsonism to chromosome 1p35-36, we investigated
whether we could exclude linkage to the PARK6 region
in the family that we studied; we tested nine markers
from the PARK6 region (table 2). The patients in this
family showed no homozygosity at any of these markers.
The PARK6 critical region, between markers D1S483
and D1S247, is localized 
25 cM centromeric of our
critical region. Considering the evidence that the critical
region in the family that we studied does not overlap
with the region encompassing the PARK6 gene identified
by Valente et al. (2001) and taking into account the
recommendations that Lander and Kruglyak (1995)
have made with regard to the reporting of linkage find-
ings, we report a significant linkage finding for the pres-
ence, on chromosome 1p, of a second locus for auto-
somal recessive early-onset parkinsonism; and we
propose to name it “PARK7.”
Both PARK6 (Valente et al. 2001) and PARK7 were
identified by homozygosity mapping. Although this is a
very powerful approach in consanguineous pedigrees
(Lander and Botstein 1987), some possible methodo-
logical problems recently have been raised in articles
published in the Journal (Miano et al. 2000). Miano et
al. (2000) have shown that patients may be homozygous
for large regions by chance—in particular if there are
multiple loops in the pedigree, such as occur in the ped-
igree that we studied. However, our most conservative
analysis, based on an analysis assuming a second-degree
relationship, still yielded a LOD score 14. In addition,
the fact that the affected individuals from the two sib-
ships share an identical homozygous haplotype, whereas
none of the unaffected first-degree relatives was ho-
mozygous for this haplotype, makes a false-positive find-
ing less likely.
Using homozygosity mapping, we have identified a
third locus for autosomal recessive early-onset parkin-
sonism: PARK7. Similar to what has been reported in
other studies of early-onset parkinsonism and Parkin
mutations (Lu¨cking et al. 2000), the disease in the pa-
tients of the family that we studied is characterized by
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a slow progression. Dystonic features, including bleph-
arospasm and laterocollis, and brisk tendon reflexes
have also been found in patients with Parkin mutations
(Abbas et al. 1999; Lu¨cking et al. 2000; Tassin et al.
2000). PARK7 is the second locus, in the chromosome
1p36 region, involved in autosomal recessive, early-on-
set parkinsonism. The region defining the disease hap-
lotype can be clearly separated from that of the more
centromeric PARK6 locus. Although the genomic se-
quence of the critical region is far from complete and
many gaps remain, a first analysis of the Project Ensembl
and Human Genome Project Working Draft at UCSC
databases showed that inside the critical region 
25
genes are located, including 7 genes with an unknown
function. Possible candidate genes are the gene encoding
the vesicle-associated membrane protein 3 (VAMP3) and
the gene encoding protein kinase C, zeta (PRKCZ). Telo-
meric of D1S243, a ubiquitin-conjugating enzyme has
been localized. Although this would be an obvious can-
didate, its location is outside the candidate region. The
observation, on chromosome 1p, of two closely linked
loci for early-onset parkinsonism raises the question
whether there might have been a duplication of this chro-
mosomal region during evolution; however, comparison
of the gene contents from the PARK6 and PARK7 critical
regions and the syntenic region in the mouse does not
support this idea.
Recessive mutations in the Parkin gene have been
shown to be a common cause of early-onset parkinson-
ism (Lu¨cking et al. 2000). Our findings and those of
Valente et al. (2001) strongly suggest there may be other
recessive mutations, in at least two unidentified genes
involved in the disease. Analysis of additional families
with early-onset parkinsonism lacking Parkin mutations
will reveal the importance of these two new loci for
early-onset parkinsonism.
The frequency of recessive mutations in early-onset
parkinsonism may even have masked the genetic origin
of PD for a long time, since familial aggregation and the
identification of consanguinity require extensive genea-
logical research. Therefore, it remains to be determined
whether these common recessive mutations are involved
in late-onset forms of the disease as well. Studies of in-
bred and/or isolated populations such as GRIP may
therefore help to further dissect the pathogenesis of PD.
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Localization of Autosomal
Recessive Early-Onset
Parkinsonism to
Chromosome 1p36 (PARK7)
in an Independent Dataset
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Two new loci, PARK6 and PARK7, for autosomal reces-
sive early-onset parkinsonism have recently been identi-
fied on chromosome 1p, in single large pedigrees. Among
4 autosomal recessive early-onset families analyzed here,
2 supported linkage to PARK7, 1 with conclusive evi-
dence. These data confirm localization of autosomal re-
cessive early-onset parkinsonism to PARK7, suggesting it
to be a frequent locus. Assignment of families to either
PARK6 or PARK7 might be difficult because of the prox-
imity of the two loci on chromosome 1p.
Ann Neurol 2002;51:253–256
DOI 10.1002/ana.10106
The etiology of Parkinson’s disease (PD) remains un-
known in most cases. However, rare mendelian forms
have been identified, and genetics appears to play a
prominent role in cases with early onset.1,2
Autosomal recessive forms of early onset parkinson-
ism (AR-EP) are caused by mutations in the parkin
gene (PARK2 locus) on chromosome 6q.3 In Europe,
mutations in the parkin gene explain for almost half of
the families with recessive parkinsonism and onset be-
fore age 45.4 These cases show good response to levo-
dopa, slow progression, frequent levodopa-induced mo-
tor fluctuations and dyskinesias, and no severe
cognitive disturbances.4 Late-onset forms can also re-
sult from parkin mutations, being clinically indistin-
guishable from classical PD.4–5 However, Lewy bodies,
the PD pathological hallmarks, have not been found in
the few brains with parkin mutations analysed, suggest-
ing a different pathological process.6,7
Two new loci for AR-EP have recently been identi-
fied on the short arm of chromosome 1,8,9 located
close to each other but clearly separated by more than
25cM. Both new loci (PARK6 and PARK7) were found
in single large consanguineous families, using homozy-
gosity mapping. The frequency of involvement of both
loci remains to be evaluated in larger series of families.
We analyze here 4 families with AR-EP, confirming
linkage to PARK7 locus in an independent dataset. In
1 family we found evidence supporting linkage to all
three AR-EP loci (PARK2, PARK6, and PARK7), illus-
trating the complexity and limitations of linkage anal-
ysis in heterogeneous disorders like AR-EP.
Patients and Methods
We studied 4 families with early-onset parkinsonism compat-
ible with autosomal recessive inheritance (Fig 1, Table), of
which 3 are consanguineous (Families 1–3). The families
originate from Italy (Families 1 and 2), Uruguay (Family 3),
and the Netherlands (Family 4). Living members were per-
sonally examined and blood samples obtained after written
informed consent. The clinical diagnosis of parkinsonism re-
quired the presence of two of the three cardinal signs (resting
tremor, bradykinesia, muscular rigidity), absence of atypical
features (dementia early in disease course, ophtalmoplegia,
pyramidal or cerebellar system involvement), and no identi-
fiable causes. Brain imaging (computed tomography and/or
magnetic resonance imaging) were unremarkable.
Genomic DNA was isolated from peripheral blood using
standard protocols. For the linkage studies we typed poly-
morphic short tandem repeat markers linked to the three
known AR-EP loci: PARK2 (6q25.2–q27, D6S441,
D6S1581, D6S305, D6S1277, D6S264, D6S446); PARK6
(1p35–p36, D1S483, D1S199, D1S2732, D1S478, D1S2828,
D1S2702, D1S2734, D1S2885, D1S234, D1S247); PARK7
(1p36, D1S243, D1S468, D1S2845, D1S2660, D1S2795,
D1S2870, D1S214, D1S2663, D1S2666, D1S508, D1S1612,
D1S503, D1S244, D1S450, D1S2736, D1S2667).
Markers were obtained from the Ge´ne´thon and Marsh-
field Center sets, and they were ordered according to the
Marshfield integrated linkage map and the April 2001 phys-
ical assembly of the Human Genome (http://genome.uc-
sc.edu).
Markers were typed by radioactive polymerase chain reac-
tion, essentially according to Weber and May.10 Fluores-
cently labeled markers were used as specified by the manu-
facturers and analyzed using an ABI377 automated sequencer
with Genescan 3.1 and Genotyper 2.1 software (Applied
Biosystems, Foster City, CA).
The entire coding region of the parkin gene,3 and exons
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3–4 of -synuclein gene (where mutations have been re-
ported in familial PD)11,12 were sequenced in probands from
pedigrees 1 and 2, using Big Dye Terminator chemistry (Ap-
plied Biosystems).
Linkage analyses were performed using MAPMAKER-
HOMOZ, a program that allows rapid generation of multi-
point log of the odds (LOD) scores in both consanguineous
and nonconsanguineous pedigrees.13 In the calculations we
Fig 1. Simplified pedigrees of the 4 families with haplotypes for the PARK7 region. Homozygous regions are indicated by black
bars. Markers are ordered according to the Marshfield integrated linkage map, and the April 2001 draft assembly of human ge-
nome (http://genome.ucsc.edu). The gender of relatives has been masked to protect family confidentiality.
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Linkage to PARK7 in an independent dataset of PD families
assumed autosomal recessive inheritance, gene frequency of
0.006, complete penetrance by age 55, and a phenocopy rate
of 0.00004. Equal recombination rates for men and women
and equal marker allele frequencies were used. Haplotypes
were constructed manually based on a minimal number of
recombination events.
Results
The main clinical features of the affected individuals in
the 4 families are summarized in the Table.
Two consanguineous families (1 and 2) showed evi-
dence for linkage to PARK7. Family 1 generated a mul-
tipoint LOD score 2 across the whole PARK7 region
(maximum 2.50), whereas Family 2 supported linkage
for a small part of the PARK7 region (maximum 0.76;
Fig 2). Haplotype analysis (see Fig 1) showed an ex-
tended homozygous interval in all affected individuals
from Family 1, flanked by heterozygous markers
D1S243 on the telomeric side and D1S450 on the
centromeric side, which overlaps completely with the
region found in the original PARK7-linked family.9
The patient from Family 2, where consanguinity is
more distant, showed a smaller homozygous interval
flanked by markers D1S2870 (telomeric) and
D1S1612 (centromeric).
In these kindreds (1 and 2), the multipoint LOD
scores were negative and all affected individuals were
heterozygous across the PARK6 and PARK2 regions
(see Fig 2, and data not shown). Sequencing the cod-
ing region of parkin and exons 3–4 of -synuclein gene
in the probands did not reveal any mutations.
Family 3 did not support linkage to any of the tested
regions (maximum LOD 0.16 in PARK7 region) (see
Fig 2, and data not shown).
Family 4 showed positive LOD scores, and the 2
patients share haplotypes for all three AR-EP loci
(maximum 0.73 in PARK7 region) (see Figs 1 and 2,
and data not shown).
A maximum cumulative multipoint LOD score of
3.63 was obtained with markers of the PARK7 region,
including all the 4 typed families (see Fig 2).
Discussion
Our current findings confirm the existence of the
PARK7 locus in an independent dataset of AR-EP fam-
ilies. Two out of 3 parkin-negative consanguineous
families show evidence for linkage to PARK7, and one
(Family 1) exceeds the accepted level of significance re-
quired for conclusive confirmation of linkage according
to the guidelines of Lander and Kruglyak.14 Because
only a small number of markers is analyzed whithin
one interval, the corrections needed for multiple testing
are minimal. As a consequence, a LOD score of 2.1
(nominal p value  0.001) is sufficient for linkage con-
firmation at interval-wide significance level.14 Family 1
is therefore the second pedigree with significant evi-
dence for linkage to PARK7 after our original report.9
Family 2 has limited statistical power because of its
small size, and the maximum observed LOD (0.76) did
not achieve interval-wide significance (p  0.05).
However, this family is of interest because of the small
homozygous region present in the patient, which
Fig 2. Multipoint log of the odds (LOD) score plots for the
PARK6 and PARK7 regions. The PARK6 and PARK7 criti-
cal intervals are indicated according to references 8 and 9.
Table. Clinical Features
Family Patient Onset Age Disease Duration (yr) T B R L-DOPA H-Y Dyt Other Remarks
1 01 28 18     III  Blepharospasm
1 03 35 21     III  Behavioral disturbances at onset
1 04 27 32     IV  Visual hallucinations (after L-DOPA)
2 R481 37 18     IV  Severe LID, DBS
3 011 35 9     II  LID
4 003 53 12     III  LID
4 005 37 17     III  LID, DBS
Phenotype at examination: T  resting tremor; B  bradykinesia; R  rigidity; L-DOPA  response to levodopa; H-Y  Hoehn-Yahr staging;
Dyt  presence of dystonia at onset; LID  levodopa-induced dyskinesias; DBS  patient treated with deep brain stimulation.
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would narrow down the critical region to less than
3cM, flanked by the heterozygous markers D1S2870
and D1S1612.
In Family 4, the 2 affected individuals share haplo-
types at all three regions implicated in AR-EP (PARK2,
PARK6, and PARK7). This family has previously been
described to provide evidence for linkage to PARK6 by
some of us (unpublished research), but the positive
linkage findings to the other loci should also be con-
sidered before definitely assigning the family to a single
locus. Although parkin gene mutations were not de-
tected in this family by genomic sequencing and exon
dosage analysis,4 other types of mutations cannot be
excluded. The presence of homozygosity for a small
part of the PARK7 region is also of interest (see Fig 1),
but because there is no known consanguinity in Family
4, this might also be a chance finding. Family 4 there-
fore illustrates some of the potential pitfalls and limi-
tations in linkage analysis of diseases such as AR-EP in
which small, nonconsanguineous sibships are often
studied, and there is genetic heterogeneity. In addition,
because of the proximity of the PARK7 and PARK6
loci, some families might support linkage to both be-
cause of presence of extended regions of homozygosity
or haplotype sharing.
In a conservative estimate (excluding Family 2 and
4), the PARK7 critical interval spans about 20cM be-
tween marker D1S243 and D1S244.9 According to the
April 2001 draft assembly of human genome, about 60
genes are present in this interval, including several with
unknown function.
The phenotype of PARK7-linked families appears
similar to the parkin-related and PARK6-linked forms.
The average age at onset was 32.1 years (range 27–40)
for PARK7 (7 patients from Families 1 and 2 in this
study, and data from van Duijn and colleagues9) versus
32 years (range 7–58) in parkin disease (100 patients).4
The onset appears slightly later (average 40.7 years,
range 32–48, 4 patients) in the PARK6-linked family.8
Other clinical features, including a good, prolonged re-
sponse to levodopa and slow progression are shared by
patients from all three AR-EP loci. This will make
their differentiation difficult on clinical grounds, indi-
cating the importance of genetic testing.
Interestingly, behavioral and psychic disturbances at
onset or early in the disease course, and focal dystonias
including blepharospasm, were noticed in the original
PARK7 kindred9 and in Family 1 described here.
Though occasionally described in families with parkin
mutations, these features could represent clinical “red
flags” for suspecting PARK7. However, larger case-
series are needed for accurate genotype-phenotype cor-
relations. An autosomal dominant form of focal-
segmental dystonia (DYT13) maps to chromosome
1p36,15 and its critical interval (telomeric border
D1S2663) overlaps for 6cM with the centromeric part
of PARK7. Despite differences in phenotype and trans-
mission pattern, DYT13 and PARK7 might be allelic
disorders.
No pathology data are so far available in PARK7
families. Presynaptic dopaminergic abnormalities were
detected by functional imaging in the original PARK7
kindred.9
In conclusion we confirm the localization of AR-EP
to the PARK7 locus in an independent dataset, suggest-
ing PARK7 as an important locus for early onset par-
kinsonism.
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Abstract: We recently reported linkage to chromosome 1p36
(the PARK7-locus) in a family with early-onset parkinsonism.
Linkage to this locus has since been confirmed in an indepen-
dent data set. We describe clinical and neuroimaging features
of the 4 patients in the original PARK7-linked kindred. Age at
onset of parkinsonism varied from 27 to 40 years. Clinical
progression was slow, and response to dopaminergic therapy
good. The clinical spectrum ranged from mild hypokinesia and
rigidity, to severe parkinsonism with levodopa-induced dyski-
nesias and motor fluctuation. Three of four patients with
PARK7-linked parkinsonism exhibited psychiatric distur-
bances. Structural neuroimaging was unremarkable, but func-
tional imaging of the brain, carried out in 3 patients, showed
significant evidence for a presynaptic dopamine deficit, and
assessment of cerebral glucose metabolism, as carried out in 1
patient, showed possible cerebellar involvement. © 2003
Movement Disorder Society
Key words: autosomal-recessive parkinsonism; PARK7; ge-
netics; phenotype; neuroimaging
The cause of Parkinson’s disease (PD), one of the
most common neurodegenerative diseases in the elderly,
is largely unknown. In recent years, attempts to dissect
the genetic background of familial, mostly early-onset,
PD have been successful.1 In PD with an autosomal
dominant pattern of inheritance, five genes or loci have
been identified.2–6 For autosomal recessive early-onset
PD, one gene and two loci have been reported so far. The
parkin gene (chromosome 6q25.2–27)7 encodes a ubiq-
uitin-protein ligase and accounts for a large part of early-
onset PD.8 The range of ages at onset in patients with
mutations in parkin is very wide, and the clinical picture
varies from parkinsonism to levodopa (L-dopa)–respon-
sive dystonia, with varying severity. Response to L-dopa
therapy is good and progression of disease is slow. After
administration of L-dopa, motor fluctuations and dyski-
nesias occur frequently.8 PARK6 (chromosome 1p35–
p36) is a second locus for autosomal-recessive parkin-
sonism, and is associated with sustained response to
L-dopa and slow progression of symptoms.9 In PARK6-
linked parkinsonism, symptoms often reported in pa-
tients with early-onset autosomal-recessive parkinson-
ism, such as early dystonia and sleep benefit, were not
observed.10
We recently mapped a third locus (PARK7) in a con-
sanguineous pedigree with early-onset autosomal reces-
sive parkinsonism.11 The PARK7 critical region lies on
chromosome 1p36, and is clearly separated from PARK6
by 25 cM. Since then, linkage to PARK7 has been
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confirmed in an independent set of families.12 In this
study, the clinical and neuroimaging features of the orig-
inal PARK7-linked family are described and compared
to other forms of autosomal recessive early-onset
parkinsonism.
PATIENTS AND METHODS
Patients
This study was carried out within the framework of a
larger research program named “Genetic Research in
Isolated Populations,” or GRIP. The scientific protocol
of GRIP has been approved by the Medical Ethics Com-
mittee of the Erasmus Medical Centre. Genealogical
information of the PARK7-linked family was obtained
and extended with local municipal and church records, as
well as computerized registers. Patients were ascertained
through their general practitioners, who informed them
about the study and requested their cooperation.
Neurological Examination
A neurological examination in each patient and avail-
able relative was carried out by 2 neurologists, blinded to
the genotype status. The clinical diagnosis of parkinson-
ism was established by the presence of at least two of the
three cardinal signs (resting tremor, muscular rigidity,
and bradykinesia) without atypical features or signs of
other neurological systems (autonomic, pyramidal and
cerebellar) being involved. The extent of motor dysfunc-
tion was evaluated by Unified Parkinson’s Disease Rat-
ing Scale (UPDRS)13 and Hoehn and Yahr scores.14 One
patient had previously undergone an extensive work-up
for mitochondrial encephalomyopathy, dopamine-re-
sponsive dystonia, and other metabolic disease (screen
for mitochondrial-DNA point mutations, biopterin-ex-
cretion assessment, bone-marrow and muscle biopsies),
which did not yield evidence for those disorders.
Neuroimaging
During the assessment of neuroimaging results, the
researchers were unaware of the genetic status of the
patients. Structural brain-imaging data were obtained and
reviewed. Functional brain-imaging was carried out in 3
of 4 patients. In all 3 patients, the presynaptic nigrostri-
atal system was assessed. Furthermore was assessed the
postsynaptic nigrostriatal system in 2 patients, and brain
glucose-metabolism in 1 patient. The scans were made in
three medical centres in The Netherlands over a 6-year
period because patients were treated by different neurol-
ogists. For this reason, the methods of neuroimaging
could vary from one patient to the next. One patient
(Patient VII-2) had a 123I-N-omega-fluoropropyl-2-car-
bomethoxy-3-(4-iodophenyl) nortropane single-photon
emission CT (FP-CIT SPECT) scan made. In another
patient (Patient VII-3), 123I-iodobenzamide (IBZM) and
FP-CIT SPECT scans were made. In the third patient
(Patient VII-7), IBZM, 2--carboxymethoxy-3--(4-io-
dophenyltropane (-CIT) SPECT, 18F-deoxyglucose
(FDG) and 18F-dopa (F-DOPA) positron emission tomog-
raphy (PET) scans were carried out.15–17
RESULTS
Patients
The PARK7 kindred consisted of two nuclear families,
indicated as Family 1 and Family 2.11 A genealogical
study linked the patients to one common ancestor six
generations ago in a pedigree that contained several
consanguineous loops (Fig. 1). All 4 patients were ho-
mozygous, and 2 of 3 unaffected siblings as well as the
parents of Patient VII-7 were heterozygous for the dis-
ease haplotype. The third unaffected sibling (VII-1) did
not carry the disease haplotype.
Patient VII-3 from Family 1 and Patient VII-7 from
Family 2 were receiving neurological treatment at the
time of the study (pergolide in Patient VII-3 and L-dopa
with entacapone in Patient VII-7). Neurological exami-
nation of the rest of the sibship of Patient VII-3 (con-
sisting of 5 other presumedly unaffected siblings)
showed 2 more affected individuals not previously
known to have parkinsonism (Patients VII-2 and VII-6).
The patient in the second sibship (Patient VII-7, Family
2) had no other affected close relatives.
Neurological Examination
Neurological examination in the parents and 2 siblings
heterozygous for the disease haplotype, and in the sibling
not carrying the haplotype yielded no evidence of neu-
rological abnormalities. Clinical features of the 4 patients
are listed in Table 1. Ages at onset of disease varied from
27 to 40 years. Patient VII-6 was 40 years old at first
neurological examination (which established the diagno-
sis of parkinsonism). All 4 patients showed the cardinal
signs of parkinsonism without atypical (pyramidal, cer-
ebellar, autonomic) features. Two patients had signs of
focal dystonia: blepharospasm occurred in Patient VII-3,
and laterocollis and foot dystonia in Patient VII-7, the
latter worsening in the off-phase of medication. Patient
VII-3 could not indicate whether the blepharospasm pre-
ceded therapy for parkinsonism, or only arose afterward.
In Patient VII-7 the laterocollis occurred within a month
of initiation of treatment. Patients VII-3 and VII-7 were
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treated with pergolide and L-dopa with entacapone, re-
spectively, and newly diagnosed Patients VII-2 and
VII-6 did not receive any dopaminergic medication. Pa-
tient VII-7 developed dyskinesias and dystonias within 1
month from L-dopa treatment. In addition to parkinson-
ism, all 3 patients VII-2, VII-3, and VII-6 in Family 1
exhibited varying degrees of anxiety, which was reported
to have existed for years before onset of parkinsonism.
Patient VII-2 was also known to have suffered from
recurrent psychotic episodes with paranoid delusions, for
which treatment was often declined. In Patient VII-7 of
Family 2, no such psychiatric or behavioral symptoms
were noted.
Neuroimaging
Structural brain-imaging was available for Patients
VII-3 (computed tomography images) and VII-7 (mag-
netic resonance images), and was unremarkable. Func-
tional brain-imaging was carried out in 3 of 4 patients
(VII-2, VII-3, and VII-7). Results are listed in Table 2.
FIG. 1. Pedigree of the PARK7-kindred. The
symbol on top represents the common ancestor,
and the symbols on the bottom row the exam-
ined individuals. Solid symbols indicate affected
individuals. *Additional psychiatric features.
TABLE 1. Clinical features of PARK7-linked parkinsonism
Patient VII-2 VII-3 VII-6 VII-7
Age at examination (yr) 50 48 40 38
Age at onset (yr) 40 31 Not known 27
Resting tremor    
Rigidity    
Bradykinesia    
Postural instability    
Asymmetry at onset    
Dystonia at examination  Blepharospasm  Laterocollis, foot dystonia
Hyperreflexia    
Dopaminergic drugs, daily
dosage (mg)
 Pergolide (1.5)  L-dopa (IDD)/entacapone
(187.5/600)
Side-effects of levodopa n.a. n.a. n.a. Dyskinesias, dystonias, motor
fluctuations
UPDRS score (on/off phase) 29 (n.a.) 57 (on) 22 (n.a.) 25 (on)
Hoehn and Yahr stage (on/
off phase)
III (n.a.) III (on) III (n.a.) III (on)
Psychiatric symptoms Anxiety, psychotic
episodes, paranoid
delusions
Anxiety Anxiety 
Psychotropic drugs, daily
dosage (mg)
Diazepam (5), haloperidol,a
olanzapinea
Temazepam (10) Diazepam (5) 
aIntermittent usage, last time of administration of at least six months before neurological examination.
UPDRS, Unified Parkinson’s Disease Rating Scale; IDD, dopa-decarboxylase inhibitor.
NEUROIMAGING PARK7-LINKED PARKINSONISM 753
Movement Disorders, Vol. 18, No. 7, 2003
120
Chapter 2.7
The fourth patient (VII-6) has not undergone neuroim-
aging. On SPECT imaging, 2 patients (VII-2 and VII-3)
had a significant, symmetrical presynaptic dopaminergic
deficit that was present bilaterally in putamen and cau-
date nucleus. The putamen was more severely affected
than the caudate nucleus. Striatal dopamine-D2 receptor
binding (assessed in Patients VII-3 and VII-7) was nor-
mal on IBZM neuroimaging. Patient VII-7 showed a
strongly reduced presynaptic dopaminergic neurotrans-
mitter function on both sides in putamen and caudate
nucleus on PET and SPECT imaging. Uptake was more
reduced in the hemisphere contralateral to the clinically
more affected body side, and the putamen was more
severely affected than the caudate nucleus. Furthermore, the
FDG PET scan carried out in Patient VII-7 showed de-
creased glucose metabolism in the cerebellum. 18F-DOPA
PET images of Patient VII-7 and of an age-matched
healthy control subject are shown in Figure 2.
DISCUSSION
Based upon observations in this original kindred,
PARK7-linked parkinsonism is of variable severity.
Some of the patients had overt parkinsonism, receiving
L-dopa or dopaminergic therapy to which they responded
well. Others had mild parkinsonism for which medical
attention was never sought. Patients VII-3 and VII-7 had
most pronounced motor dysfunction, and were on anti-
parkinson treatment. The latter 2 patients also had focal
dystonia. Patient VII-7, who received L-dopa, developed
this within a month of starting dopamine therapy, as well
as motor fluctuations, on-phase dyskinesias and off-
phase dystonia. In all 4 patients, progression as observed
over the 3-year period of our study was very slow. The
features in early-onset parkinsonism mentioned above,
such as the variable severity, the positive response to,
with motor complications of, L-dopa and slow progres-
sion of disease, are comparable to the phenotype of
parkin-related8 and PARK6-linked parkinsonism.9 Simi-
lar observations were made in other PARK7-linked kin-
dreds.12 In families with PARK6-linked parkinsonism,
however, focal dystonia was not observed and resting
tremor prevailed.10 Although the number of patients
studied is too small to draw firm conclusions, PARK6-
and PARK7-linked parkinsonism appear to be entities
that are genetically as well as clinically distinct.
The siblings and parents who were heterozygous for
the PARK7-linked haplotype showed no symptoms of
parkinsonism at neurological examination. As for parkin
and PARK6, being a heterozygous carrier of the PARK7
disease-haplotype is probably not sufficient to confer
clinical parkinsonism.
All patients in Family 1 had symptoms of anxiety, for
which they had been receiving benzodiazepine treatment
for years (Patient VII-3 had been using benzodiazepines
even before parkinsonism was diagnosed and treated).
Because the 3 siblings were treated by different general
practitioners, this common medication cannot have been
due to the propensity of 1 physician to prescribe benzo-
diazepines. In this family, complaints of anxiety may
have been superimposed on, or confused with, initial
symptoms of parkinsonism. In Family 1, the 3 siblings
who were unaffected with parkinsonism (VII-1, VII-4,
VII-5) had no psychiatric symptoms either. These psy-
chiatric symptoms may thus constitute part of the PARK7
phenotype. In 1 patient of the independent family with
significant linkage to PARK7,12 psychiatric and behav-
TABLE 2. Functional neuroimaging in PARK7-linked parkinsonism
Patient Scan performed Results
Family 1 VII-2 FP-CIT SPECT Uptake putamen and caudate bilaterally and
symmetrically decreased
VII-3 FP-CIT SPECT Uptake putamen and caudate bilaterally and
symmetrically decreased
VII-3 IBZM SPECT Normal dopamine-D2 receptor binding
VII-6 — —
Family 2 VII-7 -CIT SPECT Uptake putamen bilaterally decreased; uptake caudate
unilaterally decreased
VII-7 IBZM SPECT Normal dopamine-D2 binding
VII-7 18F-DOPA PET Uptake putamen and caudate bilaterally decreased,
more pronounced contralateral to most severely
affected body side
VII-7 FDG PET Diffuse cerebellar hypometabolism
FP-CIT SPECT, 123-I-N--fluoropropyl-2-carbomethoxy-3-(4-iodophenyl) nortropane single photon emis-
sion CT; IBZM SPECT, 123I-iodobenzamide SPECT; -CIT SPECT, 2--carboxymethoxy-3--(4-iodophenyl-
tropane) SPECT; FDG PET, 18F-deoxyglucose PET.
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ioral problems at onset of disease were also present:
aggression, irritability, and obsessive-compulsive disor-
der (V. Bonifati, personal communication). In parkin-
linked disease, psychiatric features, such as pronounced
anxiety requiring treatment, have been reported occa-
sionally,18–20 and in classical, idiopathic PD, anxiety is
also observed commonly.21 Due to the consanguineous
structure of our pedigree, however, psychiatric symp-
toms may form a ‘private’ trait in Family 1 only, and be
unrelated to the PARK7 phenotype. Additional families
are therefore required to study psychopathological as-
pects of PARK7-linked parkinsonism.
On FP CIT- and -CIT imaging in Patients VII-2 and
VII-3, there was significant evidence for a symmetrical
presynaptic dopaminergic deficit. In Patient VII-7, who
underwent PET and SPECT neuroimaging, dopa uptake
was greatly reduced bilaterally in both putamen and
caudate nucleus. This was more pronounced in the cere-
bral hemisphere contralateral to the more severely af-
fected body side. 18F-DOPA PET-scan series carried out
in parkin patients and carriers22–24 showed a bilaterally
and symmetrically decreased dopa uptake, in which pu-
tamen as well as caudate nucleus were affected. Further-
more, asymptomatic parkin-heterozygotes showed a
mild but significant decrease in dopa uptake, suggesting
a sub-clinical disease process in heterozygotes.23 In id-
iopathic, non-familial PD, dopa uptake is primarily
asymmetrically decreased, affecting the putamen much
more severely than the caudate nucleus.25
The dopa-uptake reduction is symmetrical in 2 pa-
tients in our study, but asymmetrical in a third patient,
which does not permit straightforward comparison to
dopa-uptake patterns in parkin-linked parkinsonism or to
those in idiopathic PD. The presence of impaired uptake
in putamen as well as in the caudate nucleus in our
patients resembles parkin-linked parkinsonism more
FIG. 2. 18F-DOPA PET images of an
age-matched healthy control subject and
of Patient VII-7. Two transaxial planes
through the brain of an age-matched
healthy control subject (top) and Patient
VII-7 (bottom). The subjects are viewed
from the feet. The linear color scale is
scaled for activity between the subjects.
The red color indicates maximum up-
take, and purple very low uptake. Com-
pared to the control subject, uptake into
putamen and caudate nucleus in Patient
VII-7 is reduced markedly on both sides.
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than idiopathic PD.22–24 More data on PARK7-linked
parkinsonism are therefore required to further delineate
its functional-neuroimaging pattern.
The FDG PET image of Patient VII-7 showed cere-
bellar hypometabolism of glucose. This may either be a
primary phenomenon in the disease process, or occur
secondary to striatal deafferentation. A decreased glu-
cose metabolism in the cerebellum was also observed on
FDG PET imaging in patients with a deletion in the
parkin gene,22 suggesting another feature that PARK7-
and parkin-linked parkinsonism have in common. Fur-
thermore, clinical cerebellar dysfunction and neuropa-
thology have been described in Japanese and Dutch
families with parkin-related parkinsonism.26,27 In addi-
tion to the observations in parkin-related parkinsonism, a
SPECT study reported symmetrical cerebellar hypoper-
fusion in an early-onset patient without parkin muta-
tions.28 Cerebellar involvement in autosomal recessive
parkinsonism remains unclear and therefore requires fur-
ther research.
In PET-neuroimaging studies on parkin-linked parkin-
sonism, 11C-raclopride binding, assessing status of
postsynaptic dopamine-D2 receptors, was shown to be
reduced significantly.23 In Patient VII-7, a C-raclopride
PET scan has unfortunately not been carried out, but
IBZM imaging in this patient and in Patient VII-3
showed normal dopamine-D2 receptor binding. Finally,
functional-neuroimaging studies of the PARK7-positive
confirmation families and the PARK6 families are not yet
available, nor are neuropathological data.
The number of patients of this newly described form
of parkinsonism is small, but nevertheless demands com-
parison to other forms of recessive parkinsonism and
idiopathic PD. Our first delineation of the PARK7 phe-
notype can be refined as more PARK7-linked families
become available.
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Mutations in the DJ-1 Gene
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Early-Onset Parkinsonism
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The DJ-1 gene encodes a ubiquitous, highly conserved protein. Here, we
show that DJ-1 mutations are associated with PARK7, a monogenic form of
human parkinsonism. The function of the DJ-1 protein remains unknown, but
evidence suggests its involvement in the oxidative stress response. Our
findings indicate that loss of DJ-1 function leads to neurodegeneration.
Elucidating the physiological role of DJ-1 protein may promote understand-
ing of the mechanisms of brain neuronal maintenance and pathogenesis of
Parkinson’s disease.
The causes of Parkinson’s disease (PD), a
common neurodegenerative disorder, re-
main largely unknown but genes identified
for rare Mendelian forms have increased
our understanding of disease pathogenesis
(1, 2). By homozygosity mapping in two
consanguineous families from genetically
isolated communities in the Netherlands
and Italy, we localized a gene for autoso-
mal recessive early-onset parkinsonism,
PARK7, to a 20-cM interval on chromo-
some 1p36 (supporting online text) (3, 4 ).
Fine mapping by typing available and
newly developed short tandem repeat
(STR) or single nucleotide polymorphism
(SNP) markers, reduced the critical region
in the Dutch family to a 5.6-Mb region of
homozygous sequence, spanning six con-
tigs and five gaps in NCBI build 29 of the
human genome (5) and containing as many
as 90 genes (Fig. 1) (6 ). We sequenced
obvious candidate genes from genomic
DNA, but no mutations were detected in the
two families (supporting online text).
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We then performed a systematic screen-
ing of the transcripts in the region, using
reverse-transcriptase–polymerase chain re-
action (RT-PCR) material obtained from
lymphoblastoid cell lines of one patient in
each family and a normal control. One of
the cDNAs analyzed, corresponding to the
whole DJ-1 gene open reading frame
(ORF), could not be amplified in the Dutch
patient (fig. S1). Amplification of DJ-1
exons 1A/B to 5 from genomic DNA yielded
no products in the same patient, whereas
the two more centromeric exons 6 and 7
were normally amplified. This confirmed
the presence of a homozygous genomic
deletion and placed the centromeric border
of the deletion in intron 5 of the DJ-1 gene.
From the telomeric side, we could amplify
exons of the neighboring gene TNFRSF9,
as well as sequences from the intergenic
region, delineating DJ-1 as the only gene
involved in the deletion.
Using a PCR-based strategy, we cloned
the deletion breakpoint (supporting online
text). A novel fragment of about 2000 base
pairs (bp) was amplified only from the
individuals carrying the disease allele. Se-
quencing this fragment confirmed the join-
ing of the telomeric and centromeric bor-
ders, delineating a deletion of 14.082 bp,
which includes 4 kb of sequence upstream
of the DJ-1 gene ORF start. Interestingly,
ALU elements flank the deleted sequence
on both sides, and the breakpoint occurs
within 16 bp of sequence identical in the
two ALUs, suggesting that unequal cross-
ing-over was likely at the origin of this
genomic rearrangement (fig. S1).
The deletion showed complete cosegre-
gation with the disease allele in the Dutch
family (fig. S1), whereas it was absent in
380 chromosomes from the general Dutch
population, which supports the position that
it is a pathogenic mutation. We also inves-
tigated the frequency of the DJ-1 deletion
within the genetically isolated population
where the Dutch PARK7 family was iden-
tified (3). Among 440 independent chromo-
somes from the genetic isolate we found
four heterozygous and no homozygous car-
riers of the deletion. Moreover, the deletion
was absent in 400 chromosomes from the
regions closely surrounding the genetic iso-
late. Together with our results from the
general Dutch population, these findings
indicate that, although the mutant allele is
present at 0.9% within the isolated popula-
tion, it is likely confined to this population.
None of 46 late-onset PD patients from the
isolated community carried the deletion, in-
dicating that they have a different etiology.
We then sequenced the DJ-1 cDNA
from the Italian patient and identified a
homozygous point mutation (T3C transi-
tion at position 497 from the ORF start in
cDNA), resulting in the substitution of a
highly conserved leucine at position 166
(Leu166) of the DJ-1 protein by a proline
(Fig. 2A). This change showed complete
cosegregation with the disease allele in the
Italian family (fig. S1) and was absent from
320 chromosomes from the general Italian
population. No further changes segregating
with the disease in the Italian family and
absent in the general population were
detected.
Although PARK6 and PARK7 seem to
be separate, close loci (supporting online
text), it will be interesting to search the
published PARK6 family for mutations in
DJ-1 (7 ). We have tested a limited number
of early-onset familial and sporadic PD
patients that did not have mutations in the
parkin gene; we did not find a mutation in
DJ-1 (supporting online text).
The DJ-1 gene contains 8 exons distrib-
uted over 24 kb (Fig. 1A). The first two
exons (1A and 1B) are noncoding and alter-
natively spliced in the DJ-1 mRNA (5).
One major transcript of about 1 kb contains
Fig. 1. Genetic and
physical maps of the
PARK7 region. (A)
Genomic organization
of the DJ-1 gene. The
location of the eight
exons and the muta-
tions found in the
Dutch and Italian fam-
ilies are shown. (B)
BAC/PAC clone cover-
age of a 500-kb region
spanning the DJ-1
gene. Blue and black
bars indicate finished
and unfinished clones,
respectively. (C) Physi-
cal map of the PARK7
region. Vertical bars
above contigs indicate
the location of the
polymorphic markers
typed in this study.
Contigs depicted in
yellow contain fully in-
formative, homozy-
gous markers in the
Dutch family patients.
Regions depicted in
brown contain het-
erozygous markers in
at least one patient.
The most telomeric
contig depicted in gray contains homozygous, noninformative markers. The
contig NT 022058 contains informative homozygous markers and is there-
fore placed within the PARK7 critical region. Its position in the NBCI
assembly (build 29) is more telomeric. The remaining contigs are ordered as
in the NCBI assembly. Heterozygous markers placed in contig NT 004321
telomerically and NT 032970 centromerically, flank 5.6 Mb of homozygous
sequence and define the new PARK7 critical interval (black arrowheads). (D)
Genetic map; the intermarker genetic distance is given in centimorgans,
according to the Marshfield integrated sex average linkage map. Markers
flanking the PARK7 locus in previous mapping studies are indicated with
black arrows. The marker D1S1612, located 80 kb centromeric to the DJ-1
gene, is indicated by a red arrowhead (C and D).
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a 570-bp ORF, encoding a protein of 189
amino acids, that is ubiquitously expressed
in body tissues and brain areas, includ-
ing those more affected in PD (fig. S2).
DJ-1 belongs to the ThiJ/PfpI family
( pfam01965), which includes ThiJ, a pro-
tein involved in thiamine biosynthesis in
prokaryotes; PfpI and other bacterial pro-
teases; araC and other bacterial transcrip-
tion factors; and the glutamine amidotrans-
ferases family (including bacterial cata-
lases) (Fig. 2B).
To investigate the structural conse-
quences of the Leu166Pro mutation, a mo-
lecular model of DJ-1 was built using the
programs WHAT IF (8) and YASARA (9).
With 23% sequence identity to the known
structure of protease PH1704 from Pyro-
coccus horikoshii (10) and an almost gap-
less alignment spanning 170 residues, DJ-1
can safely be assumed (11) to adopt the
same / sandwich structure as PH1704
(Fig. 2C). According to the model, Leu166
is placed right in the middle of the carbox-
yl-terminal helix. Proline is a strong helix
breaker (12) and its presence in the DJ-1
mutant is therefore likely to destabilize the
terminal helix. The PH1704 protease was
found to form a hexameric ring structure
made of a trimer of dimers (10). The gen-
eral pattern of salt bridges and hydrophobic
packing in the trimerization region of
PH1704 is conserved in the DJ-1 model,
which makes it likely that DJ-1 also forms
higher aggregates.
To explore the functional consequences of
the DJ-1 mutation, we transfected wild-type
and mutant DJ-1 in cell cultures (Fig. 2, D to
I). In COS and PC12 cells transfected with
wild-type DJ-1 we observed diffuse cytoplas-
mic and nuclear DJ-1 immunoreactivity sim-
ilar to findings from previous studies (13,
14). Transfection of the DJ-1 carrying the
Leu166Pro mutation showed a similar uni-
form nuclear staining, whereas the cytoplas-
mic staining appeared mostly colocalized
with mitochondria.
Taken as a whole, our findings indicate
that the DJ-1 protein is lacking in the Dutch
family and is functionally inactive in the
Italian family because of the Leu166Pro
change. The mutant DJ-1 (Leu166Pro) is
still present in the nucleus, which suggests
that the loss of cytoplasmic activities is
pathogenic, or that the nuclear activity is
affected by the mutation even if the protein
retains its translocation capability.
The function of DJ-1 is unknown. Hu-
man DJ-1 was first identified as an onco-
gene (13) and later as a regulatory subunit
of an RNA-binding protein (RBP) (14 ).
Moreover, DJ-1 binds to PIAS proteins
(15), a family of SUMO-1 ligases that mod-
ulate the activity of various transcription
factors (16 ). DJ-1 itself is sumoylated at
lysine 130 (15). Interestingly, in human and
murine cell lines, DJ-1 has been identified
as a hydroperoxide-responsive protein that
is converted into a variant with a more
acidic pI in response to oxidative stimuli
like H2O2 or the herbicide Paraquat, which
suggests a function as an antioxidant pro-
tein (17, 18). The transcription of
YDR533C, a yeast DJ-1 homolog, is in-
duced together with genes involved in the
oxidative stress response (19).
Oxidative damage has been implicated
in the mechanisms of neuronal death and
the pathogenesis of PD (20). Normal dopa-
mine metabolism produces reactive oxygen
species, making nigral neurons particularly
sensitive to oxidative stress, and signs of
oxidative stress are found in postmortem
studies of PD brains (2, 20). Emerging
evidence also links oxidative stress to mu-
tations in -synuclein and parkin, two PD-
related genes (21, 22).
It is possible that DJ-1 participates in
the oxidative stress response by directly
buffering cytosolic redox changes, and/or
by modulating gene expression at transcrip-
tional and post-transcriptional levels (fig.
S3), interacting with RBP complexes and
Fig. 2. DJ-1 protein analysis, and transfection ex-
periments. (A) Alignment of DJ-1 homologs show-
ing the conservation of the amino acid mutated in
the Italian family (Leu166). (B) Phylogenetic tree of
DJ-1 and other ThiJ/PfpI family proteins. The
length of the connecting lines reflects evolution-
ary distance between family members. (C) Molec-
ular model of DJ-1. The purple and yellow ribbons
correspond to -helix and -sheet structures, re-
spectively. Indicated is the position of the residue
(Leu166) mutated in the Italian family. (D to I) COS
cells transfected with constructs expressing wild-
type (D to F) or Leu166Pro mutant (G to I) v5-His-
tagged DJ-1 protein. Immunostaining: v5-His tag
[green (D and G)]; HSP60, a mitochondrial marker
[red (E and H)]; v5-His tag and HSP60 merged (F
and I).
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H. sapiens DJ-1
B. taurus DJ-1
M. musculus DJ-1
X. laevis DJ-1
F. rubripes DJ-1
S. salar DJ-1
D. melanogaster DJ-1a
D. melanogaster DJ-1b
C. elegans DJ-1a
C. elegans DJ-1b
E. coli ThiJ
P. furiosus PfpI
P. horikoshii PH1704
S. coelicolor AraC
P. ostreatus catalase
M. avium catalase
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transcriptional cofactors such as PIAS or
other, unknown factors.
Our discovery of DJ-1 mutations in
PARK7 opens new avenues for understand-
ing the neuronal function of DJ-1, that,
when lost, causes neurodegeneration. Fur-
thermore, the observation that DJ-1 may be
involved in the oxidative stress response
links a genetic defect in this pathway to
the development of parkinsonism, with
possible implications for understanding
the pathogenesis of the common forms
of PD.
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Materials and methods
Marker development and genotyping 
Sequence data from selected BAC or PAC clones were downloaded from GenBank (1). Short 
Tandem Repeat (STR) sequences were selected by repeat length and type using the program 
FileProcessor (2). Single Nucleotide Polymorphisms (SNPs) were downloaded from NCBI (3) or 
they were generated through use of the Celera Discovery System and Celera's associated 
databases. STR markers were typed by radioactive polymerase chain reaction, essentially 
according to Weber and May (4). SNP markers were typed using a touch-down PCR protocol and 
digestion with restriction endonucleases. Heterozygosity of markers was determined using a 
panel of independent chromosomes from the general population. The complete lists of typed 
STRs and SNPs is available on request.
Genetic analyses 
Genomic DNA was isolated from peripheral blood using standard protocols.
For mutation analysis of the DJ-1 gene, PCR reactions were performed in 25 or 50 μl containing 
1x GibcoBRL PCR buffer, 1.5mM MgCl2, 0.01% W-1, 250μM of each dNTP, 0.4μM forward 
primer, 0.4μM reverse primer, 2.5 units of Taq DNA polymerase (GibcoBRL) and 50 ng genomic 
DNA/25 μl of PCR volume. For exon 2, the concentration of each primer was 2μM. For exon 1, 
DMSO 7% was used.
Cycle conditions were: 5 min at 94°C; 35 cycles of 30 s denaturation at 94°C, 30 s annealing at 
temperatures reported below, and 90 s extension at 72°C; final extension 5 min at 72°C. Primers, 
annealing temperatures, and size of amplified fragments were as follows: 
Exon  Forward  Primer 5’→3’  Reverse Primer 5’→3’  annealing T   size (bp)
1A/B GAGGTAGACTCGGCCGGAC TTCTGGACGCTTCAGCGTTG  70°→60° (-1°/cycle), then 60°    405 
2 TAGGAAGTACTTACTCTGCTTG TATTTATTCTTATGTCATCTCTG 66°→58° (-1°/cycle), then 58°  359 
3 CAGCTGTGTAAACGTTACTC ATTCTGTATCAAGCAATTGCC  65°→56° (-1°/cycle), then 56°   546 
4  CTATCTCCTGTACTTCCCAC  ACAGAACATAAGCAGATGCTG 66°→58° (-1°/cycle), then 58°   254 
5  TGAGAAATGCCTTGCTTGGG GCTATTTGGAATCAAACCATCG 70°→60° (-1°/cycle), then 60°  354 
6  TTTGCCAGATGTGCTCAGCAAATCG ACTGCACTCCAGCCTGGGCGATGG  68°,   total:35 cycles  495 
7  CACATAGCCCATTAGGATGTC AGCTGCAAATGAAGGTGATAC  66°→58° (-1°/cycle), then 58°   504 
________________________________________________________________________________________________________________
Direct sequencing of both strands was performed using Big Dye Terminator ver. 3.0 chemistry 
(Applied Biosystems). Fragments were loaded on an ABI3100 automated sequencer and analysed 
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with DNA Sequencing Analysis (ver 3.7) and SeqScape (ver 1.1) packages (Applied Biosystems). 
Analysis of the genomic deletion found in the Dutch family.
For sequencing purposes, a 1761 bp DNA fragment containing the deletion breakpoint was 
amplified using 2μM forward 5’-GCAAATAGCCAAAAGTGAAGTC-3’ and 2μM reverse 5’-
CGTACAAGACCTGCCAGGG-3’ primers. PCR conditions were as above, with annealing 
temperatures of 70°→60° (-1°/cycle), then 60°, total 35 cycles.
For testing the cosegregation in the Dutch family and the occurrence in population controls, a 
2011 bp fragment containing the deletion breakpoint was amplified using 1μM forward 5’-
GCAAATAGCCAAAAGTGAAGTC-3’ and 1μM reverse 5’-
TACTTTCAGCAGAATCATAAGG-3’ primers; a 354 bp fragment containing exon 5 of DJ-1
gene was also amplified in the same PCR reaction using 0.2μM forward 5’-
TGAGAAATGCCTTGCTTGGG-3’ and 0.2μM reverse 5’-
GCTATTTGGAATCAAACCATCG-3’ primers. PCR conditions were as above, with annealing 
temperatures of 70°→60° (-1°/cycle), then 60°, total 35 cycles. Fragments were resolved using 
agarose 1.5% gel electrophoresis. 
For RT-PCR analyses, lymphoblastoid cell lines were established from one patient of each 
PARK7-linked family and one unrelated normal control. Total mRNA was isolated, and cDNA 
was prepared according to standard protocols. The following primers (0.4μM each) were used to 
amplify the DJ-1 cDNA: forward-I 5’-GGGTGCAGGCTTGTAAACAT-3’, reverse-I 5’-
TGACTTCCATACTTCCGCAAA-3’, forward-II 5’-CGCGTCCGCAGGAAGAGG-3’, reverse-
II 5’-TAGACACAATTTGTAGGCTGAG-3’, forward-III 5’-GCGTGCTGGCGTGCGTTC-3’. 
The primers were used in the following combinations: forward-I/reverse-I (product size 741 bp); 
forward-II/reverse-I (763 bp); forward-III/reverse-I (770 bp); forward-I/reverse-II (780 bp); 
forward-II/reverse-II (802 bp); forward-III/reverse-II (809 bp). In some experiments, a 285 bp 
fragment of the KIAA833 cDNA was amplified as internal PCR control, using 0.4μM forward 5’-
AGCTGCCGTCGTGCTGTAC-3’ and 0.4μM reverse 5’-GGGTTGGTGCTTGCAATAAC-3’ 
primers. PCR conditions were as above, with annealing temperatures of 66°→58° (-1°/cycle),
then 58°, total 35 cycles.
For allele specific oligo (ASO) hybridization, PCR products containing DJ-1 exon 7 were blotted 
into Hybond-N+ membranes (Amersham Biosciences). The blots were hybridized for 1 hour at 
37°C in 5X SSPE, 1% SDS and 0.05 mg/ml single strand salmon sperm DNA with either the 
normal or mutated sequence oligo. Filters were washed until a final stringency of 0.3 x SSC/0.1% 
SDS at 37°C. The following oligos were used for hybridization: wild-type allele 
TTTGCGCTTGCAATT, mutated allele (L166P) TTTGCGCCTGCAATT.
Northern blot analysis was performed according to manufacturers protocols (Clontech). 
GenBank accession numbers: DJ-1 genomic sequence: AL034417. DJ-1 transcripts: 
AB073864, AF021819, BC008188, D61380. DJ-1 protein: CAB52550, BAB71782, AAC12806, 
AAH08188, BAA09603. 
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Bioinformatics of DJ-1 protein 
Multiple sequence alignments were produced with ClustalW (5) at the European Bioinformatics 
Institute (http://www2.ebi.ac.uk/clustalw). The phylogenetic tree of DJ-1 protein family was 
generated with TreeTop at GeneBee (6).
Molecular modeling of DJ-1 protein
Initial alignments for DJ-1 were obtained from the 3D-PSSM fold recognition server (7) which 
identified PDB entry 1G2I as the closest homolog of known structure. The alignment and also the 
model does not cover the N-terminal three and C-terminal 16 residues of DJ-1 protein. Side 
chains were built using WHAT IF (8). The model was energy minimized with the YASARA 
NOVA force field which was shown to improve models (9). Validation of the model with 
WHAT_CHECK (10) showed a Ramachandran Z-score of -2.46 and all other quality Z-scores 
about one standard deviation below the average high resolution X-ray structure, which is good for 
a model based on only 23% sequence identity. 
DJ-1 expression vectors 
Wild-type and mutant (L166P) DJ-1 cDNAs were cloned in pcDNA3.1/V5-His TOPO TA vector 
(Invitrogen) and checked by sequencing using the Big Dye Terminator ver. 3.0 chemistry 
(Applied Biosystems).  
Cell culture and transfection 
COS cells were cultured in DMEM supplemented with 10% fetal calf serum, 100 units/ml 
penicillin and 100μg/ml streptomycin and were kept at 37°C in 5% CO2 (all from GIBCO BRL). 
PC12 cells were grown in DMEM supplemented with 10% horse serum (Sigma) and 5% fetal calf 
serum, 100 units/ml penicillin and 100μg/ml streptomycin and kept at 37°C in 10% CO2. COS 
and PC12 cells were transiently transfected with the constructs mentioned above using the 
Lipofectamine + Reagent (Gibco) according to the manufacturer’s recommendations. Transfected 
cells were fixed for immunofluorescence staining 24 and 48 h after transfection.  
Immunofluorescence staining 
Cells were rinsed with phosphate-buffered saline (PBS), fixed with 3% paraformaldehyde (10 
min), permeabilized with methanol (15 min), blocked with PBS/5% bovine serum albumin 
/0.15% glycine (15 min) and incubated for 1h with monoclonal mouse anti-V5 antibody 
(Invitrogen), dilution 1:500. FITC-conjugated goat anti-mouse immunoglobulin G (1:500 1h) was 
used as secondary antibody (Sigma). Cells were mounted in Vectashield media (Vector) 
containing DAPI and examined with a Zeiss Axioplan 2 microscope equipped with digital 
camera. Mitochondrial staining was performed by using rhodamine-conjugated MitoTrack 
(1:2000) or by double-labeling immunofluorescence with rabbit anti-HSP60 antibody (1:200, 1h 
Stressgen) and TRITC-conjugated goat anti-rabbit immunoglobulin (1:500, 1h). 
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Clinical studies 
The Dutch and Italian PARK7-linked families have been described previously (11,12). The 
diagnosis of parkinsonism required the presence of two of three cardinal signs (resting tremor, 
bradykinesia, muscular rigidity), absence of atypical features (dementia early in disease course, 
ophtalmoplegia, pyramidal or cerebellar involvement), and no other identifiable causes. Brain 
imaging with computed tomography and/or magnetic resonance were unremarkable. Response to 
levodopa or dopamine agonist therapy was present in all patients except two who were untreated 
at the time of study. Autopsy data are not available. Functional brain imaging studies performed 
in patients of the Dutch family using dopamine-transporter tracers and SPECT or PET showed 
severe abnormalities, indicating presynaptic dysfunction of the nigrostriatal dopamine system, the 
pattern typically observed in Parkinson’s disease (PD) (13).
In comparison with classical, late-onset PD, the clinical phenotype in the Dutch and Italian 
PARK7-linked families is characterized by an early onset (in the thirties) and a slow disease 
progression. Furthermore, behavioral and psychic disturbances, and dystonic features (including 
blepharospasm) have been reported in both families (11,12). However, more detailed genotype-
phenotype correlation studies are needed to accurately define the clinical spectrum associated to 
mutations in DJ-1 gene. 
Fine mapping studies
The PARK7 locus as delineated by initial linkage studies (11,12) spans more than 8 Mb in the 
current physical map of the Human Genome (NCBI, build 29), including 9 contigs separated by 8 
gaps, containing a large number of genes.  
In the last four NCBI builds of the human genome, released during the course of this study, the 
order of several contigs inside and in the proximity of the PARK7 region has fluctuated 
considerably, and for some contigs the internal assembly remains provisional.  
In order to overcome these difficulties, we have used extensive homozygosity mapping by typing 
available STR or SNP markers in the two definitely linked families to characterize each of the 
contigs located inside and flanking the PARK7 genetic borders. For contigs where STRs or SNPs 
were not available or not informative we developed new polymorphic STR markers by scanning 
clones of interest for repetitive sequences. 
Analysis of candidate genes
The refinement of PARK7 critical interval allowed us to exclude many genes located in contigs 
showing heterozygous markers, including obvious candidates: UBE4B and Ubc6p, encoding 
enzymes involved in ubiquitination; ISG15, encoding an ubiquitin-like protein; FLJ10782
(PANK4), encoding a homolog of the gene mutated in pantothenate kinase-associated 
neurodegeneration, an autosomal recessive neurodegenerative disease, and FRAP1, encoding an 
immunophilin ligand.  
Obvious candidate genes located in contigs showing homozygous markers were analysed by 
direct sequencing from genomic DNA (primers and PCR conditions are available on request).
We detected no mutations in the coding region of the following genes: WDR8, encoding a protein 
containing WD40 repeats, a domain also found in ubiquitin ligase protein complexes; VAMP3,
encoding a vesicle-associated protein, possibly involved in docking or fusion of synaptic vesicles; 
FLJ10737, encoding a protein with a DnaJ domain, also present in molecular chaperones; 
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KCNAB2, encoding a subunit of the potassium voltage-gated channel, shaker-related subfamily.
Strategy for cloning the deletion breakpoint
In order to identify the deletion breakpoint, we designed primer sets to amplify fragments of 
DNA evenly distributed between the minimal deleted area and the two flanking areas of non-
deleted sequence. Iteration of this technique reduced the interval between the deleted region and 
the flanking, non-deleted borders to less than 3 kb. We then used primers placed on the non-
deleted borders to amplify a fragment of about 2000 bp across the deletion breakpoint. In the 
normal chromosomes, these two primers are separated by about 16 kb.  
Replacing the reverse primer with another primer located 250 bases upstream yielded a novel 
fragment of about 1750 bp in the same individuals, confirming the specificity of the reaction and 
the presence of the deletion (data not shown). 
Cloning of the deletion breakpoint allowed us to test for the presence of the mutation in both  
heterozygous or homozygous state using PCR. 
Relationships between PARK6 and PARK7
A different locus for autosomal recessive early onset parkinsonism (PARK6) has been localized 
25 cM centromeric of PARK7 on chromosome 1p35-p36, in a single large pedigree (14). Given 
the similarities between PARK6- and PARK7-associated phenotypes, and the proximity of the 
two loci, it is possible that mutations in similar or functionally-related genes underlie both forms. 
As an alternative possibility, a large genomic rearrangement could account for both linkage 
reports.
Linkage analysis of autosomal recessive parkinsonism is complicated by the small size of most 
recessive pedigrees, presence of further locus heterogeneity, proximity of the two loci on chr.1p. 
As a result, the assigment of additional smaller families to either PARK6 or PARK7 must be 
considered as provisional (12,15).
Mutation analyses of DJ-1 gene in smaller families and isolated early onset cases
Nine additional families with a diagnosis of clinically definite idiopathic parkinsonism in at least 
two siblings, possible autosomal recessive inheritance (affected sibs, unaffected parents), disease 
onset before age 50 in at least one sibling, exclusion of linkage to PARK2 locus, or parkin gene 
mutations excluded by sequencing and exon dosage, were available for analysis. 
By haplotype analysis, four of these families were compatible with linkage to PARK7; three 
families to both PARK7 and PARK6; and two families to PARK6 only (16). None of the above-
mentioned families could be definitely linked to either of the two loci.  
Furthermore, twenty-two patients with idiopathic parkinsonism, negative family history and onset 
below age 40 were also studied. In nine cases mutations in parkin gene had been excluded by 
genomic sequencing and exon dosage. 
Sequencing the exons and exon-intron boundaries of the DJ-1 gene in the patients and families 
described above revealed no pathogenic mutations. Among the same patients and families, there 
were no carriers of the DJ-1 deletion identified in the Dutch family. However, detection of 
compound heterozygosity for different genomic rearrangements requires gene dosage analysis 
which is currently being developed and therefore will be the subject of future studies. 
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Fig.S1  Mutation analyses 
A. Cosegregation of the genomic deletion in the Dutch family. Duplex PCR from genomic 
DNA using primers designed to amplify the deletion breakpoint (2011 bp band) and one of the 
deleted DJ-1 exons (exon 5 - 354 bp band). Exon 5 is absent from all patients (hom deletion, 
lanes 2,3,6,8); the deletion breakpoint band is present in homozygous (lanes 2,3,6,8) and 
heterozygous (lanes 4,5,7,9) carriers of the mutant allele (note the dosage effect). Individual 1 is 
not carrying the disease haplotype, in agreement with data in ref.11.
B. Cosegregation of the L166P mutation in the Italian family. Allele specific oligo 
hybridization: mut - mutant; wt - wild-type; C - unrelated normal control. 
C. Sequence of the deletion breakpoint in the Dutch family showing the joining of the 
telomeric and centromeric borders. The breakpoint lies within a 16 bp of sequence identical in the 
Alus and is depicted in a frame. The specific nucleotides in telomeric and centromeric sequences 
are indicated by upper lines.
D. Electropherograms showing the L166P mutation in the Italian family. Sequencing from 
genomic DNA and cDNA.  
E. Scheme of the genomic rearrangement in the Dutch family.  
F. RT-PCR amplification of a 741 bp fragment corresponding to the DJ-1 cDNA indicates 
absence of expression in the Dutch patient, and presence of expression in the Italian patient. To 
exclude the possibility of a polymorphism in one of the primer binding sites this was replicated 
using six different primer combinations (data not shown). A 285 bp fragment of the KIAA0833
cDNA is amplified as internal PCR control in the left lanes.  
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Fig.S2   Northern blot – different human tissues and brain regions 
Upper panels: DJ-1 probe. Lower panels: control probe (β-actin). DJ-1 expression is higher in 
subcortical regions (caudate nucleus, thalamus, s.nigra) than in cortical regions.  
Fig.S3  Model of putative DJ-1 function 
Modification of the DJ-1 protein (by chemical or multimerization changes) may directly buffer 
cytosolic redox fluctuations; activated DJ-1 may influence expression of genes for oxidative 
stress response post-transcriptionally (binding to RBP complexes); DJ-1 may also translocate to 
the nucleus, be sumoylated, and influence gene transcription.  
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Linking DJ-1 to neurodegeneration
The discovery of DJ-1 mutations in autosomal recessive, early-onset PD establishes that 
the loss of the DJ-1 function leads to neurodegeneration (chapter 2.8). The exact role 
of this protein remains unknown but several pieces of information are available in the 
literature which provide clues to a possible function. Here, the current knowledge about 
DJ-1 is reviewed, and hypotheses linking DJ-1 to neurodegeneration are formulated. 
The current evidence suggests an involvement of DJ-1 in processes as different as cell 
cycle regulation and oncogenesis, sperm maturation and fertilization, control of gene 
transcription, regulation of mRNA stability, and response to cell stress. 
A human cDNA termed DJ-1 was fi rst cloned in 1997, as a result of a yeast two-
hybrid screen for human proteins interacting with C-MYC, the protein encoded by 
the oncogene c-myc. The DJ-1 protein was reported to have oncogenic properties 
in cooperation with the oncogene ras.1 The biological relevance of this fi nding is 
questioned by the fact that the DJ-1 protein did not bind C-MYC, and the interaction 
with C-MYC was actually due to translation of a sequence upstream of the DJ-1 open 
reading frame in the construct used in the two-hybrid system.1 Nevertheless, recent 
proteomic-based studies found increased expression of the DJ-1 protein in various 
human tumours, once again suggesting an involvement of DJ-1 in oncogenesis.2-4
In 1999 a human protein named RS that was identical to DJ-1 was identifi ed as the 
regulatory (inhibitory) subunit of a 400 kD RNA-binding protein (RBP) complex.5 DJ-
1 immunoreactivity was shown in the cytoplasm, in association with microtubules, 
and the nucleus, depending on the cell-cycle phase, or the cell-types studied. The 
authors suggested that DJ-1 might be a multifunctional protein with important role(s), 
including cytoskeleton-coupled RNA sorting, RNA degradation, and functions in the 
nucleus as well. Interestingly, in the last study5 DJ-1 was co-purifi ed with glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). Whether GAPDH is a genuine DJ-1 interactor 
remains to be explored. However, this is a fi rst, potentially important link between 
DJ-1 and neurodegeneration. GAPDH is increasingly recognized as a multifunctional 
protein, which is not only involved in glycolysis, but also in other processes.6 Notably, 
by translocating from the cytoplasm to the nucleus, GAPDH mediates the induction of 
a neuronal apoptotic pathway.7, 8 Evidence also links GAPDH to the pathogenesis of 
classical PD, as nuclear translocation of GAPDH was detected in nigral neurons in post-
mortem PD brains, and GAPDH co-localised with D-synuclein in Lewy bodies.9 In the light 
of these evidences, the possible interaction between DJ-1 and GAPDH warrants further 
investigation. Interestingly, the yeast genes encoding DJ-1 and GAPDH homologues 
are induced during cell stress, together with chaperones, antioxidants and other stress-
response genes.10
Furthermore, two independent groups identifi ed a rat protein called CAP1 
(Contraception Associated Protein 1) or SP22 (Sperm Protein 22), putatively involved 
in spermatogenesis and fertilization, as the rat DJ-1 homolog.11, 12 Whether DJ-1 is also 
involved in these processes in humans remains unclear. However, DJ-1 is present in 
human sperm, mainly as a fl agellum protein, whereas in rats the homologue CAP1 or 
SP22 is also abundant in sperm heads.13 In the tail DJ-1 co-localises with ǃ-tubulin, a 
major axoneme component. An infertile patient with morphological and functional 
abnormalities, and undetectable levels of DJ-1 in sperm has been reported.13 It would 
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be interesting to search whether this individual carries DJ-1 mutations and will develop 
a neurological phenotype.
DJ-1 and parkin are highly expressed in the testis, in addition to the brain, and loss 
of function of both DJ-1 and parkin proteins are linked to male infertility in animal 
species.11, 12, 14 This could be coincidental, but it could also refl ect the involvement in 
common pathways that could be important in the brain as well. The issue of fertility has 
not been studied in male patients with parkinsonism due to mutations in these genes, 
and this should also be actively explored in the future. 
In a yeast two-hybrid system, PIASxD/ARIP3 was detected as a DJ-1 binding 
protein.15 PIASxD/ARIP3 is expressed predominantly in the testis, and is a modulator 
of the androgen receptor (AR) transcriptional activity.16 In cell cultures, the effects of 
PIASxD/ARIP3 on the AR activity depend from the cell lines and the reporter genes 
used.17 However, in most cell lines, including Sertoli cells, PIASxD/ARIP3 is a negative 
modulator of the AR transcriptional activity.15 DJ-1 might therefore positively regulate 
the AR-mediated transcriptional activity by recruiting PIASxD and thereby removing its 
inhibitory activity.15
PIASxD/ARIP3 belongs to a family of proteins (PIAS, Protein Inhibitor of Activated STAT) 
that modulate the activity of transcription factors by functioning as SUMO-1 (Small
Ubiquitin-like MOdifi er) ligases.18 Interestingly, a DJ-1 mutant at Lys130 (K130R) was 
unable to regulate the AR activity.15 As the Lysine 130 of DJ-1 seems to be sumoylated,15
it is possible that this modifi cation is necessary for the full activity of DJ-1. 
More recently another DJ-1-binding protein, DJBP, was identifi ed in a yeast two hybrid 
screen.19 DJBP is also an AR-binding protein, which is specifi cally expressed in the 
testis, and appears to inhibit AR activity by recruiting a histone deacetylase (HDAC) 
complex.19 The binding of DJ-1 to the DJBP-AR complex abrogates the HDAC-DJBP 
interaction, resulting in the enhancement of the AR activity. DJ-1 appears therefore to 
positively regulate AR by antagonizing the inhibitory effects of PIASxD and DJBP.15, 19
DJBP is expressed exclusively,19 and PIASxD/ARIP3 predominantly in the testis,16 and 
therefore, these proteins appear not relevant for the neuronal function of DJ-1. 
However, other members of the PIAS family, PIAS3 and PIASy, were also shown to bind 
DJ-1.15 These interactions remain to be characterized and could be more relevant for 
the effects of DJ-1 on gene expression in neurons. 
Recent observations suggest that sumoylation plays an important role in brain function 
and neurodegeneration.20, 21 Most of the known substrates for sumoylation are nuclear 
proteins, and sumoylation might infl uence protein function by changing the substrate 
localization, by competing with ubiquitylation, thereby inhibiting substrate degradation, 
and lastly, by directly modulating the functional properties of the substrate.22
Sumoylation regulates the activity not only of the steroid receptor superfamily, but 
also of transcription factors mediating the heat-shock response, like HSF1 and HSF2.22
Another member of the steroid receptor super-family of transcription factors, NR4A2,23,
24 is mutated in familial forms of PD.25 It will be interesting to see if these transcription 
factors are also targeted by DJ-1 either directly or through interaction with PIAS. 
Future studies will reveal the real targets of DJ-1 activity in the nucleus, but perhaps an 
important contribution of the discovery of DJ-1 mutations in PARK7 is the focusing to the 
nuclear mechanisms and the control of gene expression in PD pathogenesis.
Sumoylation can also infl uence synaptic function via regulation of calcium/calmodulin-
dependent kinase II (CaMKII),20 suggesting yet another possible link between DJ-1 and 
neuronal function. There is evidence that sumoylated proteins are increased in the 
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brain of patients with polyglutamine diseases,26 and altered sumoylation increases 
neurodegeneration in Drosophila models of polyglutamine disease.21 Whether these 
fi ndings are relevant for other neurodegenerative diseases is unknown. However, by 
linking sumoylation to the pathogenesis of PD, DJ-1 might extend the involvement 
of this ubiquitin-like protein-conjugation system in the neurodegenerative diseases 
characterized by protein aggregation in the cytoplasm.
Recent studies showed that human DJ-1 is converted into a variant having a more 
acidic pI in response to exogenous oxidative stress (including the herbicide paraquat 
or hydrogen peroxide) or endogenous reactive oxygen species, suggesting a role for 
DJ-1 as an antioxidant, or a sensor of oxidative stress.27, 28 The oxidative conversion of 
a sulphydryl group at a cysteine residue to a cysteine sulfi nic acid is proposed as the 
most plausible explanation of the observed variation of DJ-1 pI in response to oxidative 
stress.
Furthermore, the transcription of the yeast DJ-1 homologue YDR533C is up-regulated 
together with many chaperones and antioxidants during cell stress paradigms, notably 
the stress induced by weak acids,10 external pH changes,29 or by protein misfolding,30
which in turn are associated with oxidative stress, raising the question of whether DJ-1 
also plays a role as a molecular chaperone. Another, recently identifi ed member of the 
DJ-1-ThiJ-PfpI superfamily, the E.coli EcHsp31, is a stress-inducible chaperone.31
On the basis of the available evidence, we have proposed that DJ-1 might be involved 
in the cellular response to stress at multiple levels (chapter 2.8):
• First, it might directly react to stress signals (e.g. redox changes, misfolded 
proteins) by a chemical shift and/or change in multimerization state.
• Second, DJ-1 might modulate the gene-expression of the stress-response at 
post-transcriptional level, by the known interaction with RNA-binding protein 
complexes. Interestingly, the post-transcriptional regulation of gene expression 
is important for both neuronal function and spermatogenesis.
• Third, DJ-1 might translocate to the nucleus in response to stress signals. In the 
nucleus, it might interact with PIAS or other co-factors, and modulate the gene 
expression at the transcriptional level. 
Although an involvement of human DJ-1 in the oxidative stress response, or in the 
response to misfolded protein stress remains to be proven and the exact function of 
DJ-1 remains unknown, the proposed model is intriguing in the light of the evidence of 
oxidative stress and protein misfolding documented in the brains of patients with PD.32,
33
Recent studies have shown that mutations in D-synuclein and parkin, two other 
PD-related genes, might also be linked to oxidative stress.34, 35 A redox regulation of 
sperm maturation and motility has been proposed,36, 37 and such a mechanism of 
“physiologically controlled oxidative stress” could explain why DJ-1 is involved in the 
spermatogenesis and fertilization.
One can speculate that DJ-1 signals in a specifi c pathway regulated by redox state. 
Reactive oxygen species can also be viewed as regulators of cellular functions by the 
effect that redox status has on key proteins like JNK and MAPK kinases, and transcription 
factors, which are activated in response to redox changes. For instance, the c-Jun NH2-
terminal kinases (JNKs) are activated in response to redox and other stressors, and they 
phosphorylate the transcription factor c-Jun, increasing its activity.38 The JNK signalling 
pathway plays an important role in the neuronal apoptotic response, dopamine- and 
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excitotoxicity-induced apoptosis, and MPTP-model of PD.39, 40 D-Synuclein might confer 
neuroprotection from oxidative stress by inactivating JNK.35 Being targeted by PIAS,18
c-Jun is also possibly regulated by DJ-1. 
It is therefore clear that much work is still ahead to clarify the biology of DJ-1 and 
the mechanisms of DJ-1-related neurodegeneration. Clarifying these mechanisms 
might potentially shed light on novel pathways of neuronal survival and promote 
the understanding of pathogenesis of common forms of PD. In the current scenario, 
the possible involvement of DJ-1 as an antioxidant and/or a molecular chaperone 
appears particularly intriguing.
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General  discussion
The recent discovery of genes causing rare inherited forms of PD has provided 
tremendous help for the understanding of the molecular mechanisms of this 
devastating disease. Furthermore, the genetic dissection of monogenic forms has 
important implications for the nosology of PD, and for the diagnostic work-up of early-
onset patients. 
Is Parkinson’s disease a single entity?
The classical concept of Parkinson’s disease (PD) is based on a clinical-pathological 
triad, namely: 
• presence of parkinsonism (a combination of akinesia, resting tremor, and 
muscular rigidity),
• good response to dopaminergic therapy,
• presence of neuronal loss and gliosis, mainly in the substantia nigra pars 
compacta but also in other brain areas, with formation of cytoplasmic inclusions 
called Lewy bodies (LB) and Lewy neurites in the surviving neurons.1-4
This defi nition refl ects the common clinical and pathological fi ndings, but it also 
highlights the current lack of biological markers, and none of the triad components is 
specifi c for PD.1, 2 Parkinsonism can be the clinical correlate of lesions or dysfunctions 
at various levels in the basal ganglia, including the substantia nigra and striatum, 
which can be caused by neurodegeneration, infl ammation, drugs, toxins, tumors, and 
vascular lesions. Response to l-dopa or synthetic dopamine agonists is characteristic, 
but again, non-specifi c of PD, resulting from the loss of nigral dopaminergic neurons in 
presence of spared post-synaptic striatal dopamine receptors. Last, Lewy bodies are 
observed in conditions as different as Alzheimer’s disease (AD),5 Lewy body dementia,6
progressive supranuclear palsy,7 neurodegeneration with iron accumulation-type 1 
(formerly Hallervorden-Spatz disease),8 and importantly, in a minority of brains from 
elderly individuals died without neurological disease (“incidental” Lewy bodies).9
According to these criteria, PD corresponds to the overlap of two spectra: that 
of l-dopa-responsive parkinsonian syndromes, and that of Lewy-body-associated 
conditions. This concept of PD has survived for long, not only because of the lack of 
a better defi nition, but also for its practical implications for the clinical work-up and 
treatment of patients.
However, the lack of a defi nition in terms of molecular mechanisms, and the lack 
of biomarkers have been major factors hampering the research for cause(s) and 
mechanism(s) of PD, and other common neurodegenerative diseases. The problematic 
disease defi nition also translates in problematic disease boundaries and debated 
relationships between PD and other entities like AD. Clinical and pathological overlaps 
are documented between PD and AD,10 and common genetic susceptibility factors 
might also exist,11 supporting the contention that these seemingly different diseases are 
closer at the molecular level. 
The discovery of mutations in different genes causing rare Mendelian forms of PD 
has further highlighted the need of a new nosology of the disease. Some of these 
forms (like PARK1 and PARK3) are associated with Lewy body pathology but the 
resulting phenotype includes typical PD but also additional motor signs, autonomic 
disturbances, and dementia in few patients.12, 13 On the contrary, different monogenic 
forms (like PARK2 and PARK8) are not associated with Lewy body pathology in most 
cases,14, 15 yet they can produce clinically typical PD phenotypes. 
What is clear today is that PD, as defi ned by the classical clinical-pathological criteria, 
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is etiologically heterogeneous. This leads to two possibilities. A fi rst, “splitting” view is 
that PD includes many distinct diseases with distinct molecular mechanisms, but similar 
clinical and/or pathological endpoints. A second, “lumping”view, which in my opinion 
is more convincing, is that there are few common pathways underlying PD, which 
can be initiated by several etiologies including Mendelian mutations in rare cases, or 
combinations of small genetic as well as non-genetic effects in the common forms.
The place of parkin in the context of Parkinson’s disease
The discovery of parkin mutations in PARK2 provided a second landmark contribution 
to the understanding of PD, after D-synuclein. Soon after the cloning of the parkin gene 
in 1998,16 other groups confi rmed the presence of mutations in PD families.17-19 However, 
the frequency of involvement of parkin in early onset PD and the mutational spectrum 
were not fully appreciated until the study described in chapter 2.1, which explored 
for the fi rst time this gene in a large dataset of families and isolated early-onset cases, 
including genomic sequencing and gene copy dosage. The results revealed mutations 
in this gene in about half of the families compatible with recessive inheritance and 
PD onset before age of 45, and in about 20% of the isolated cases with early onset. 
Another important fi nding of the study is that only half of the mutations detected in 
parkin are point mutations and small deletions or insertions, whereas the remaining 
half consists of a variety of large genomic rearrangements, such as deletions and, less 
often, multiplications of whole exons. These mutations are present in the patients in 
any possible combination, and therefore, for a sensitive screening gene copy analysis 
is needed in addition to gene sequencing. Subsequent studies of large datasets 
confi rmed the frequent involvement of parkin in early-onset PD, and the importance of 
gene dosage assays.20-23 A caveat is that all of these studies were hospital-based, and 
the frequency of the parkin mutations might be lower in population-based series of PD 
cases.24 Nevertheless, a parkin mutation is a major cause of early-onset PD, which in 
turn represents 5-10% of all PD cases.25
The involvement of the parkin gene in late-onset PD has been explored to a lesser 
extent, as patients with early onset and/or recessive inheritance were pre-selected in 
most of the mutational screens performed so far (chapter 2.1).20, 21 Recently, a large 
study went beyond because it included PD sib pairs supporting linkage to the PARK2 
locus, irrespective of the onset age, and used gene dosage in addition to sequencing. 
Parkin mutations were found in 62% of the selected patients with onset before age 50, 
but also in 11% of those with onset after that age.22 In our experience, mutations are 
found in 28% of recessive families with onset between 46 and 55 years (chapter 2.4). 
These data clearly implicate the parkin gene in a substantial fraction of late-onset 
families, underlining the importance of gene testing in late-onset PD with family history 
compatible with recessive inheritance.
A few studies provide evidence that parkinsonism due to a parkin mutation might 
be dominantly inherited in a minority of cases.26-28 However, the possibility of pseudo-
dominant inheritance must be considered as an alternative explanation of the disease 
in multigeneration families. If the frequency of recessive mutations in a given gene is high 
in the population, the mating of a homozygous (or a compound heterozygous) and a 
heterozygous carrier might lead to appearance of the recessive disease in subsequent 
generations, mimicking a dominant pattern of transmission. This was demonstrated in 
at least four different studies in Japanese and Italian families (chapters 2.2, 2.3).29, 30
The occurrence of pseudo-dominant inheritance suggests that parkin gene mutations 
might be frequent in some populations. 
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However, apart from these pseudo-dominant families, the issue of whether single 
heterozygous parkin mutations can lead to disease, and particularly can increase 
the risk to develop late–onset forms of PD remains unclear. PET studies showing that 
heterozygous carriers have mild nigrostriatal dysfunctions, suggest that parkin mutations 
might be co-dominant at least at a subclinical level.31, 32 In comprehensive mutation 
screenings, several cases (up to ~50%) remain where only a single mutation has been 
found, and the onset age appears later in these cases.20-22, 24, 28, 33 In a recent series, most 
cases (42/50) with onset after 50 years had only one parkin mutation.22
Taken as a whole, these studies suggest that a single heterozygous mutation in 
parkin might be sometimes suffi cient to cause PD, perhaps in combination with other 
genetic and non-genetic factors. Mechanisms to explain the disease in these cases 
might involve haploinsuffi ciency of the ubiquitin-ligase activity, or dominant negative 
effects.
However, other evidence militates against this view: fi rst, some studies (even very 
recent) did not include gene dosage analysis,23 and therefore might have missed 
many heterozygous exon rearrangements. Secondly, some of the variants identifi ed 
in heterozygous form might be rare, neutral polymorphisms. Even the well-known 
Ser167Asn polymorphism (1% frequent in Caucasians)19 has been considered a 
pathogenic mutation in a recent study.22 Thirdly, in our experience only one of 34 
heterozygous relatives of patients with two mutations developed PD (notably of 
late-onset)(chapter 2.4). Although these 34 heterozygous carriers were examined 
at an age older than the age of disease onset in their affected relatives, some of 
them might develop the disease later in life. However, these results suggest that the 
mutations concerned were strictly recessive. This does not exclude the possibility that 
other mutations are dominant. Fourth, in another study, among nine early-onset cases 
remaining with one heterozygous mutation found after sequencing of coding region 
and of the promoter, and after testing gene copy dosage,34 all carried mutations which 
were observed in other families in homozygous form, or in compound heterozygosity 
with a second mutation. This is somehow confi rmed by other studies, which included 
testing gene copy dosage and sequencing, and found that missense and truncating 
mutations were similarly represented among carriers of one or two mutations.21, 22
All these evidences suggest that most parkin mutations are recessive, but in some 
cases the second mutation still escapes detection by current methods. In this regard, 
it is interesting that the –258 T/G polymorphism in the parkin promoter, associated with 
reduced expression in in vitro assays,35 is much overrepresented in cases with single 
mutations, and might also be pathogenic (chapter 2.4).35 Mutations in the large introns, 
large inversions, or large deletions in the promoter can also be envisaged, and the 
possibility that a second heterozygous mutation is present in a different gene encoding 
a protein involved in the same pathway, cannot be excluded. In this regard, it will be 
interesting to screen the DJ-1 gene (as well as other genes to be identifi ed) in cases 
where only one parkin mutation has been found. Perhaps, the defi nitive answer to the 
question of whether single parkin mutations cause PD will come when (and if) linkage 
to the parkin locus will be found in families with dominantly inherited PD, assuming a 
dominant model of inheritance in the linkage analysis. This has not happened so far, 
but preliminary results suggest that it might indeed be the case.22
Last, whether the –258 T/G polymorphism in the parkin promoter, or heterozygous 
missense mutations in exon 7, encoding the fi rst RING domain, are risk factors for late 
onset PD, as it has been proposed,23, 35 remains to be seen. A recent study performed in a 
large dataset found no evidence of association between known parkin polymorphisms 
(including –258 T/G) and susceptibility to classical, late-onset PD.36 However, in order to 
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fully explore the role of parkin in late-onset PD we probably need to understand better 
how this gene is regulated.
Implications of parkin for the clinical work-up of early-onset PD
In addition to the importance for researchers, the mutations in the parkin gene have 
diagnostic implications because of their frequency in early-onset cases. Testing the 
parkin gene is today recommended in the clinical work-up of PD cases, whenever the 
family history is compatible with a recessive mechanism of inheritance, and especially 
if the disease onset is before age of 50 (even when only in one of the affected siblings). 
If the family history is negative, testing parkin is still important, especially in the cases 
with a very early onset. In fact, among the sporadic patients, most of the mutations are 
found in those with a very early-onset (before age of 30), whereas after that age of 
onset mutations in this gene are a much rarer fi nding (chapter 2.1).21
An early onset and the presence of a family history compatible with recessive 
inheritance are therefore critical to prioritise cases for parkin testing. The importance of 
collecting an accurate family history in every PD patient should always be highlighted, 
because this is still a frequently neglected item by the clinicians who follow PD patients. 
The presence of consanguinity between parents of the patient is another critical 
item, for which clinical records are often non-informative, and which can suggest the 
presence of a recessive mechanism of inheritance in cases presenting without any 
family history of PD. 
Due to the large size of the gene and the wide spectrum of associated abnormalities, 
the mutation screening of parkin is diffi cult, and it should always include gene copy 
analysis in addition to genomic sequencing. Clinicians should be aware that limiting 
the screening to genomic sequencing only, leads to the erroneous exclusion of the 
parkin gene in many cases carrying heterozygous genomic rearrangements. It is 
possible that rapid, microarray-based methods will facilitate the diagnostic screening 
of genomic rearrangements in parkin in the near future. Apart from the complexity in 
diagnostic screening, the genetic counselling of patients with parkin mutations and of 
their relatives is diffi cult because of the current uncertainties about the role of single 
heterozygous alleles, and the broad phenotypical spectrum associated, including a 
very large intra-familial variance of onset age and phenotypes (chapter 2.4). 
Parkin and genotype phenotype correlations
Genotype phenotype correlations for parkin disease (as for many disorders) are poorly 
understood, and there are several potential explanations for this. The spectrum of 
mutations is very wide and probably incomplete. Due to this, large series of patients 
are needed for accurate studies. More importantly, we do not understand much of 
the regulation of the gene itself and of the encoded protein. Due to this, it is diffi cult to 
defi nitely establish if and how a given mutation has a biological effect. However, the 
analysis of a large number of cases is providing indications that a specifi c genotype 
might infl uence the phenotype (chapter 2.4), suggesting for instance, that missense 
mutations in functional domains result in earlier onset than mutations in other regions 
of the protein. Surprisingly, patients with at least one missense mutation did not differ in 
age of onset but they had a more severe disease than the patients with two truncating 
mutations, as if some missense mutations result in more than a loss of parkin function 
(chapter 2.4). 
We are starting to disentangle the phenotypical effects of specifi c genetic etiology 
from the effects of other variables like aging. For example, dystonia and brisk refl exes 
are more frequent in patients with parkin mutations than in cases without, but both 
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these clinical features correlate better with young onset age than genetic etiology 
(chapter 2.4), suggesting that they are not specifi c of parkin disease, but are rather the 
phenotypical correlate of the brain dopaminergic defi ciency at a younger age.
The wide intrafamilial variability of the phenotype strongly suggests that other genetic, 
as well as non-genetic modifi ers exist for this disease, and support the notion that 
Mendelian diseases are not always simple traits. For instance, the role of smoking or 
caffeine intake in parkin disease has not been explored, and it is interesting to see 
whether a protective effect is also present in this monogenic form like it is in idiopathic 
PD.37 Genome scans in families with parkin disease could reveal modifi er loci, and the 
homogeneity of the dataset will likely confer high power to detect additional genetic 
risk factors. One of such studies performed in a small dataset suggested already 
candidate regions including the PARK8 locus.38 The fact that parkin mutations are a 
frequent cause of early onset PD supports the contention that the parkin protein is 
another key player in PD in general.
The contribution of DJ-1
The DJ-1 gene has been highly conserved in evolution and is abundantly and 
ubiquitously expressed in the brain and other body tissues (chapter 2.8). Yet, its 
function has remained elusive, and nobody had previously linked the DJ-1 protein 
to brain function or brain disorders. The discovery that mutations in DJ-1 cause 
autosomal recessive early-onset forms of PD is therefore relevant for two reasons. First, 
it establishes that the loss of the DJ-1 function leads to human neurodegeneration. 
Second, clarifying of mechanisms of DJ-1-related disease might potentially shed light 
on novel mechanisms of brain neuronal maintenance and promote the understanding 
of pathogenesis of common forms of PD (chapter 2.8). 
A total number of nine different mutations in DJ-1 have been identifi ed so far, including 
missense, truncating, splice site mutations, and large deletions (table) (chapter 2.8).39-41
In particular, a PD patient carrying compound heterozygous DJ-1 mutations (including 
one truncating and one splice site mutation) (case #8 in the table) provides strong 
support to the contention that DJ-1 mutations are pathogenic in early onset PD. For 
other mutations, especially the single heterozygous ones, a pathogenic role is not 
defi nitely demonstrated yet. 
On the basis of the fi rst screening in large series of patients, DJ-1 mutations are the 
second most frequent identifi able genetic cause of PD after parkin, but the frequency 
of DJ-1 mutations seems rather low, being estimated at about 1-2 % in early onset 
PD.39-41 Testing the DJ-1 gene should therefore be considered in the clinical work-up 
of patients with early-onset PD. However, due to the low frequency of involvement, 
testing the DJ-1 gene should be recommended only after exclusion of parkin gene 
mutations.
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Clinical and genetic features in patients with DJ-1 mutations 
Code Presentation Origin Gender Onset  Duration 1st mutation 2nd mutation Reference 
#1   Familial Dutch F 31 17 Δ exon 1-5 Δ exon 1-5 46
#2 Familial Dutch M 40 10 Δ exon 1-5 Δ exon 1-5 46
#3   Familial Dutch M <40 na Δ exon 1-5 Δ exon 1-5 46
#4  Familial Dutch M 27 11 Δ exon 1-5 Δ exon 1-5 46
#5  Familial Italian M 28 18 L166P L166P 46
#6 Familial Italian F 35 21 L166P L166P 46
#7  Familial Italian M 27 32 L166P L166P 46
#8 Sporadic Hispanic F 24 5 IVS6-1G→C c.56delC, c.57G→A 39
#9 Sporadic Hispanic M 35 9 A104T --- * 39
#10 Sporadic Jewish na 39 na M26I M26I 40
#11 Sporadic Afro-Caribbean na 36 na D149A --- * 40
#12 Sporadic South Tyrolean M 42 17 Δ exon 5-7 --- 41
#13 Sporadic Russian F 17 na IVS5+2-12del --- 41
*Gene copy dosage not performed. 
The c.56delC, c.57G→A mutation leads to frameshift and truncation of DJ-1 protein after the first 18 amino acids. 
The occurrence of heterozygous genomic rearrangements in DJ-1 emphasizes the 
importance of gene dosage assays for a sensitive screening. This has been performed 
in only one study so far.41 Further studies, including gene dosage assays, and promoter 
analysis, are therefore needed in order to accurately estimate the frequency of this form 
among early-onset PD, and to characterize the associated phenotype. That the DJ-1 
protein exists as a dimer also suggests the possibility of dominant-negative mutations, 
and therefore a dominant pattern of inheritance should not preclude testing the
DJ-1 gene. The identifi cation of additional disease-linked missense mutations will help 
pinpointing functionally important domains in the DJ-1 protein, and will complement 
the biochemical and structural biology studies in the common effort to elucidate the 
role of DJ-1 and the mechanisms of DJ-1-related disease.
The genomic regions containing parkin and DJ-1 are rich in low-copy-repeat elements 
(chapter 2.8),42 which might explain why these regions are prone to rearrangements. 
Genomic instability might be important in other forms of PD as well, and future studies 
should target this kind of genetic mechanism more specifi cally.
Evidence for linkage to the PARK7 region was not found in genome scans for late onset 
familial PD, suggesting that DJ-1, like the other known genes for Mendelian PD, is not 
a major locus in common familial forms. However, whether genetic variation in DJ-1
modifi es the susceptibility to, or modulates the expression of sporadic, late-onset PD or 
different neurodegenerative diseases remains an important question, which will require 
further genetic work.
Investigating the presence of the DJ-1 protein (and its acidic variant) in brain from 
patients with Lewy body disease, as well as other neurodegenerative diseases is 
urgently warranted. These studies might provide important clues on the involvement 
of DJ-1 in common forms of neurodegeneration. We have recently explored the 
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presence of the DJ-1 protein in brain from patients with common neurodegenerative 
diseases. While we did not fi nd evidence of DJ-1 immunoreactivity in Lewy bodies 
with the available antibodies, we did fi nd that the DJ-1 immunoreactivity co-localizes 
within a subset of pathological tau inclusions in a diverse group of neurodegenerative 
disorders, supporting the view that different neurodegenerative diseases may have 
similar pathogenetic mechanisms, which likely include DJ-1.43 This fi nding raises the 
question of whether tau pathology is also present in the brain of patients with DJ-1 
mutations. Interestingly, tau pathology has been found in patients with parkin disease. 
Therefore, if this would also be the case in DJ-1-related disease, it would suggest the 
existence of a common pathological signature in DJ-1- and parkin-related forms. 
Investigating the expression of the DJ-1 protein in the brain of patients with parkin 
disease and vice versa is also warranted.
The exact role of the DJ-1 protein remains unknown, but the available information 
about DJ-1 interactions provides clues to a possible function, and to possible ways of 
linking DJ-1 to neurodegeneration (chapter 2.9). An involvement of DJ-1 in processes as 
different as oncogenesis, male fertility, gene transcription, mRNA stability, and response 
to cell stress is suggested by the current evidence. Although much work remains to be 
done to clarify the biology of this protein, the possible involvement of DJ-1 as molecular 
chaperone and/or an antioxidant appears particularly intriguing in the light of our 
current understanding of the pathogenesis of PD (chapter 1.2). 
However, the importance of identifying a novel gene causing PD is even greater if 
this leads to innovative ideas about pathogenesis. In the case of DJ-1, potential novel 
insights are the focus on the nuclear mechanisms and the control of gene expression 
in PD pathogenesis. Moreover, by linking sumoylation to the pathogenesis of PD, DJ-1 
might extend the involvement of this ubiquitin-like protein-conjugation system in the 
neurodegenerative diseases characterized by protein aggregation in the cytoplasm 
(chapter 2.9).
Our fi nding that mutant DJ-1L166P is localised to mitochondria once again suggests 
a possible link to oxidative stress (chapter 2.8). This localisation has recently been 
confi rmed using untagged DJ-1 constructs, therefore excluding tagging effects on the 
conformation of the mutant protein.44 This localization is also intriguing in the light of the 
mitochondrial abnormalities described in classical PD,45 and assessing the mitochondria 
functions in the patients with DJ-1 mutations is therefore warranted. 
Due to the high levels of expression in cell systems analysed,46 we could not exclude 
that a fraction of wild type DJ-1 also localises to mitochondria, as recently suggested 
by others.47 This possibility warrants further investigations. Furthermore, we observed that 
the mutant DJ-1L166P protein is unstable and rapidly degraded, resulting in much lower 
steady state levels in both transfected cells and patient lymphoblasts.44 The mutant 
DJ-1 could therefore be targeted to mitochondria as a result of abnormal structure, 
or, the reduced levels of expression could lead DJ-1 to occupy only its sites of highest 
affi nity binding, which could include mitochondria and the nucleus (as the mutant 
retains the nuclear localization). The instability of DJ-1L166P suggests that the mutant 
is misfolded and, as such, underlies rapid degradation, as observed in many other 
genetic diseases.48 The instability of mutant DJ-1L166P has been recently confi rmed in an 
independent study.47
Important insights about the function of DJ-1 are coming from the structural biology 
studies. The crystal structure of human DJ-1, at resolutions ranging from 1.95 to 1.1 Å, 
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has been recently reported by four independent groups.49-52 These structures are very 
similar to each other, with DJ-1 assuming an D/ǃ sandwich fold similar to the so-called 
fl avodoxin-like or Rossmann fold, that is conserved in the DJ-1-ThiJ-PfpI superfamily. 
An important fi nding in these studies is that DJ-1 exists as dimer, a fi nding that we 
and others independently observed in gel fi ltration experiments.44, 47, 50, 51 Most of the 
residues involved in the dimerization are highly conserved, but DJ-1 and its closest 
homologues share a peculiar dimerization pattern in the superfamily, which is partly 
determined by the presence of an additional C-terminal helix. A putative active site 
has been identifi ed close to the dimer interface, with some similarities to the active 
site of cysteine proteases, the residues Cys106, His126, and perhaps Glu18 being likely 
involved.49-51 However, these residues do not show the orientation required for the 
proton transfer which is typical of the cysteine protease catalysis.51 In keeping with this, 
biochemical attempts to detect protease49, 51 or kinase51 activity of DJ-1 have been 
unsuccessful so far.
Moreover, the crystal studies confi rm our prediction that the residue mutated in the PD 
patients (L166) is located in a C-terminal D-helix,49-52 and show that this helix is part of 
a hydrophobic core formed by three helices (two contributed by the C-terminal and 
one by the N-terminal part of the monomer), which is involved in the dimerization.50, 51
The L166P mutation appears to disrupt the C-terminal domain and the dimerization 
capability, suggesting that the dimerization is functionally important. A novel disease-
linked missense mutation (M26I) has been recently reported.40 Intriguingly, the residue 
Met26 is located in the N-terminal helix which contributes to the same hydrophobic 
core, and is spatially close to Leu166; furthermore, this N-terminal helix contributes to 
the putative active site of DJ-1.50
Our fi ndings in gel fi ltration studies also suggest that the mutant does not form dimers 
but adopts a different higher order structure or complexes with other proteins.44
Interestingly, a deletion mutant lacking residues 173 to 189 is also reported to form 
higher aggregates.50 Taken as a whole, these evidences suggest that the dimeric 
structure is important for the function of DJ-1. 
Despite the rapid progress in elucidating the structure of DJ-1, the biochemical function 
of this protein remains elusive. Whether it possesses one of more of the proposed 
enzymatic properties (protease, hydrolase, kinase, amidotrasferase, catalase), or 
whether it functions as a chaperone, or a transcription factor, or it has more than one 
function, is unknown. Initial biochemical studies suggest that protease, kinase, and 
amidotransferase activities are unlikely, whereas catalase or other catalytic activities 
remain unexplored and still intriguing possibilities. Moreover, it remains to be seen 
whether the dimer represents the active form, or whether in response to specifi c signals, 
DJ-1 undergoes other structural changes that make it functionally active.
Interestingly, it has been reported that replacement of the Cys53 residue, located 
in the dimer interface, abolished the pI shift of DJ-1 in response to oxidative stimuli, 
suggesting that this shift is mediated by the oxidative conversion of the sulphydrylic 
group of cysteine to cysteine sulfi nic acid.49 It has been proposed that this modifi cation 
leads to functional activation of the protein in response to oxidative stress.49 However, 
the observation that another conserved cysteine (Cys106) displays extreme sensitivity 
to radiation damage, suggests that Cys106 also mediates the oxidative conversion of 
DJ-1.51 The presence of one or more cysteines, which react to oxidative conditions, 
supports the idea that DJ-1 is an oxidation-response protein.
The E.coli stress-inducible chaperone EcHsp31belongs to the DJ-1-ThiJ-PfpI superfamily, 
and possesses a putative hydrolytic site.53 It has been suggested that it might switch 
from chaperone to protease function on the basis of the temperature shift,53 and 
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this has previously been observed for another bacterial protein.54 Similarly, one could 
speculate that DJ-1 has also dual function of chaperone and enzyme depending on 
the cell stress level. Despite the fact that many questions remain unanswered, the 
resolution of the structure of DJ-1 has been an important step forward to clarify the 
exact function of the protein.
The effect of the loss of DJ-1 function, either alone or in combination with mutations in 
other PD-related genes, is now being investigated in cell culture and animal models, 
including mice and fl ies, and models of PD induced by dopaminergic neurotoxins, like 
MPTP and rotenone. In transgenic fl ies, it will be possible to rapidly screen for genetic 
modifi ers, either enhancers or suppressors of any resulting DJ-1-related phenotype. 
Transgenic mice overexpressing the human DJ-1 gene have been generated and 
show no infl uence on fertility in comparison to the wild type animals.55 Expression of the 
transgene was high in testis but also in the brain, and these mice might also be useful 
to investigate putative brain functions of DJ-1, including resistance to dopaminergic 
toxins (MPTP, rotenone), oxidative stress and protein misfolding. 
Expression profi ling in cell cultures in which the DJ-1 gene is manipulated, or in 
patient-derived cells, might facilitate the characterization of DJ-1-related pathways. 
Biochemical and cell biology studies have also been initiated in order to understand 
further the function of DJ-1, identify its interacting partners, and explore possible 
relationships between DJ-1 and the proteins encoded by genes, which are fi rmly 
implicated in PD and other common neurodegenerative diseases. Initial studies in 
our lab suggest that DJ-1 is not directly interacting with D-synuclein and tau.44 These 
complementary approaches will help clarifying the pathogenesis of DJ-1-related
disease, but, more importantly, they will provide new insights for understanding of the 
molecular mechanisms of classical PD.
Refl ections and perspectives for future studies
During the last few years molecular genetics has provided tremendous contributions 
to our understanding of the mechanisms of neurodegeneration in general and PD in 
particular. Most of this progress has come from the analysis of rare inherited forms of 
the disease. We know that other monogenic forms of PD exist (chapter 1.1), and the 
identifi cation of the genes involved holds the promise of yielding further signifi cant 
steps-forward. The importance of the classical linkage mapping and positional cloning 
strategies in Mendelian forms of PD should not be underscored, and further potentially 
critical contributions are expected from this approach in the near future. 
Yet, we are just beginning to disentangle the complexity of the common forms of the 
disease. In this regard, the genome-wide linkage screens have only recently produced 
the fi rst statistically signifi cant results (chapter 1.1). It remains to be seen whether these 
fi ndings will be confi rmed, and whether they will lead to the identifi cation of biologically 
relevant genetic variants determining susceptibility to the disease. Nevertheless, more 
and more studies in the coming years will be based on small families with affected 
relative pairs, and on patient cohorts from genetically isolated populations.56
Modelling neurodegenerative diseases in transgenic animals has also revealed to 
be a very powerful strategy. These studies contributed signifi cantly to support the 
contention that critical proteins such as tau, ǃ-amyloid precursor, polyglutamine 
repeats, or D-synuclein play primary roles in the pathogenesis.57 Moreover, these 
studies demonstrated that it is possible to modify the neurodegenerative process by 
manipulating components of the molecular chaperones, or of the ubiquitin-proteasome 
systems, thus suggesting novel avenues to design future therapeutic approaches.57 As 
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novel genes for PD are identifi ed, experiments in transgenic models will continue to 
explore their role and their relationship with the other genes, which were previously 
implicated in the pathogenesis. Animal and cell culture models will also be used to test 
novel ways of therapeutic intervention, for instance, silencing of dominant mutations 
by small interfering RNAs,58 or overexpressing genes for neuroprotective proteins (such 
as parkin or DJ-1).59
There is no evidence of a spontaneous PD-like neurodegenerative disease in other 
animals.60 Moreover, the full pathological picture of AD (the most frequent human 
neurodegenerative disease) has never been reported in non-human primates.61, 62 The 
apparent absence of these neurodegenerative diseases in our closest evolutionary 
relatives, leads to the idea that the biological bases of these common disorders of the 
human brain are somehow related to what makes us unique among primates. The 
genomes of humans and chimpanzees (the closest evolutionary relatives) are almost 
99% identical,63 and it appears unlikely that this little genotypic divergence alone 
explains the wide phenotypic differences, such as those in cognitive performances 
and susceptibility to neurodegeneration. An alternative hypothesis is that inter-species 
differences might be due to quantitative changes in the level of gene or protein 
expression, and that this mechanism might have been particularly important for the 
evolution of the brain differences.64 It is possible that our susceptibility to common age-
related neurodegeneration is also related to the peculiar levels of brain gene and 
protein expressions, which make us humans. 
Perhaps the next few years will see the shift from the current “anatomical” screening 
of the genome in PD, to a more functional analysis exploring quantitative changes in 
gene and protein expression. Profi ling the transcriptome and the proteome in human 
tissue, animal and cell-based models might provide functional signatures of the disease 
process, allowing recognition of pathways and development of integrative views. 
It is important that these studies are made in the different stages, including ideally 
the pre-symptomatic phase of the disease, in order to distinguish the primary from 
secondary events, and the factors determining the initiation from those infl uencing the 
progression of the disease.
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SUMMARY
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
after Alzheimer’s disease, with a prevalence of 1-2% in the population aged t 65. 
The disease is clinically defi ned by the presence of parkinsonism (the combination of 
akinesia, resting tremor, and muscular rigidity), and a good response to dopaminergic 
therapy. These features are associated at the pathological level with neuronal loss and 
gliosis, mainly in the substantia nigra pars compacta but also in other brain areas, and 
formation of cytoplasmic inclusions called Lewy bodies in the surviving neurons. 
PD is mostly a sporadic disorder, but in 10-15% of cases it runs in families without a 
clear-cut Mendelian pattern. More rarely, it segregates as a Mendelian trait with either 
autosomal dominant or recessive inheritance. The common form of PD is therefore likely 
to be a complex trait, determined by several genetic as well as non-genetic factors. 
In the last few years, family-based linkage analysis and positional cloning have led to 
the identifi cation of several loci and genes for the rare monogenic forms and more 
recently, of two loci harboring susceptibility genes for the common, non-Mendelian 
forms. Although the monogenic forms explain a very small fraction of PD cases at the 
population level, they are promoting the understanding of the molecular events and 
the metabolic pathways involved in the common forms of PD as well.
The fi rst section of this thesis (Introduction) reviews the genetics of PD, and the 
pathogenesis of two monogenic forms previously identifi ed. In chapter 1.1, the clinical 
and molecular genetic aspects of the Mendelian forms of PD are reviewed, and 
the results of genome-wide screens to localise genes involved in the common, non-
Mendelian forms of the disease are also discussed. In chapter 1.2, the pathogenesis of 
PD forms caused by mutations in D-synuclein and parkin, the two genes which have 
been fi rmly associated with PD in the past, are reviewed, highlighting the implications 
of these knowledge for the understanding of the mechanisms underlying the common 
forms of PD.
The research work on which this thesis is based is presented in the second section, and it 
deals with molecular genetic studies and phenotypical characterization of autosomal 
recessive, early onset PD forms associated with mutations in the parkin (chapters 2.1-
2.4) and the DJ-1 (chapters 2.5-2.8) gene.
Soon after the cloning of the parkin gene in 1998, other groups confi rmed the presence 
of mutations in PD families. However, the frequency of involvement of parkin in early 
onset PD and the mutational spectrum were not fully appreciated until the study 
described in chapter 2.1, which explored for the fi rst time this gene in a large dataset 
of families and isolated early-onset cases, including genomic sequencing and gene 
copy dosage. The results revealed mutations in this gene in about half of the families 
compatible with recessive inheritance and PD onset before age of 45, and in about 
20% of the isolated cases with early onset. Another important fi nding of the study is that 
half of the mutations consists of large genomic rearrangements, and therefore, for a 
sensitive screening gene copy analysis is needed in addition to gene sequencing. 
If the frequency of recessive mutations in a given gene is high in the population, 
the mating of a homozygous (or a compound heterozygous) and a heterozygous 
carrier might lead to appearance of the recessive disease in subsequent generations, 
mimicking a dominant pattern of transmission (pseudo-dominance). These matings 
might also result in allele heterogeneity within the same sibship. These phenomena 
were demonstrated in different studies in Japanese and Italian families (chapters 2.2, 
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2.3), suggesting that parkin gene mutations might be frequent in some populations. 
Genotype phenotype correlations for parkin-related disease are still poorly understood. 
However, the analysis of a large number of cases is providing indications that a specifi c 
genotype might infl uence the phenotype (chapter 2.4).
A novel locus for autosomal recessive, early-onset PD (PARK7) was localised to the 
chromosome 1p36 region by a genome-wide scan and homozygosity mapping in a 
large consanguineous family with four affected individuals, belonging to a genetically 
isolated population in the south-west of the Netherlands (chapter 2.5). Linkage to the 
PARK7 region was later confi rmed in a second, consanguineous family with three 
siblings affected by early-onset PD and coming from central Italy (chapter 2.6). The 
phenotype in both families is characterized by parkinsonism of early onset (ranging from 
age 27 to 40), good levodopa response and slow progression. Behavioral and psychic 
disturbances, and dystonic features (including blepharospasm) are also present, and 
a positron emission tomography study in the Dutch family showed dopaminergic 
presynaptic dysfunctions (chapter 2.7).
Fine mapping studies and a positional cloning strategy led to the identifi cation of 
pathogenic mutations in the DJ-1 gene in the two families defi nitely linked to PARK7 
(chapter 2.8). The DJ-1 gene has been highly conserved in evolution and is abundantly 
and ubiquitously expressed in the brain and other body tissues. The exact role of the 
DJ-1 protein remains mostly unknown but a review of the literature provides clues 
to a possible function and allows hypotheses linking DJ-1 to neurodegeneration to 
be formulated (chapter 2.9). The discovery that mutations in DJ-1 cause autosomal 
recessive early-onset forms of PD establishes that the loss of the DJ-1 function leads to 
human neurodegeneration. Clarifying the mechanisms of DJ-1-related disease might 
also potentially shed light on novel mechanisms of brain neuronal maintenance and 
promote the understanding of pathogenesis of common forms of PD.
The chapter 3 contains the general discussion of the results of our experimental work. 
First, it deals with the implications of the knowledge resulting from the genetic studies 
for the nosology of PD. Moreover, it discusses the place of parkin-related disease in 
the context of PD, highlighting the importance of this form for the diagnostic work-up 
of early-onset patients, and the issue of the genotype phenotype correlation. Last, 
the contribution resulting from the discovery of DJ-1 mutations in PARK7, and the most 
recent fi ndings from biochemical and structural biology studies on the DJ-1 protein are 
discussed. The thesis ends with some refl ections and perspectives for the future studies 
aiming at elucidating further the causes and molecular mechanisms of PD.
Summary
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SAMENVATTING
De ziekte van Parkinson, na de ziekte van Alzheimer de meest voorkomende 
neurodegeneratieve aandoening,  komt voor bij 1-2% van de bevolking  65 jaar. 
De klinische diagnose van de ziekte kan worden gesteld indien parkinsonisme wordt 
aangetoond (de combinatie van akinesie, tremor en musculaire rigiditeit) en indien er 
een positieve reactie is op behandeling met dopamine. Pathologisch wordt de ziekte 
gekenmerkt door selectief neuronaal verlies en gliose, welke voornamelijk voorkomt in 
de substantia nigra pars compacta, maar ook in andere gebieden van de hersenen, 
en door de vorming van cytoplasmatische insluitsels, genaamd Lewy-lichaampjes, in 
de overlevende neuronen.
De ziekte van Parkinson is een sporadisch voorkomende aandoening. Echter, in 10-15% 
van de gevallen is de aandoening familiair, maar vaak zonder een helder en duidelijk 
Mendeliaans overervingspatroon. In zeldzame gevallen ziet men overerving volgens 
de wetten van Mendel met ofwel een autosomaal dominante of recessieve vorm van 
overerving. Aangenomen wordt dat bij het ontstaan van de meest gangbare vorm 
van de ziekte van Parkinson zowel genetische als niet-genetische factoren een rol 
spelen. Gedurende de laatste jaren heeft linkage-analyse binnen families, gevolgd 
door positionele klonering, geleid tot identifi catie van verschillende loci en genen 
voor zeldzame monogenetische vormen. Meer recent zijn twee loci geïdentifi ceerd 
waar zich waarschijnlijk genen bevinden voor de meer algemene, niet Mendeliaanse 
vormen van overerving. 
Alhoewel de monogenetische vormen van overerving maar een klein deel van de 
gevallen van de ziekte van Parkinson binnen de populatie verklaren, zorgen zij er toch 
voor dat er meer inzicht ontstaat in de moleculaire en metabole processen welke 
betrokken zijn bij de ziekte van Parkinson.
Het eerste deel van dit proefschrift (Introduction) geeft een overzicht van de genetica 
van de ziekte van Parkinson en de pathogenese van twee monogenetische vormen 
van de ziekte waarvan de genen zijn geïdentifi ceerd. In Hoofdstuk 1.1 worden de 
klinische en moleculair genetische aspecten nader beschreven, en worden de 
resultaten besproken van genoom-analyse voor het lokaliseren van genen betrokken 
bij de meer algemene, niet-Mendeliaanse vormen van overerving van de ziekte. 
In Hoofdstuk 1.2 wordt de pathogenese besproken van de ziekte van Parkinson, 
veroorzaakt door mutaties in het alpha-synuclein en parkin gen, de twee genen 
die in het verleden al werden geassocieerd met de ziekte van Parkinson. De nadruk 
wordt gelegd op de implicaties van deze kennis voor het begrijpelijk maken van de 
mechanismen welke betrokken zijn bij de meer algemene vormen van de ziekte van 
Parkinson.
Het onderzoek waarop dit proefschrift is gebaseerd, wordt gepresenteerd in de 
tweede deel, en deze sectie heeft betrekking op de moleculair genetische studies en 
phenotypische karakterisering van autosomaal recessieve, vroeg beginnende vormen 
van de ziekte van Parkinson, welke worden geassocieerd met mutaties in het parkin
(hoofdstuk 2.1-2.4) gen en het  DJ-1 (hoofdstuk 2.5-2.8) gen. 
Al snel na de klonering van het parkin gen in 1998 bevestigden andere 
onderzoeksgroepen de aanwezigheid van mutaties in genen van families waarin de 
ziekte van Parkinson voorkomt. Echter, de frequentie waarin het parkin gen betrokken 
is bij de vroegbeginnende vorm van de ziekte van Parkinson en het spectrum van 
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mutaties in dit gen kwamen pas duidelijk aan het licht na de studie beschreven in 
Hoofdstuk 2.1. Voor het eerst werd in families en geïsoleerde gevallen de betrokkenheid 
van dit gen onderzocht bij  de vroegbeginnende vormen van de ziekte van Parkinson, 
waarbij DNA analyse werd uitgevoerd en het aantal aanwezige kopieën van het parkin
gen werden bepaald. In ongeveer de helft van de families met recessieve overerving, 
waarin de ziekte van Parkinson aanvangt voor het 45ste levensjaar, en in 20% van de 
geïsoleerde gevallen met een vroegbeginnende vorm van de ziekte van Parkinson 
werden mutaties in dit gen gezien. Een andere belangrijke ontdekking gedurende deze 
studie is dat de helft van de mutaties bestaat uit grote veranderingen op DNA-niveau. 
Daarom is een gevoelige screening van het aantal genkopieën nodig ter aanvulling 
van de reguliere mutatie-analyse. Als binnen de algemene populatie de frequentie 
van recessieve mutaties in een gegeven gen hoog is, dan bestaat de kans dat een 
homozygoot (of een samengesteld heterozygoot) individu en een heterozygote drager 
voor nageslacht zorgen. Dit kan leiden tot het voorkomen van de recessieve vorm van 
de ziekte in opeenvolgende generaties, waarbij een dominant patroon van transmissie 
wordt nagebootst (pseudo-dominantie). Dit kan resulteren in heterogeniteit van allelen 
binnen een familie. Dit fenomeen werd aangetoond in verschillende studies binnen 
Japanse en Italiaanse families (hoofdstukken 2.2, 2.3), hetgeen suggereert dat Parkin
gen mutaties frequent voorkomen in sommige populaties. 
Genotype fenotype correlaties voor de ziekte gerelateerd aan het parkin gen zijn nog 
onderwerp van nadere studie. De analyse van een groot aantal gevallen geeft een 
indicatie dat een specifi ek genotype invloed zou kunnen hebben op het fenotype 
(hoofdstuk 2.4).
Een nieuwe locus voor een autosomaal recessieve, vroegbeginnende vorm van de 
ziekte van Parkinson (PARK7) werd gelokaliseerd binnen de chromosomale 1p36 regio. 
Met behulp van een genetische scan van het hele genoom werd een homozygote 
regio gevonden binnen een grote consanguine familie met vier aangedane personen, 
die afkomstig is uit een genetisch geïsoleerde populatie in het Zuid-Westen van 
Nederland (hoofdstuk 2.5).
Koppeling van de ziekte met de PARK7 regio is later bevestigd in een tweede, 
consanguine familie met drie bloedverwanten uit midden Italië met de vroegbeginnende 
vorm van de ziekte van Parkinson (hoofdstuk 2.6). Het fenotype binnen beide families 
wordt gekenmerkt door vroegbeginnende Parkinsonisme  (variërend van 27 tot 40 jaar), 
goede levodopa respons en langzame progressie. Gedrags- en psychische stoornissen, 
en dystonische gelaatstrekken (inclusief blepharospasmus) worden ook gezien en een 
positron emissie tomografi e studie in de Nederlandse familie liet ook dopaminerge 
presynaptische dysfuncties zien (hoofdstuk 2.7).
Karakterisering van de PARK7 regio en positionele klonering leidde tot de identifi catie 
van mutaties in het DJ-1 gen in de twee families waar PARK7 zeker voorkomt (hoofdstuk
2.8). Het DJ-1 gen is zeer goed geconserveerd gebleven gedurende de evolutie en 
komt hoog tot expressie in de hersenen en andere lichaamsweefsels. De preciese rol 
van het DJ-1 eiwit is vooralsnog onbekend maar in de literatuur worden aanwijzingen 
gevonden over de mogelijke functie van het eiwit. Dit geeft de mogelijkheid tot het 
poneren van hypotheses waarin DJ-1 wordt gerelateerd aan neurodegeneratie 
(hoofdstuk 2.9). De ontdekking dat mutaties in DJ-1 de oorzaak zijn van autosomaal 
recessieve, vroegbeginnende vormen van de ziekte van Parkinson bewijst dat 
verlies van de DJ-1 functie leidt tot humane neurodegeneratie. Verklaring van de 
mechanismen van de DJ-1 gerelateerde ziekte kan eventueel ook licht werpen op 
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nieuwe mechanismen van onderhoud van de neuronale hersencellen en leiden 
tot meer begrip van de pathogenese van de algemene vormen van de ziekte van 
Parkinson.
Hoofdstuk 3 bevat de discussie van de resultaten van ons experimentele werk. Ten 
eerste worden hier de implicaties behandeld van de kennis, welke resulteerde uit de 
genetische studies naar de ziekte van Parkinson. Bovendien wordt de bijdrage van de 
Parkin gerelateerde ziekte binnen de context van de ziekte van Parkinson besproken, 
waarbij de nadruk wordt gelegd op het belang voor de diagnostiek bij patiënten met 
de vroegbeginnende vorm van de ziekte van Parkinson, en de mogelijke genotype 
phenotype correlatie. Tenslotte wordt de ontdekking van DJ-1 mutaties in PARK7 
besproken, en wordt aandacht besteed aan de meest recente bevindingen uit 
biochemische en structurele biologische studies naar het DJ-1 eiwit. 
Dit proefschrift eindigt met enkele refl ecties, en mogelijkheden voor onderzoek in 
de toekomst, gericht op het nader verklaren van de oorzaken en de moleculair 
mechanismen van de ziekte van Parkinson.
Samenvatting
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RIASSUNTO
La malattia di Parkinson (MP) e’ la forma piu’ frequente di malattia neurodegenerativa 
dopo la malattia di Alzheimer, con una prevalenza intorno all’1-2% nella popolazione 
con piu’ di 65 anni. La malattia e’ defi nita sul piano clinico dalla presenza di 
parkinsonismo (la combinazione di acinesia, tremore a riposo, e rigidita’ muscolare), 
e da una buona risposta alla terapia dopaminergica. Sul piano neuropatologico, 
queste caratteristiche sono associate a perdita neuronale e gliosi, principalmente 
a carico della substantia nigra pars compacta, ma anche in altre aree cerebrali, 
con formazione di inclusioni citoplasmatiche, chiamate corpi di Lewy, nei neuroni 
superstiti.
La MP e’ per lo piu’ una malattia sporadica, ma nel 10-15% dei casi ricorre nella famiglia 
in assenza di un chiaro pattern di tipo Mendeliano. Piu’ raramente, la malattia segrega 
come un tratto Mendeliano con trasmissione di tipo autosomico dominante o recessivo. 
Pertanto, la forma comune di MP e’ probabilmente un tratto complesso, determinato 
da molti fattori di tipo genetico e non-genetico. Negli ultimi anni, gli studi di linkage in 
forme familiari, e gli studi di “positional cloning” hanno portato alla identifi cazione di 
diversi loci e geni per forme monogeniche rare, e piu’ recentemente, di due loci per 
geni di suscettibilita’ per le forme comuni, non-Mendeliane della malattia. Sebbene 
le forme monogeniche spieghino una piccolissima parte dei casi di MP a livello di 
popolazione, esse stanno facilitando la comprensione degli eventi molecolari e delle 
vie metaboliche implicate anche nelle forme comuni della malattia.
La prima sezione di questa tesi (Introduzione) passa in rassegna la genetica della 
MP, e la patogenesi delle due forme monogeniche identifi cate in precedenza. Il 
capitolo 1.1 contiene una rassegna degli aspetti genetici clinici e molecolari delle 
forme Mendeliane di MP, e dei risultati degli studi genomici volti alla localizzazione di 
geni implicati nelle forme comuni, non-Mendeliane della malattia. Nel capitolo 1.2
viene trattata la patogenesi delle forme di MP causate dalle mutazioni di D-synuclein
e parkin, i due geni sicuramente associati alla MP noti in precedenza, evidenziando 
le implicazioni di queste conoscenze per la comprensione dei meccanismi alla base 
delle forme comuni della malattia.
Le ricerche su cui si basa questa tesi sono presentate nella seconda sezione, e 
riguardano studi genetici molecolari e fenotipici in forme autosomiche recessive di MP 
ad esordio precoce, associate alle mutazioni dei geni parkin (capitoli 2.1-2.4) e DJ-1
(capitoli 2.5-2.8).
Poco dopo il clonaggio del gene parkin nel 1998, altri gruppi hanno confermato la 
presenza di mutazioni in famiglie con MP. Tuttavia, la frequenza del coinvolgimento 
del parkin nella MP ad esordio precoce e lo spettro mutazionale sono stati compresi 
pienamente grazie allo studio descritto nel capitolo 2.1, che ha esplorato per la prima 
volta questo gene in una ampia casistica di famiglie e di casi isolati con esordio 
precoce, mediante sequenziamento a livello genomico e dosaggio delle copie del 
gene. Lo studio ha rivelato mutazioni in questo gene in circa meta’ delle famiglie 
compatibili con ereditarieta’ di tipo recessivo ed esordio della MP prima dei 45 anni, 
ed in circa il 20% dei casi isolati con esordio precoce. Un ulteriore importante risultato 
dello studio e’ che meta’ delle mutazioni consistono in vasti riarrangiamenti genomici, 
e pertanto, per effettuare uno screening di sensibilita’ accettabile, e’ necessario il 
dosaggio delle copie geniche oltre al sequenziamento. 
Se nella popolazione la frequenza di mutazioni di tipo recessivo in un certo gene e’ 
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elevata, l’unione di un omozigote (o un eterozigote composto) con un portatore 
eterozigote puo’ condurre alla comparsa della malattia recessiva in generazioni 
successive, simulando cosi’ un pattern di trasmissione dominante (pseudo-dominanza). 
Queste unioni possono anche dare luogo ad eterogeneita’ allelica all’interno di una 
stessa fratria. Questi fenomeni sono stati dimostrati in diversi studi in famiglie Giapponesi 
ed Italiane (capitoli 2.2, 2.3), suggerendo che le mutazioni nel gene parkin siano 
frequenti in certe popolazioni. La comprensione delle correlazioni genotipo-fenotipo 
nella malattia della parkina e’ ancora limitata. Tuttavia, dalla analisi di una ampia serie 
di casi proviene l’indicazione che genotipi particolari possono infl uenzare il fenotipo 
(capitolo 2.4).
Un nuovo locus per una forma di MP autosomica recessiva ad esordio precoce (PARK7) 
e’ stato da noi localizzato sul cromosoma 1p36 mediante una scansione genomica 
con mappatura di omozigosi in una estesa famiglia consanguinea contenente 
quattro individui affetti, ed appartenente ad una popolazione geneticamente isolata 
della parte sud-occidentale dei Paesi Bassi (capitolo 2.5). Il linkage per la regione 
PARK7 e’ stato successivamente confermato in una seconda famiglia consanguinea 
contenente tre germani affetti da MP ad esordio precoce, e proveniente dalla 
Italia centrale (capitolo 2.6). In entrambe le famiglie il fenotipo e’ caratterizzato da 
parkinsonismo ad esordio precoce (dai 27 ai 40 anni), buona risposta alla levodopa e 
lenta progressione. Sono inoltre presenti disturbi psichici e comportamentali e distonie 
(tra cui blefarospasmo), ed uno studio con tomografi a ad emissione di positroni nella 
famiglia Olandese ha mostrato disfunzioni dopaminergiche di tipo presinaptico 
(capitolo 2.7).
Studi di mappaggio fi ne ed una strategia di “positional cloning” hanno condotto alla 
identifi cazione di mutazioni patogene nel gene DJ-1 nelle due famiglie defi nitivamente 
legate al PARK7 (capitolo 2.8). Il gene DJ-1 e’ stato strettamente conservato nel 
corso dell’evoluzione ed e’ espresso in maniera abbondante ed ubiquitaria sia nel 
cervello che in altri tessuti. Il ruolo esatto della proteina DJ-1 rimane in gran parte 
sconosciuto, ma una revisione della letteratura ci fornisce indizi circa una possibile 
funzione e ci permette di formulare ipotesi per mettere in collegamento il DJ-1 e la 
neurodegenerazione (capitolo 2.9). La scoperta che mutazioni nel DJ-1 causano forme 
autosomiche recessive di MP ad esordio precoce permette di stabilire che nell’uomo, 
la perdita della funzione del DJ-1 conduce a neurodegenerazione. Il chiarimento 
dei meccanismi alla base della malattia correlata alla proteina DJ-1 puo’ fare luce 
su nuovi meccanismi che regolano il mantenimento dei neuroni nel cervello, e puo’ 
favorire la comprensione della patogenesi delle forme comuni di MP.
Il capitolo 3 contiene la discussione generale dei risultati del nostro lavoro 
sperimentale. Dapprima, sono trattate le implicazioni delle conoscenze derivanti 
dagli studi genetici per la nosologia della MP. La malattia correlata alla parkina 
viene quindi discussa nel contesto generale della MP, evidenziando l’importanza di 
questa forma nell’iter diagnostico dei pazienti con esordio precoce, e le correlazioni 
genotipo-fenotipo. Infi ne, viene discusso il contributo apportato dalla scoperta 
delle mutazioni del DJ-1 nel PARK7, ed i piu’ recenti risultati degli studi biochimici e 
di biologia strutturale sulla proteina DJ-1. La tesi si conclude con alcune rifl essioni e 
prospettive per gli studi futuri volti a chiarire ulteriormente le cause ed i meccanismi 
della MP.
Riassunto
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